Pharma & Biotech Sector Financials, Performance and Ratios
-
Sector Score
37.7 /100
Rank 15 out of 27 Sectors -
Advance/Decline
172/479
-
No. of Companies651
-
Avg. Market Cap8,107
-
Price to Earning Ratio9.83
-
Price to Earning Growth Ratio1.06
-
Price to Book Ratio25.98
-
Return on Equity5.91
-
Return on Capital Employed-
-
Return on Assets3.06
-
Dividend yield 1 year %0.74 %
-
Net Profit Growth Annual YoY %9.84 %
-
Net Profit Growth Qtr YoY %95.37 %
-
Net Profit Growth Qtr QoQ %179.99 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Pharma & Biotech Sector Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Pharma & Biotech Peer comparison
Compare all stocks in Pharma & Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
362,598.4
|
205.1
|
L
 -0.6%
H
203.1
207.8
|
L
 -6.7%
H
203.1
224.4
|
L
 -8.8%
H
203.1
237.1
|
L
 -9.6%
H
203.1
237.1
|
L
 -3.3%
H
164.4
244.8
|
L
 31.4%
H
131.0
244.8
|
L
 98.3%
H
102.1
244.8
|
L
 262.5%
H
55.1
244.8
|
| Adc Therapeutics SA |
|
490.4
|
3.9
|
L
 -4.5%
H
3.8
4.1
|
L
 -6.5%
H
3.8
4.3
|
L
 -5.9%
H
3.8
5.0
|
L
 3.5%
H
3.3
5.0
|
L
 127.1%
H
1.1
5.0
|
L
 83.8%
H
0.4
6.0
|
L
 -86.2%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
3,722.1
|
11.8
|
L
 -4.1%
H
11.8
12.4
|
L
H
11.8
12.5
|
L
 -18.4%
H
11.8
14.8
|
L
 -5.9%
H
11.8
15.4
|
L
 31.3%
H
6.7
15.4
|
L
 727.3%
H
1.2
15.4
|
L
 65.0%
H
1.2
15.4
|
L
 -62.4%
H
1.2
37.2
|
| Annovis Bio Inc |
|
73.7
|
2.6
|
L
 -2.6%
H
2.5
2.7
|
L
 3.2%
H
2.3
3.0
|
L
 4.8%
H
2.3
3.0
|
L
 -28.8%
H
2.3
4.1
|
L
 44.4%
H
1.1
5.5
|
L
 -83.0%
H
1.1
23.9
|
L
 -93.2%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
1,856.5
|
5.0
|
L
 -0.4%
H
4.9
5.1
|
L
 1.0%
H
4.9
5.3
|
L
 -18.3%
H
4.9
6.3
|
L
 -27.2%
H
4.9
8
|
L
 -29.7%
H
4.3
8.7
|
L
 -34.2%
H
4.0
11.5
|
L
 -84.8%
H
4.0
34.5
|
L
 -81.4%
H
4.0
38.5
|
| Bristol-Myers Squibb |
|
117,056.5
|
57.5
|
L
 -1.1%
H
56.9
58.5
|
L
 -2.7%
H
56.9
60.8
|
L
 -5.2%
H
56.9
62.9
|
L
 6.1%
H
52.1
62.9
|
L
 -4.9%
H
42.5
62.9
|
L
 -14.5%
H
39.4
71.1
|
L
 -8.3%
H
39.4
81.4
|
L
 -8.5%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
424.0
|
8.2
|
L
 1.4%
H
8.0
8.2
|
L
 1.5%
H
7.9
8.4
|
L
 -25.1%
H
7.8
11.5
|
L
 -34.1%
H
7.8
14.1
|
L
 42.9%
H
4.0
14.1
|
L
 1.5%
H
1.4
15.1
|
L
 -91.0%
H
1.4
96.0
|
L
 -73.1%
H
1.4
137.6
|
| Elanco Animal Health Inc |
|
11,922.1
|
24.0
|
L
 -4.5%
H
23.8
24.9
|
L
 4.5%
H
22.9
25.6
|
L
 -4%
H
22.4
27.7
|
L
 7.5%
H
22.0
27.7
|
L
 126.7%
H
8.0
27.7
|
L
 157.3%
H
7.9
27.7
|
L
 -22.9%
H
7.9
37.5
|
L
H
7.9
37.6
|
| GSK PLC (ADR) |
|
103,734.9
|
51.8
|
L
 -1.0%
H
51.5
52.4
|
L
 -2.9%
H
51.5
54.6
|
L
 -12.9%
H
51.5
59.9
|
L
 6.6%
H
47.6
61.7
|
L
 31.5%
H
32.4
61.7
|
L
 48.4%
H
31.7
61.7
|
L
 39.0%
H
28.5
61.7
|
L
 27.1%
H
28.5
61.7
|
| Johnson & Johnson |
|
566,915.3
|
235.4
|
L
 -0.9%
H
234.5
238.3
|
L
 -2.6%
H
234.5
245.1
|
L
 -2.9%
H
234.5
251.7
|
L
 14.1%
H
200.9
251.7
|
L
 44.4%
H
141.5
251.7
|
L
 52.9%
H
140.7
251.7
|
L
 47.1%
H
140.7
251.7
|
L
 118.9%
H
106.6
251.7
|
| Eli Lilly |
|
809,676.2
|
906.7
|
L
 -1.2%
H
899.3
925.4
|
L
 -8.0%
H
899.3
998.2
|
L
 -10.2%
H
899.3
1064.5
|
L
 -15.4%
H
899.3
1134.0
|
L
 7.6%
H
623.8
1134.0
|
L
 171.8%
H
323.3
1134.0
|
L
 392.0%
H
178.6
1134.0
|
L
 1177.9%
H
64.2
1134.0
|
| Merck & Company |
|
282,297.7
|
114.2
|
L
 0.0%
H
112.7
115.2
|
L
 -0.5%
H
112.7
116.8
|
L
 -6.6%
H
112.7
125.1
|
L
 13.0%
H
100.4
125.1
|
L
 20.5%
H
73.3
125.1
|
L
 7.9%
H
73.3
134.6
|
L
 54.4%
H
69.5
134.6
|
L
 129.0%
H
49.7
134.6
|
| Nuvation Bio Inc (Class A) |
|
1,466.9
|
4.2
|
L
 -0.9%
H
4.2
4.4
|
L
 -5.0%
H
4.1
4.6
|
L
 -22.4%
H
4.1
5.9
|
L
 -55.3%
H
4.1
9.8
|
L
 115.3%
H
1.5
9.8
|
L
 152.7%
H
1.0
9.8
|
L
 -71.0%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Novo Nordisk (ADR) |
|
162,230.9
|
36.5
|
L
 -1.5%
H
36.2
37
|
L
 -3.8%
H
36.2
39.3
|
L
 -23.0%
H
35.9
41.1
|
L
 -24.0%
H
35.9
64.2
|
L
 -53.6%
H
35.9
81.4
|
L
 -49.1%
H
35.9
148.2
|
L
 3.9%
H
33.3
148.2
|
L
 33.8%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
278,647.4
|
146.0
|
L
 -1.5%
H
145.3
148.9
|
L
 -4.8%
H
145.3
155.8
|
L
 -10.2%
H
145.3
170.5
|
L
 7.3%
H
135.6
170.5
|
L
 29.0%
H
97.7
170.5
|
L
 75.0%
H
82.0
170.5
|
L
 69.9%
H
74.1
170.5
|
L
 127.2%
H
59.2
170.5
|
| Organon & Co. |
|
1,569.7
|
6.0
|
L
 -3.8%
H
6.0
6.3
|
L
 -5.0%
H
6.0
6.5
|
L
 -25.4%
H
6.0
8.2
|
L
 -11.7%
H
6.0
9.9
|
L
 -61.4%
H
6.0
15.9
|
L
 -73.1%
H
6.0
24.8
|
L
H
6.0
39.5
|
L
H
6.0
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,886.0
|
61.0
|
L
 1.6%
H
60.0
64.5
|
L
 -0.8%
H
60.0
64.5
|
L
 -12.4%
H
60.0
71.1
|
L
 -1.2%
H
60.0
71.1
|
L
 -27.7%
H
57.3
89.4
|
L
 -1.0%
H
56.0
90.0
|
L
 33.1%
H
42.7
90.0
|
L
 16.7%
H
26.3
90.0
|
| Pfizer |
|
153,415.0
|
27.0
|
L
 -1.6%
H
26.8
27.6
|
L
 1.5%
H
26.5
27.8
|
L
 1.2%
H
26.2
27.8
|
L
 7.1%
H
24.8
27.9
|
L
 3.0%
H
20.9
27.9
|
L
 -33.9%
H
20.9
42.2
|
L
 -24.1%
H
20.9
61.7
|
L
 -3.3%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,273.3
|
9.3
|
L
 -4.2%
H
9.2
9.7
|
L
 -0.5%
H
9.2
10.5
|
L
 -38.2%
H
9.2
15.0
|
L
 -30.1%
H
9.2
15.4
|
L
 -67.5%
H
9.2
28.4
|
L
 -73.5%
H
9.2
40.3
|
L
 -78.3%
H
9.2
50.9
|
L
 -92.8%
H
9.2
133.9
|
| Arcus Biosciences Inc |
|
2,712.6
|
21.6
|
L
 -3.5%
H
21.6
22.7
|
L
 -1.5%
H
21.6
23.2
|
L
 14.0%
H
18.5
24.9
|
L
 -1.6%
H
18.5
24.9
|
L
 138.6%
H
6.5
26.4
|
L
 30.8%
H
6.5
26.4
|
L
 -41.6%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,456.5
|
13.8
|
L
 -2.7%
H
13.8
14.1
|
L
 -2.6%
H
13.8
14.3
|
L
 -5.0%
H
13.8
14.8
|
L
 -3.0%
H
12.8
14.8
|
L
 1.3%
H
12.3
16.2
|
L
 26.0%
H
10.6
74.9
|
L
 16.6%
H
9.6
74.9
|
L
 46.1%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
56,328.4
|
17.8
|
L
 -1.6%
H
17.8
18.1
|
L
 0.3%
H
17.8
18.5
|
L
 -4.5%
H
17.5
18.8
|
L
 19.7%
H
14.9
18.8
|
L
 17.6%
H
13.0
18.8
|
L
 8.9%
H
12.6
18.8
|
L
 -10.0%
H
12.3
20.0
|
L
 -24.5%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
33,460.1
|
28.7
|
L
 -2.4%
H
28.5
29.8
|
L
 0.6%
H
28.5
30.3
|
L
 -16.0%
H
28.4
34.9
|
L
 -5.3%
H
28.4
37.3
|
L
 76.9%
H
12.5
37.3
|
L
 236.8%
H
7.1
37.3
|
L
 149.4%
H
6.8
37.3
|
L
 -46.9%
H
6.1
58.2
|
| Usana Health Sciences Inc |
|
312.1
|
16.9
|
L
 -1.3%
H
16.8
17.4
|
L
 -2.5%
H
16.8
18.1
|
L
 -22.0%
H
16.7
22.2
|
L
 -15.1%
H
16.7
22.9
|
L
 -38.1%
H
16.7
38.3
|
L
 -72.6%
H
16.7
69.6
|
L
 -83.3%
H
16.7
107.9
|
L
 -71.6%
H
16.7
138.0
|
| Zoetis (Class A) |
|
48,827.5
|
115.7
|
L
 -0.3%
H
114.4
117.2
|
L
 0.0%
H
114.4
122.5
|
L
 -10.2%
H
114.4
132.3
|
L
 -5.4%
H
114.4
132.5
|
L
 -29.1%
H
114.4
172.2
|
L
 -30.2%
H
114.4
201.9
|
L
 -24.5%
H
114.4
249.3
|
L
 183.1%
H
40.9
249.3
|
| Biohaven Ltd |
|
1,343.3
|
8.9
|
L
 -0.3%
H
8.9
9.3
|
L
 -6.8%
H
8.8
10.0
|
L
 -20.5%
H
8.8
12.1
|
L
 -17.7%
H
8.8
14.0
|
L
 -68.3%
H
7.5
31.2
|
L
 -35.9%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Whitehawk Therapeutics Inc |
|
169.4
|
3.6
|
L
H
3.4
3.7
|
L
 -8.2%
H
3.4
4.1
|
L
 17.7%
H
2.9
4.5
|
L
 40.2%
H
2.4
4.5
|
L
 83.2%
H
1.4
4.5
|
L
 -52.7%
H
1.2
8.7
|
L
 -85.7%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,030.7
|
3.4
|
L
 -3.7%
H
3.4
3.6
|
L
 -2.6%
H
3.4
3.6
|
L
 11.8%
H
3.0
3.8
|
L
 -5.6%
H
2.7
4.9
|
L
 42.9%
H
1.9
6.5
|
L
 -55.1%
H
1.9
8.1
|
L
 -89.1%
H
1.9
39.1
|
L
H
1.9
71.9
|
| Abeona Therapeutics Inc |
|
241.2
|
4.5
|
L
 -2.0%
H
4.4
4.6
|
L
 -6.5%
H
4.4
5
|
L
 -15.4%
H
4.4
5.6
|
L
 -12.9%
H
4.4
5.7
|
L
 -13.4%
H
3.9
7.5
|
L
 93.5%
H
2.3
9.0
|
L
 -91.8%
H
2.2
55
|
L
 -93.9%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,927.7
|
38.9
|
L
 0.2%
H
37.6
39.6
|
L
 -2.7%
H
37.6
42.9
|
L
 20.3%
H
31.3
42.9
|
L
 22.2%
H
25.2
42.9
|
L
 225.6%
H
5.5
42.9
|
L
 55.9%
H
2.2
53.9
|
L
 -22.4%
H
2.2
53.9
|
L
 -95.2%
H
2.2
939.6
|
| Acumen Pharma Inc |
|
161.7
|
2.7
|
L
 -8.6%
H
2.7
2.9
|
L
 -18.4%
H
2.7
3.6
|
L
 3.9%
H
2.5
3.6
|
L
 24.2%
H
1.7
3.6
|
L
 126.3%
H
0.9
3.6
|
L
 -28.8%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
815.5
|
4.2
|
L
 -3.0%
H
4.2
4.4
|
L
 -0.5%
H
4.1
4.5
|
L
 -0.7%
H
4.1
4.9
|
L
 -4.3%
H
3.5
5.1
|
L
 28.1%
H
2.7
5.1
|
L
 40.4%
H
1.7
5.1
|
L
 16.2%
H
1.7
6.5
|
L
 7.1%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
31.0
|
1.2
|
L
 -5.4%
H
1.2
1.4
|
L
 -3.9%
H
1.2
1.4
|
L
 -19.2%
H
1.2
1.7
|
L
 -44.3%
H
1.2
2.5
|
L
 84.9%
H
0.7
5.5
|
L
 -81.2%
H
0.4
9.6
|
L
 -97.2%
H
0.4
299.5
|
L
 -99.9%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,536.1
|
20.7
|
L
 0.1%
H
20.6
21.1
|
L
 0.6%
H
19.9
21.6
|
L
 -13.6%
H
19.9
25.4
|
L
 -23.6%
H
19.9
28.4
|
L
 20.7%
H
13.4
28.4
|
L
 5.0%
H
13.4
33.9
|
L
 -25.3%
H
12.2
33.9
|
L
 4.8%
H
12.2
58.7
|
| Adicet Bio Inc |
|
66.4
|
6.9
|
L
 -2.1%
H
6.8
7.1
|
L
 -4.0%
H
6.8
7.5
|
L
 -3.1%
H
6.7
8.1
|
L
 -12.4%
H
6.4
9.1
|
L
 -43.4%
H
6.4
17.4
|
L
 -93.3%
H
6.4
120
|
L
 -97.0%
H
6.4
349.9
|
L
H
6.4
349.9
|
| Achieve Life Sciences Inc |
|
212.9
|
4
|
L
 -2.2%
H
4.0
4.1
|
L
 -4.1%
H
4.0
4.3
|
L
 -6.3%
H
4.0
4.8
|
L
 -7.4%
H
3.9
6.0
|
L
 45.5%
H
1.8
6.0
|
L
 -8.7%
H
1.8
10.3
|
L
 -67.5%
H
1.8
12.6
|
L
 -99.8%
H
1.8
3123.8
|
| AC Immune SA |
|
286.7
|
2.9
|
L
 -3.4%
H
2.8
3.2
|
L
 -5.6%
H
2.8
3.4
|
L
 13.1%
H
2.4
3.4
|
L
 -5.9%
H
2.4
3.9
|
L
 31.9%
H
1.4
4
|
L
 31.9%
H
1.4
5.1
|
L
 -64.3%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Arcellx Inc |
|
6,711.7
|
114.8
|
L
 0.4%
H
114.3
114.9
|
L
 0.3%
H
114.3
114.9
|
L
 79.0%
H
113.6
114.9
|
L
 79.4%
H
60.4
114.9
|
L
 60.8%
H
47.9
114.9
|
L
 286.4%
H
27.3
114.9
|
L
H
6.0
114.9
|
L
H
6.0
114.9
|
| Aclaris Therapeutics Inc |
|
446.8
|
3.7
|
L
 -1.3%
H
3.6
3.8
|
L
 4.2%
H
3.5
3.9
|
L
 13.9%
H
2.8
3.9
|
L
 17.5%
H
2.5
4.9
|
L
 135.0%
H
1.1
4.9
|
L
 -53.6%
H
0.6
11.1
|
L
 -86.2%
H
0.6
30.4
|
L
 -76.5%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
52.4
|
1.7
|
L
 -2.4%
H
1.6
1.7
|
L
 2.5%
H
1.5
1.8
|
L
 8.5%
H
1.4
1.9
|
L
 -23.2%
H
1.4
3.6
|
L
 -67.7%
H
1.1
5.7
|
L
 -85.7%
H
1.1
14.4
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
14.1
|
0.8
|
L
 2.5%
H
0.8
0.9
|
L
 3.8%
H
0.8
0.9
|
L
 6.4%
H
0.8
1
|
L
 -24.6%
H
0.8
1.3
|
L
 66%
H
0.4
1.6
|
L
 43.1%
H
0.4
1.6
|
L
 -97.6%
H
0.4
35.8
|
L
 -98.7%
H
0.4
115
|
| Grace Therapeutics Inc |
|
68.4
|
4.4
|
L
 0.9%
H
4.4
4.7
|
L
 5.2%
H
4.2
4.7
|
L
 13.9%
H
3.6
4.7
|
L
 30%
H
3.3
4.7
|
L
 72.7%
H
1.8
4.7
|
L
 70%
H
1.7
5.0
|
L
 -86.5%
H
1.7
35.7
|
L
 -94.3%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
16.0
|
5.6
|
L
 -15.5%
H
5.4
6.6
|
L
 44.3%
H
3.9
7.5
|
L
 237.4%
H
1.3
7.5
|
L
 68.2%
H
1.3
7.5
|
L
 -33.2%
H
1.3
21
|
L
 -90.8%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
2.9
|
2
|
L
 7.0%
H
1.9
2.1
|
L
 2.0%
H
1.7
2.1
|
L
 -18.4%
H
1.5
2.7
|
L
 -66.8%
H
1.5
6.8
|
L
 -88.9%
H
1.5
30.3
|
L
 -99.2%
H
1.5
350
|
L
 -99.9%
H
1.5
3175
|
L
H
1.5
5900
|
| Adma Biologics Inc |
|
3,410.4
|
14.3
|
L
 -4.7%
H
14.2
15.2
|
L
 -5.5%
H
14.2
16.4
|
L
 -11.1%
H
14.2
17.2
|
L
 -26.9%
H
14.2
19.9
|
L
 -27.1%
H
13.8
25.7
|
L
 364.9%
H
3.0
25.7
|
L
 575.5%
H
1.0
25.7
|
L
 147.3%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,091.1
|
13.6
|
L
 0.6%
H
13.2
13.6
|
L
 3.1%
H
13.0
13.9
|
L
 -10.7%
H
12
17.0
|
L
 -20.1%
H
12
19.8
|
L
 75.2%
H
6.7
20.8
|
L
 69.1%
H
2.3
20.8
|
L
 -67.6%
H
2.3
45.0
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.7
|
1.3
|
L
 4%
H
1.2
1.3
|
L
 -28.6%
H
1.2
1.8
|
L
 -68.0%
H
1.2
4.4
|
L
 -86.1%
H
1.2
14.7
|
L
 -100.0%
H
1.2
9181.0
|
L
 -100.0%
H
1.2
10000000000
|
L
 -100.0%
H
1.2
10000000000
|
L
H
1.2
10000000000
|
| Agenus Inc |
|
127.6
|
3.7
|
L
 -2.6%
H
3.7
3.8
|
L
 19.7%
H
2.9
4.1
|
L
 21.2%
H
2.9
4.1
|
L
 7.9%
H
2.7
4.9
|
L
 122.2%
H
1.4
7.3
|
L
 -88.5%
H
1.4
196
|
L
 -93.9%
H
1.4
196
|
L
 -95.0%
H
1.4
196
|
| Agios Pharma Inc |
|
1,632.4
|
27.9
|
L
 -0.2%
H
27.5
28.4
|
L
 0.0%
H
27.5
29.5
|
L
 -4.8%
H
26.8
31.0
|
L
 13.9%
H
24.2
31.0
|
L
 -14.8%
H
22.2
46
|
L
 22.6%
H
19.8
62.6
|
L
 -44.7%
H
16.8
62.6
|
L
 -22.8%
H
16.8
99.8
|
| Aeglea BioTherapeutics Inc |
|
167.0
|
41.3
|
L
 -2.5%
H
41.2
43.2
|
L
 3.4%
H
40.7
45.4
|
L
 -4.5%
H
38.4
45.8
|
L
 23.5%
H
28
45.8
|
L
 171.7%
H
13.9
45.8
|
L
 450%
H
2.7
45.8
|
L
 -79.1%
H
2.7
219.8
|
L
H
2.7
318.8
|
| Akebia Therapeutics Inc |
|
380.4
|
1.4
|
L
H
1.4
1.5
|
L
 -2.7%
H
1.4
1.6
|
L
 20.3%
H
1.2
1.6
|
L
 -14.5%
H
1.1
1.7
|
L
 -30.4%
H
1.1
4.1
|
L
 108.8%
H
0.5
4.1
|
L
 -59.5%
H
0.2
4.3
|
L
 -83.6%
H
0.2
20.3
|
| Avalon GloboCare Corp |
|
3.3
|
0.6
|
L
 5.6%
H
0.5
0.6
|
L
 -17.4%
H
0.5
0.7
|
L
 3.6%
H
0.4
1.6
|
L
 -53.3%
H
0.4
1.6
|
L
 -91.1%
H
0.4
6.5
|
L
 -74.9%
H
0.2
11.7
|
L
 -95.5%
H
0.2
15.7
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
108.9
|
1.8
|
L
 -1.1%
H
1.8
2.0
|
L
 -56.1%
H
1.1
4.5
|
L
 -63.4%
H
1.1
5.7
|
L
 -63.5%
H
1.1
5.9
|
L
 -73.1%
H
1.1
6.8
|
L
 -75.7%
H
1.1
12.0
|
L
 -84.9%
H
1.1
16.0
|
L
 -59.6%
H
1.1
16.7
|
| Alector Inc |
|
226.2
|
2.1
|
L
 -0.5%
H
2
2.1
|
L
 -6.8%
H
2.0
2.3
|
L
 3.0%
H
1.9
2.7
|
L
 46.4%
H
1.4
2.7
|
L
 57.7%
H
0.9
3.4
|
L
 -67.9%
H
0.9
9.1
|
L
 -90.2%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Aligos Therapeutics Inc |
|
42.1
|
6.8
|
L
 -7.2%
H
6.8
7.6
|
L
 -10.0%
H
6.8
8.1
|
L
 0.2%
H
6.3
8.1
|
L
 -36.2%
H
6.2
11.5
|
L
 -40.9%
H
3.8
13.7
|
L
 -78.4%
H
3.8
46.3
|
L
 -98.9%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
4,691.2
|
28.2
|
L
 -0.9%
H
27.9
28.9
|
L
 1.4%
H
27
28.9
|
L
 -11.8%
H
27
33.9
|
L
 -1.1%
H
27
35.3
|
L
 -17.0%
H
25.2
36.3
|
L
 5.7%
H
22.0
36.5
|
L
 40.4%
H
18.4
36.5
|
L
 -6.8%
H
12.0
71.2
|
| Allogene Therapeutics Inc |
|
465.2
|
2.1
|
L
 -6.8%
H
2.1
2.3
|
L
 -13.8%
H
2.1
2.5
|
L
 1.0%
H
2.0
2.8
|
L
 45.8%
H
1.3
2.8
|
L
 27.0%
H
0.9
2.8
|
L
 -61.5%
H
0.9
6.9
|
L
 -94.4%
H
0.9
38.4
|
L
H
0.9
55
|
| Allarity Therapeutics Inc |
|
17.4
|
1.1
|
L
 -1.8%
H
1.0
1.1
|
L
 -14.3%
H
1.0
1.3
|
L
 17.4%
H
0.9
1.4
|
L
 4.9%
H
0.8
1.4
|
L
 12.5%
H
0.6
2.1
|
L
 -100.0%
H
0.1
3612
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
41,401.0
|
312.2
|
L
 0.3%
H
311.1
322.4
|
L
 -0.4%
H
309.7
327.0
|
L
 -7.1%
H
309.6
341.4
|
L
 -22%
H
298
427.1
|
L
 23.1%
H
205.9
495.6
|
L
 66.5%
H
142.0
495.6
|
L
 116.5%
H
117.6
495.6
|
L
 422.0%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
32.6
|
1.2
|
L
 -4.6%
H
1.2
1.4
|
L
 -4.6%
H
1.2
1.5
|
L
 2.5%
H
1.1
1.5
|
L
 -12.7%
H
1.0
1.6
|
L
 -35.8%
H
1.0
2.4
|
L
 -11.4%
H
1.0
7.4
|
L
 -96.3%
H
1.0
35.2
|
L
H
1.0
309.6
|
| Altimmune Inc |
|
434.6
|
3.3
|
L
 -2.3%
H
3.3
3.5
|
L
 -4.6%
H
3.3
3.7
|
L
 -23.7%
H
3.3
4.8
|
L
 -14.4%
H
3.3
6.4
|
L
 -42.2%
H
2.9
7.7
|
L
 -69.4%
H
2.1
14.8
|
L
 -79.7%
H
2.1
23.5
|
L
 -99.4%
H
1.5
1050
|
| Alvotech |
|
1,100.0
|
3.5
|
L
 -1.4%
H
3.4
3.6
|
L
 1.7%
H
3.4
3.9
|
L
 -14.7%
H
3.4
4.3
|
L
 -28.0%
H
3.4
5.6
|
L
 -69.4%
H
3.4
11.9
|
L
 -73.7%
H
3.4
18
|
L
H
3.4
18
|
L
H
3.4
18
|
| Kalaris Therapeutics Inc |
|
150.5
|
6.6
|
L
 -3.5%
H
6.6
6.9
|
L
 -24.2%
H
6.6
9.3
|
L
 -34.3%
H
6.6
11.2
|
L
 -28.0%
H
6.6
11.2
|
L
 -42.4%
H
2.1
12.5
|
L
 44.4%
H
0.4
12.9
|
L
 -74.1%
H
0.4
26.5
|
L
H
0.4
49.0
|
| Alzamend Neuro Inc |
|
7.0
|
1.8
|
L
 -3.2%
H
1.7
1.9
|
L
 -10.3%
H
1.7
2.4
|
L
 -7.1%
H
1.7
2.4
|
L
 -13.3%
H
1.6
2.5
|
L
 -79.2%
H
1.6
10.2
|
L
 -99.6%
H
1.6
1071.9
|
L
H
1.6
45292.5
|
L
H
1.6
45292.5
|
| Amgen |
|
187,487.7
|
347.8
|
L
 -0.6%
H
345.0
351.2
|
L
 -5.0%
H
345.0
370.9
|
L
 -7.2%
H
345.0
391.3
|
L
 6.2%
H
318.2
391.3
|
L
 10.4%
H
261.4
391.3
|
L
 48.2%
H
211.7
391.3
|
L
 41.4%
H
198.6
391.3
|
L
 139.0%
H
133.6
391.3
|
| Amylyx Pharma Inc |
|
1,526.5
|
13.8
|
L
 -1.7%
H
13.7
14.4
|
L
 -1.3%
H
13.7
14.8
|
L
 -1.4%
H
13.5
15.7
|
L
 14.9%
H
10.8
17.5
|
L
 270.2%
H
3.1
17.5
|
L
 -56.5%
H
1.6
32.7
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
884.7
|
19.5
|
L
 -0.2%
H
19.2
19.8
|
L
 7.3%
H
18.7
20
|
L
 -31.7%
H
17.0
28.8
|
L
 -26.7%
H
17.0
29.5
|
L
 -30.1%
H
17.0
31.3
|
L
 -47.6%
H
17.0
67.7
|
L
 7.9%
H
16.9
67.7
|
L
 67.5%
H
11.4
67.7
|
| AnaptysBio Inc |
|
1,792.7
|
62.4
|
L
 -3.7%
H
61.6
65.7
|
L
 -3.8%
H
61.6
68.4
|
L
 15.1%
H
52.7
68.4
|
L
 27.1%
H
42
68.4
|
L
 254.9%
H
15.4
68.4
|
L
 188.4%
H
12.2
68.4
|
L
 189.8%
H
12.2
68.4
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,673.7
|
74.7
|
L
 -0.2%
H
73.8
75.6
|
L
 5.9%
H
70.4
76
|
L
 -4.0%
H
70.2
78.2
|
L
 -9.9%
H
70.2
87.1
|
L
 16.0%
H
56.7
99.5
|
L
 89.8%
H
36.5
99.5
|
L
 117.5%
H
22.3
99.5
|
L
 133.1%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
88.1
|
2.7
|
L
 -4.3%
H
2.6
2.9
|
L
 -6.4%
H
2.6
2.9
|
L
 -8.0%
H
2.6
3.1
|
L
 -19.7%
H
2.6
3.6
|
L
 -15.9%
H
2.3
5.5
|
L
 -32.9%
H
2.1
6.5
|
L
 -62.0%
H
2.1
7.1
|
L
 -7.0%
H
0.6
8.1
|
| Annexon Inc |
|
761.7
|
5.1
|
L
 -6.9%
H
5.1
5.6
|
L
 -9.7%
H
5.1
5.9
|
L
 4.3%
H
4.8
6.3
|
L
 -1.2%
H
4.5
7.2
|
L
 105.2%
H
1.3
7.2
|
L
 24.6%
H
1.3
8.4
|
L
 -82.9%
H
1.3
30.9
|
L
H
1.3
38.0
|
| AN2 Therapeutics Inc |
|
143.8
|
4
|
L
 2.3%
H
3.8
4.3
|
L
 -19.0%
H
3.8
5.2
|
L
 284.6%
H
1.0
6.9
|
L
 257.1%
H
1
6.9
|
L
 174.0%
H
1
6.9
|
L
 -53.3%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
4.4
|
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 6.6%
H
0.7
0.8
|
L
 3.9%
H
0.6
0.9
|
L
 -67.7%
H
0.6
2.6
|
L
 -97.2%
H
0.6
35.9
|
L
 -100.0%
H
0.6
27900
|
L
 -100.0%
H
0.6
149400
|
L
 -100.0%
H
0.6
2244000
|
| Apollomics Inc (Class A) |
|
39.7
|
18.5
|
L
 -3.2%
H
18.3
18.7
|
L
 -7.1%
H
18.3
20.1
|
L
 -7.2%
H
18.3
21.5
|
L
 10.6%
H
16.3
24.2
|
L
 78.0%
H
3.7
42.1
|
L
 -98.4%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
2,200.0
|
17.2
|
L
 -4.2%
H
17.2
18.1
|
L
 -9.1%
H
17.2
19.4
|
L
 -22.8%
H
17.2
22.8
|
L
 -30.2%
H
17.2
27.5
|
L
 -28.7%
H
16.1
30.5
|
L
 -72.7%
H
16.1
94.8
|
L
 -60.8%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Aptorum Grp Ltd (Class A) |
|
8.8
|
1.1
|
L
 14.9%
H
0.9
1.1
|
L
 36.7%
H
0.8
1.1
|
L
 36.7%
H
0.8
1.1
|
L
 -4.4%
H
0.7
1.2
|
L
 17.4%
H
0.7
4.5
|
L
 -53.8%
H
0.5
17.5
|
L
 -96.7%
H
0.5
35.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
5.9
|
0.8
|
L
H
0.7
0.8
|
L
 2.7%
H
0.7
0.8
|
L
H
0.7
1.0
|
L
 -18.3%
H
0.6
1.5
|
L
 -68.6%
H
0.6
2.4
|
L
 -85.2%
H
0.6
8.9
|
L
 -99.3%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aptevo Therapeutics Inc |
|
7.1
|
4.6
|
L
 1.3%
H
4.3
4.7
|
L
 3.2%
H
4.3
4.8
|
L
 -31.5%
H
4.0
7.6
|
L
 -76.3%
H
4.0
20.0
|
L
 -99.5%
H
4.0
1299.6
|
L
 -100.0%
H
4.0
1233639.7
|
L
 -100.0%
H
4.0
20184595.2
|
L
H
4.0
68020444.8
|
| AquaBounty Tech Inc |
|
3.7
|
1.0
|
L
 3.3%
H
0.9
1.0
|
L
 1.1%
H
0.9
1.0
|
L
 9.2%
H
0.9
1.1
|
L
 11.8%
H
0.8
1.2
|
L
 61.0%
H
0.5
3.0
|
L
 -91.3%
H
0.5
12.7
|
L
 -99.4%
H
0.5
162.6
|
L
H
0.5
610
|
| Aquestive Therapeutics Inc |
|
485.7
|
4.0
|
L
 -2.0%
H
4.0
4.1
|
L
 -1%
H
4.0
4.3
|
L
 0.8%
H
3.9
4.5
|
L
 -31.4%
H
2.9
6.6
|
L
 28.0%
H
2.1
7.6
|
L
 403.8%
H
0.8
7.6
|
L
 -23.0%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
188.4
|
6.6
|
L
 -1.3%
H
6.5
6.8
|
L
 -0.8%
H
6.4
6.8
|
L
 -13.6%
H
6.4
8.7
|
L
 1.5%
H
6.0
8.7
|
L
 -48.4%
H
5.9
24.2
|
L
 -56.8%
H
5.9
45
|
L
 -85.7%
H
5.9
65
|
L
 -76.5%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,302.3
|
5.3
|
L
 -3.5%
H
5.3
5.5
|
L
 -8.1%
H
5.3
5.9
|
L
 -7.3%
H
5.3
6.8
|
L
 -6.5%
H
5.3
8.4
|
L
 -3.3%
H
3.2
8.4
|
L
 36.9%
H
3.2
10.1
|
L
 -23.7%
H
0.5
10.1
|
L
 -25.9%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,754.8
|
22.2
|
L
 -3.1%
H
22.1
23.3
|
L
 -2.4%
H
21.9
23.3
|
L
 -12.6%
H
21.9
28.8
|
L
 -20.7%
H
21.9
30.8
|
L
 32.4%
H
11.9
31.8
|
L
 92.0%
H
1.8
31.8
|
L
 -28.0%
H
1.8
36.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
5.6
|
8.0
|
L
 11.3%
H
7.6
9.8
|
L
 112.0%
H
3.8
9.8
|
L
 101.3%
H
3.2
9.8
|
L
 69.2%
H
3.2
9.8
|
L
 -55.2%
H
3.2
85.8
|
L
 -78.9%
H
3.2
85.8
|
L
 -98.6%
H
3.2
567
|
L
H
3.2
46656
|
| Arvinas Inc |
|
699.7
|
10.9
|
L
 -2.1%
H
10.7
11.2
|
L
 -10.2%
H
10.7
12.5
|
L
 -8.8%
H
10.7
14.5
|
L
 -6.3%
H
10.7
14.5
|
L
 21.6%
H
5.9
14.5
|
L
 -64.1%
H
5.9
53.1
|
L
 -83.7%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
7,888.0
|
56.3
|
L
 -1.1%
H
54.9
58
|
L
 2.3%
H
54.9
58.9
|
L
 -11.4%
H
54.0
67.2
|
L
 -17.4%
H
54.0
76.8
|
L
 272.8%
H
9.6
76.8
|
L
 124.8%
H
9.6
76.8
|
L
 -16.4%
H
9.6
93.7
|
L
 1143.5%
H
1.2
93.7
|
| Assembly Biosciences Inc |
|
450.2
|
28.5
|
L
 3.5%
H
27.7
30.1
|
L
 1.2%
H
27.1
30.1
|
L
 -1.0%
H
27
30.6
|
L
 -19.3%
H
24.7
39.0
|
L
 166.2%
H
7.8
39.7
|
L
 92.8%
H
7.7
39.7
|
L
 -51.1%
H
7.7
59.2
|
L
 -57.6%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
528.0
|
4.2
|
L
 -3.4%
H
4.0
4.4
|
L
 -20.1%
H
4.0
5.5
|
L
 -18.9%
H
4.0
6.5
|
L
 -30.6%
H
4.0
8.6
|
L
 -0.5%
H
3.9
14.5
|
L
 251.7%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
85.9
|
13.4
|
L
 -2.6%
H
13.0
13.8
|
L
 15.9%
H
11.3
13.9
|
L
 12.9%
H
11.1
13.9
|
L
 23.8%
H
8.6
13.9
|
L
 25.4%
H
7.7
15.2
|
L
 -84.6%
H
7.7
120.2
|
L
 -76.1%
H
7.7
120.2
|
L
 -98.3%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,267.6
|
3.5
|
L
 -2.2%
H
3.4
3.6
|
L
 -5.4%
H
3.4
3.9
|
L
 -10.1%
H
3.4
4.4
|
L
 -11.9%
H
3.3
4.7
|
L
 154.7%
H
1.2
6.8
|
L
 193.3%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| LeonaBio Inc |
|
92.6
|
9.9
|
L
 -0.1%
H
9.5
10.7
|
L
 29.5%
H
6.9
14.2
|
L
 78.4%
H
5.1
14.2
|
L
 42.3%
H
4.2
14.2
|
L
 201.5%
H
2.2
14.2
|
L
 -61.8%
H
2.2
43.0
|
L
 -94.8%
H
2.2
236.4
|
L
H
2.2
347.9
|
| ETHZilla Corp |
|
53.4
|
2.8
|
L
H
2.7
2.8
|
L
 -2.8%
H
2.7
3.1
|
L
 -22.2%
H
2.7
3.9
|
L
 -59.3%
H
2.7
6.9
|
L
 -73.2%
H
2.7
174.6
|
L
 -99.3%
H
2.7
513
|
L
 -100.0%
H
2.7
49571
|
L
H
2.7
49571
|
| Atossa Therapeutics Inc |
|
45.9
|
5.3
|
L
 3.9%
H
5.1
6.0
|
L
 6.4%
H
4.9
6.0
|
L
 26.6%
H
3.8
6.0
|
L
 -51.4%
H
3.8
11.2
|
L
 -50.4%
H
3.8
19.4
|
L
 -46.2%
H
3.8
34.7
|
L
 -87.2%
H
3.8
147
|
L
 -99.4%
H
3.8
1133.7
|
| Atara Biotherapeutics Inc |
|
68.3
|
4.9
|
L
 -4.1%
H
4.8
5.3
|
L
 -24.5%
H
4.8
6.5
|
L
 17.5%
H
3.9
7.3
|
L
 -71.4%
H
3.9
19.1
|
L
 -27.2%
H
3.9
19.1
|
L
 -93.4%
H
0.4
79.3
|
L
 -98.7%
H
0.4
501
|
L
 -98.8%
H
0.4
1361.3
|
| Aurinia Pharma Inc |
|
1,864.3
|
14.0
|
L
 -0.4%
H
13.9
14.2
|
L
 0.5%
H
13.9
14.5
|
L
 -2.6%
H
13.5
15.2
|
L
 -13.4%
H
13.5
16.5
|
L
 68.5%
H
6.8
16.5
|
L
 52.1%
H
4.7
16.5
|
L
 2.8%
H
4.1
34.0
|
L
 361.2%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
415.9
|
6.6
|
L
 -0.5%
H
6.4
6.8
|
L
 10.3%
H
5.9
7.0
|
L
 21.1%
H
5.2
7.0
|
L
 11.8%
H
4.7
7.0
|
L
 -11.7%
H
4.3
7.7
|
L
 -35.8%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Atea Pharma Inc |
|
450.9
|
5.7
|
L
 -5.7%
H
5.6
6.1
|
L
 -7.2%
H
5.6
6.2
|
L
 21.7%
H
4.5
6.5
|
L
 80.3%
H
3.1
6.5
|
L
 79.7%
H
2.5
6.5
|
L
 61.7%
H
2.5
6.5
|
L
 -92.8%
H
2.5
78.7
|
L
H
2.5
94.2
|
| Tectonic Therapeutic Inc |
|
561.0
|
29.9
|
L
 -3.1%
H
29.4
31.4
|
L
 -10.3%
H
29.4
34.5
|
L
 39.8%
H
21.0
36.0
|
L
 52.8%
H
16.8
36.0
|
L
 34.7%
H
13.7
36.0
|
L
 102.4%
H
1.4
61.1
|
L
 -80.1%
H
1.4
158.6
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
690.4
|
14
|
L
 -0.6%
H
13.7
14.2
|
L
 0.6%
H
13.1
15.2
|
L
 -1.9%
H
13.1
15.3
|
L
 -17.8%
H
12.5
17.5
|
L
 -84%
H
6.6
100.1
|
L
 -98.1%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Avalo Therapeutics Inc |
|
248.4
|
13.4
|
L
 -5.6%
H
13.2
14.8
|
L
 -15.1%
H
13.2
16.4
|
L
 -5.6%
H
13.2
19.1
|
L
 -27.9%
H
13.0
20.0
|
L
 63.3%
H
3.4
20.7
|
L
 521.3%
H
0.0
34.5
|
L
 -65.2%
H
0.0
44.4
|
L
 -73.6%
H
0.0
91.8
|
| Anavex Life Sciences Corp |
|
376.2
|
4.1
|
L
 -3.3%
H
4.0
4.3
|
L
 -12.7%
H
4.0
4.8
|
L
 -1.5%
H
4.0
5.2
|
L
 10.6%
H
3.5
5.4
|
L
 -59.1%
H
2.9
14.0
|
L
 -56.2%
H
2.9
14.4
|
L
 -72.7%
H
2.9
31.5
|
L
 -17.5%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
8,027.0
|
156.9
|
L
 -1.2%
H
155.4
160.0
|
L
 0.5%
H
155.4
161.4
|
L
 -14.6%
H
153.4
181.8
|
L
 2.8%
H
148.1
191.5
|
L
 24.3%
H
87.0
191.5
|
L
 148.3%
H
55.0
191.5
|
L
 142.9%
H
19.4
191.5
|
L
 1737.5%
H
1.9
191.5
|
| Aytu BioPharma Inc |
|
28.0
|
2.6
|
L
 0.8%
H
2.6
2.7
|
L
 2.8%
H
2.6
2.7
|
L
 13.5%
H
2.2
2.7
|
L
 2.4%
H
2.1
3.1
|
L
 108.8%
H
1.0
3.1
|
L
 27.9%
H
1.0
3.5
|
L
 -98.7%
H
1.0
193
|
L
 -100.0%
H
1.0
672000
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1.1
|
L
 4.8%
H
1.0
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 1.9%
H
1.0
1.4
|
L
 86.4%
H
0.5
1.4
|
L
 -36.1%
H
0.5
2.6
|
L
 -24.1%
H
0.5
2.8
|
L
 -93.2%
H
0.5
15.8
|
L
H
0.5
18.2
|
| Adagene Inc (ADR) |
|
171.1
|
3.6
|
L
 -1.6%
H
3.5
3.9
|
L
 -12.1%
H
3.5
4.5
|
L
 15.6%
H
2.8
4.6
|
L
 99.5%
H
1.5
4.6
|
L
 103.9%
H
1.3
4.6
|
L
 134.2%
H
1.1
4.6
|
L
 -82.7%
H
0.9
21.0
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
7.0
|
5.7
|
L
 -2.9%
H
5.7
5.7
|
L
 -17.7%
H
5.6
6.9
|
L
 -21.5%
H
5.6
8.0
|
L
 -27.7%
H
5.6
10.4
|
L
 -26.1%
H
5.6
12.1
|
L
 -76.2%
H
5
27.9
|
L
 -97.4%
H
5
229.6
|
L
H
5
750.4
|
| Akari Therapeutics PLC (ADR) |
|
6.0
|
0.1
|
L
 -13.3%
H
0.1
0.2
|
L
 -43.5%
H
0.1
0.2
|
L
 -45.8%
H
0.1
0.3
|
L
 -50%
H
0.1
0.3
|
L
 -91.3%
H
0.1
1.6
|
L
 -97.2%
H
0.1
5.7
|
L
 -99.8%
H
0.1
64
|
L
 -99.9%
H
0.1
444
|
| Amarin Corp (ADR) |
|
301.4
|
14.5
|
L
 -3.4%
H
14.3
15.0
|
L
 -5.5%
H
14.3
15.8
|
L
 -7.1%
H
13.5
17
|
L
 5%
H
13.1
17.3
|
L
 3193.2%
H
0.4
20.9
|
L
 822.9%
H
0.4
20.9
|
L
 125%
H
0.4
20.9
|
L
 906.3%
H
0.4
26.1
|
| Argen X SE (ADR) |
|
41,086.3
|
663.9
|
L
 -3.0%
H
661.9
688.1
|
L
 -5.2%
H
661.9
716.3
|
L
 -21.4%
H
661.9
848.8
|
L
 -22.4%
H
661.9
881.9
|
L
 8.3%
H
510.1
934.6
|
L
 81.9%
H
327.7
934.6
|
L
 117.0%
H
248.2
934.6
|
L
H
17.3
934.6
|
| Ascendis Pharma A/S (ADR) |
|
13,621.9
|
221.9
|
L
 -0.9%
H
221.3
226.2
|
L
 -1.8%
H
219.8
232
|
L
 -1.4%
H
219.6
248.6
|
L
 11.0%
H
188.1
248.6
|
L
 35.9%
H
124.1
248.6
|
L
 102.1%
H
64.3
248.6
|
L
 53.6%
H
61.6
248.6
|
L
 1156.4%
H
11.9
248.6
|
| Alterity Therapeutics Ltd (ADR) |
|
59.6
|
3.3
|
L
 -4.6%
H
3.3
3.5
|
L
 -8.6%
H
3.3
3.7
|
L
 -0.3%
H
3.3
3.8
|
L
 6.5%
H
2.9
3.8
|
L
 -16.1%
H
2.5
7
|
L
 20.5%
H
1
7
|
L
 -79.7%
H
1
27.5
|
L
 -89.6%
H
1
66.9
|
| Autolus Therapeutics PLC (ADR) |
|
364.6
|
1.4
|
L
 -4.2%
H
1.4
1.4
|
L
 -4.9%
H
1.4
1.5
|
L
 -18.0%
H
1.4
1.9
|
L
 -16.0%
H
1.3
2.1
|
L
 -18.5%
H
1.1
2.7
|
L
 -33.5%
H
1.1
7.5
|
L
 -80.1%
H
1.1
8.2
|
L
H
1.1
53.2
|
| Astrazeneca plc |
|
569,264.1
|
183.6
|
L
 -2.8%
H
182.6
188.4
|
L
 -3.3%
H
182.6
194.0
|
L
 -10.1%
H
182.6
209.9
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
L
 -2.6%
H
182.6
212.7
|
| BridgeBio Pharma Inc |
|
13,287.4
|
68.5
|
L
 -2.2%
H
68
72.4
|
L
 -1.3%
H
68
72.4
|
L
 0.6%
H
62.8
75.9
|
L
 -10.2%
H
62.8
84.9
|
L
 102.1%
H
28.3
84.9
|
L
 389.6%
H
11.8
84.9
|
L
 1.3%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
12.6
|
0.2
|
L
 6.3%
H
0.2
0.2
|
L
 6.3%
H
0.2
0.2
|
L
H
0.2
0.3
|
L
 -77.3%
H
0.1
0.8
|
L
 -52.8%
H
0.1
1.4
|
L
 -93.1%
H
0.1
4.1
|
L
 -99.8%
H
0.1
69.2
|
L
H
0.1
76.6
|
| BioCardia Inc |
|
12.7
|
1.2
|
L
H
1.2
1.2
|
L
 -4.8%
H
1.2
1.4
|
L
 6.2%
H
1.1
1.4
|
L
 -5.5%
H
1.1
1.4
|
L
 -51.4%
H
1
3.2
|
L
 -95.8%
H
1
43.8
|
L
 -98.2%
H
1
76.5
|
L
 -99.0%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
2,432.8
|
9.7
|
L
 -1.1%
H
9.6
10.3
|
L
 18%
H
8.2
10.3
|
L
 30.2%
H
7.4
10.3
|
L
 30.9%
H
6.2
10.3
|
L
 26.1%
H
6
11.3
|
L
 21.1%
H
4.0
11.3
|
L
 -26.7%
H
4.0
20.0
|
L
 268.8%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
30.3
|
4.2
|
L
 -7.5%
H
4.2
4.5
|
L
 -1.0%
H
4.1
4.6
|
L
 6.6%
H
3.6
4.6
|
L
 -53.3%
H
3.6
12.1
|
L
 -99.1%
H
3.6
982
|
L
 -100.0%
H
3.6
11514
|
L
 -99.9%
H
3.6
18526.5
|
L
 -100.0%
H
3.6
138373.2
|
| Black Diamond Therapeutics Inc |
|
120.2
|
2.1
|
L
 -1.9%
H
2.1
2.2
|
L
 -0.5%
H
2.1
2.3
|
L
 -9.4%
H
1.9
2.6
|
L
 -16.9%
H
1.9
2.9
|
L
 12.2%
H
1.2
4.9
|
L
 24.1%
H
1.2
7.7
|
L
 -91.6%
H
1.2
29.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,508.7
|
24.6
|
L
 -2.2%
H
24.6
25.8
|
L
 -2.1%
H
24.6
26.3
|
L
 -10.7%
H
24.6
34.2
|
L
 -7.3%
H
24.3
36.4
|
L
 7.7%
H
13.5
36.4
|
L
 -23.6%
H
13.5
49.5
|
L
 -73.5%
H
13.5
138.5
|
L
H
13
138.5
|
| Biofrontera Inc |
|
10.1
|
0.9
|
L
 1.2%
H
0.8
0.9
|
L
H
0.8
1.0
|
L
 -2.3%
H
0.8
1.0
|
L
 13.0%
H
0.6
1.0
|
L
 -15.5%
H
0.5
1.2
|
L
 -93.1%
H
0.5
13.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biogen |
|
26,630.8
|
181.5
|
L
 -1.1%
H
180.5
183.7
|
L
 -0.1%
H
180.5
186.5
|
L
 -5.5%
H
180.5
198.7
|
L
 3.8%
H
160.4
202.4
|
L
 28.4%
H
110.0
202.4
|
L
 -32.3%
H
110.0
319.8
|
L
 -32.1%
H
110.0
468.6
|
L
 -21.4%
H
110.0
468.6
|
| BioVie Inc |
|
9.0
|
1.2
|
L
 -17.8%
H
1.2
1.5
|
L
 -14.9%
H
1.2
1.5
|
L
 -4.8%
H
1.2
1.5
|
L
 -14.9%
H
1.1
1.5
|
L
 -89.6%
H
1.1
13.2
|
L
 -99.9%
H
1.1
1028
|
L
 -99.9%
H
1.1
2386
|
L
 -99.9%
H
1.1
5625
|
| Biomea Fusion Inc |
|
80.6
|
1.1
|
L
 4.6%
H
1.1
1.2
|
L
 -16.2%
H
1.1
1.4
|
L
 -13.6%
H
1.1
1.6
|
L
 -18.6%
H
1.0
1.7
|
L
 -58.8%
H
0.9
3.1
|
L
 -92.5%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Biomarin pharma Inc - Registered Shares |
|
10,410.5
|
54.1
|
L
 -1.6%
H
53.8
55.7
|
L
 -7.5%
H
53.8
58.8
|
L
 -15.5%
H
53.8
66.3
|
L
 -11.5%
H
53.8
66.3
|
L
 -24.4%
H
50.8
73.2
|
L
 -41.4%
H
50.8
100.4
|
L
 -30.8%
H
50.8
117.8
|
L
 -33.1%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
11.7
|
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 3.6%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -28.1%
H
1.1
1.8
|
L
 -64.6%
H
1.1
5.5
|
L
 -89.4%
H
0.1
11.8
|
L
 -98.7%
H
0.1
93.3
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
376.1
|
11.0
|
L
 -4.5%
H
10.9
11.6
|
L
 -6.6%
H
10.9
12.3
|
L
 3.2%
H
10.3
13.4
|
L
 -4.5%
H
9.9
14.4
|
L
 -34.6%
H
9.9
17.2
|
L
 191.2%
H
1.9
17.2
|
L
 -80.4%
H
1.9
178.3
|
L
 -97.5%
H
1.9
1371.3
|
| Bolt Biotherapeutics Inc |
|
9.1
|
4.8
|
L
 4.9%
H
4.5
4.9
|
L
 21.7%
H
4.0
4.9
|
L
 -5.7%
H
3.9
5.3
|
L
 -7.8%
H
3.9
7.2
|
L
 -45.9%
H
3.9
9.7
|
L
 -83.4%
H
3.9
40.6
|
L
 -99.4%
H
3.9
755.8
|
L
H
3.9
861.4
|
| Bon Natural Life Ltd |
|
11.6
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -3.4%
H
1.4
1.6
|
L
 -10.1%
H
1.3
1.7
|
L
 -15.9%
H
1.3
1.8
|
L
 -78%
H
1.1
5.1
|
L
 -99.6%
H
1.1
410
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
36.8
|
1.5
|
L
 -5.6%
H
1.5
1.6
|
L
 1.3%
H
1.5
1.8
|
L
 -3.8%
H
1.4
1.8
|
L
 -12.7%
H
1.4
2.1
|
L
 -36.0%
H
1.2
8.1
|
L
 -92.0%
H
0.2
29.6
|
L
 -96.6%
H
0.2
47.1
|
L
H
0.2
71.5
|
| Blue Water Biotech Inc |
|
11.0
|
0.6
|
L
 29.2%
H
0.5
0.6
|
L
 14.8%
H
0.5
0.6
|
L
 -18.4%
H
0.4
1.0
|
L
 -65.0%
H
0.4
2.3
|
L
 675%
H
0.1
5.9
|
L
 -40.4%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
65.8
|
1.6
|
L
 2.6%
H
1.5
1.7
|
L
 -5.3%
H
1.5
1.9
|
L
 23.1%
H
1.2
1.9
|
L
 -31.9%
H
1.2
2.2
|
L
 -4.2%
H
1.0
3.4
|
L
 37.9%
H
0.7
4
|
L
 -87.1%
H
0.5
33
|
L
H
0.5
48.5
|
| Bicycle Therapeutics PLC (ADR) |
|
301.7
|
4.4
|
L
 -4.4%
H
4.3
4.6
|
L
 -9%
H
4.3
5.3
|
L
 -19.0%
H
4.3
5.9
|
L
 -36.7%
H
4.3
7.3
|
L
 -54.2%
H
4.3
9.7
|
L
 -79.6%
H
4.3
28.9
|
L
 -83.3%
H
4.3
62.1
|
L
H
4.3
62.1
|
| Biodexa Pharma PLC (ADR) |
|
0.6
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 -15.7%
H
0.7
0.9
|
L
 -39.7%
H
0.7
1.2
|
L
 -80.8%
H
0.7
3.6
|
L
 -96.5%
H
0.7
19.4
|
L
 -100.0%
H
0.7
815034.7
|
L
 -100.0%
H
0.7
36100000
|
L
 -100.0%
H
0.7
2720000000
|
| BeiGene Ltd (ADR) |
|
29,324.5
|
275.3
|
L
 -2.6%
H
275.0
285.5
|
L
 -3.1%
H
275.0
293.1
|
L
 -24.0%
H
275.0
372.7
|
L
 -12.9%
H
275.0
372.7
|
L
 20.5%
H
228.9
385.2
|
L
 23.4%
H
127.0
385.2
|
L
 -21.1%
H
118.2
426.6
|
L
 894.1%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
11.5
|
2.7
|
L
 -2.2%
H
2.5
2.7
|
L
 -0.8%
H
2.5
2.8
|
L
 -8.6%
H
2.5
3.0
|
L
 -12.8%
H
2.5
3.2
|
L
 -22.5%
H
2.3
7.8
|
L
 -89.5%
H
0.1
101.2
|
L
 -97.8%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
5,599.0
|
154.6
|
L
 -2.9%
H
153
160.0
|
L
 -5.8%
H
153
166.3
|
L
 -14.6%
H
153
192.3
|
L
 -0.9%
H
146.1
200
|
L
 128.2%
H
49
200
|
L
 424.0%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
24.9
|
4.6
|
L
 4.8%
H
4.4
4.7
|
L
 1.5%
H
4.3
4.7
|
L
 6.0%
H
4.1
4.9
|
L
 18.5%
H
3.6
4.9
|
L
 -11%
H
3.6
21.4
|
L
 78.0%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| BioNTech SE (ADR) |
|
22,435.8
|
89.3
|
L
 0.0%
H
87.2
89.6
|
L
 -2.1%
H
87.2
95.1
|
L
 -19.0%
H
79.5
112.4
|
L
 -3.5%
H
79.5
124
|
L
 -7.2%
H
79.5
124
|
L
 -32.4%
H
76.5
136.9
|
L
 -17.0%
H
76.5
464
|
L
H
12.5
464
|
| Biondvax Pharma Ltd (ADR) |
|
-
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
H
0.7
0.8
|
L
 -1.4%
H
0.7
1.1
|
L
 -10.1%
H
0.6
1.1
|
L
 -75.6%
H
0.6
6.2
|
L
 -69.1%
H
0.6
6.2
|
L
 -98.3%
H
0.6
99
|
L
 -98.2%
H
0.6
620
|
| Cabaletta Bio Inc |
|
283.0
|
2.9
|
L
 -3.3%
H
2.9
3.2
|
L
 -3.9%
H
2.8
3.3
|
L
 1.0%
H
2.8
3.8
|
L
 23.0%
H
2
3.8
|
L
 68%
H
1.0
3.8
|
L
 -61.5%
H
1.0
26.4
|
L
 -74.0%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
9.1
|
0.6
|
L
 -21.6%
H
0.6
0.7
|
L
 -30.1%
H
0.6
0.9
|
L
 7.4%
H
0.5
0.9
|
L
 -90.9%
H
0.5
7.2
|
L
 -72.4%
H
0.5
7.2
|
L
 -89.5%
H
0.5
8.6
|
L
 -99.5%
H
0.5
108.8
|
L
H
0.5
530.3
|
| Capricor Therapeutics Inc |
|
1,669.5
|
29.1
|
L
 -6.6%
H
29.1
32.5
|
L
 -4.6%
H
29.1
32.5
|
L
 2.1%
H
25.1
36.5
|
L
 4.6%
H
21.1
36.5
|
L
 102.7%
H
4.3
40.4
|
L
 549.6%
H
2.7
40.4
|
L
 443.9%
H
2.6
40.4
|
L
 11.9%
H
0.9
54
|
| Tvardi Therapeutics Inc |
|
33.0
|
3.5
|
L
 -4.4%
H
3.4
3.7
|
L
 -10.2%
H
3.4
4.0
|
L
 -3.3%
H
3.4
4.2
|
L
 -11.6%
H
3.4
4.9
|
L
 -77.2%
H
3.4
43.7
|
L
 -98.2%
H
3.4
199.3
|
L
 -99.5%
H
3.4
1067.3
|
L
 -98.1%
H
3.4
1067.3
|
| Crescent Biopharma Inc |
|
-
|
10.9
|
L
 2.6%
H
10.6
11.1
|
L
 -2.5%
H
9.9
11.8
|
L
 -6.4%
H
9.9
13.5
|
L
 -8.0%
H
8.7
14.7
|
L
 -4.0%
H
7.6
21.4
|
L
 285.2%
H
2.9
21.4
|
L
 -21.6%
H
0.9
21.4
|
L
 -82.0%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
263.5
|
2.7
|
L
 3.5%
H
2.6
2.9
|
L
 -0.7%
H
2.5
2.9
|
L
 25%
H
2.1
3.8
|
L
 33%
H
1.7
3.8
|
L
 23.3%
H
1.1
3.8
|
L
 -32.7%
H
1.1
11.9
|
L
 -93.0%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Niagen Bioscience Inc |
|
373.2
|
4.7
|
L
 -1.7%
H
4.6
4.8
|
L
 -2.5%
H
4.4
5.0
|
L
 -4.1%
H
4.4
5.8
|
L
 -28.5%
H
4.4
7.1
|
L
 -39.0%
H
4.4
14.7
|
L
 198.7%
H
1.3
14.7
|
L
 -60.8%
H
1.2
14.7
|
L
 3.6%
H
1.2
23.7
|
| Cullinan Oncology Inc |
|
771.1
|
12.7
|
L
 -2.6%
H
12.7
13.2
|
L
 -5.6%
H
12.7
14.5
|
L
 -6.7%
H
12.7
16.7
|
L
 31.6%
H
9.4
16.7
|
L
 46.1%
H
5.7
16.7
|
L
 17.1%
H
5.7
30.2
|
L
 -69.0%
H
5.7
43.5
|
L
H
5.7
59.9
|
| Compugen Ltd |
|
197.6
|
2.1
|
L
 -1.0%
H
2.1
2.2
|
L
 -6.7%
H
2.1
2.3
|
L
 20.1%
H
1.7
2.4
|
L
 37.5%
H
1.4
2.4
|
L
 30.6%
H
1.1
2.4
|
L
 190.3%
H
0.5
3.0
|
L
 -77.0%
H
0.5
9.4
|
L
 -62.6%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
94.5
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 1.9%
H
1.0
1.2
|
L
 2.9%
H
1
1.2
|
L
 -30.5%
H
1.0
1.6
|
L
 148.8%
H
0.2
3.8
|
L
 -37.1%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Coherus Biosciences Inc |
|
227.8
|
1.5
|
L
 -5.6%
H
1.5
1.6
|
L
 -6.8%
H
1.5
1.7
|
L
 -6.8%
H
1.5
2.1
|
L
 11.8%
H
1.3
2.6
|
L
 60%
H
0.7
2.6
|
L
 -75.7%
H
0.7
8.7
|
L
 -90.2%
H
0.7
19.3
|
L
 -92.2%
H
0.7
32.0
|
| Cingulate Inc |
|
80.7
|
7.4
|
L
 -1.7%
H
6.6
8.0
|
L
 -15.1%
H
6.6
11.9
|
L
 25.3%
H
5.8
11.9
|
L
 85.9%
H
3.9
11.9
|
L
 80.4%
H
3.2
11.9
|
L
 702.2%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
62.7
|
5.3
|
L
 -9.4%
H
5.2
6.1
|
L
 -7.0%
H
5.2
6.7
|
L
 14.7%
H
4.4
6.7
|
L
 -20.4%
H
3.9
7.0
|
L
 24.6%
H
2.3
13.5
|
L
 -77.5%
H
2.3
24.8
|
L
 -98.0%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
13.7
|
3.2
|
L
 1.9%
H
3.0
3.2
|
L
 1.3%
H
3.0
3.4
|
L
 -4.1%
H
2.6
3.7
|
L
 20.9%
H
2.5
4.1
|
L
 -71.6%
H
2.5
20.6
|
L
 -92.8%
H
2.5
133.5
|
L
 -99.4%
H
2.5
573
|
L
 -100.0%
H
2.5
15300
|
| Clearmind Medicine Inc |
|
1.4
|
0.7
|
L
H
0.6
0.7
|
L
 -15.4%
H
0.6
0.9
|
L
 -43.6%
H
0.6
1.3
|
L
 -75.9%
H
0.6
2.8
|
L
 -98.6%
H
0.6
52.4
|
L
 -100.0%
H
0.6
3780
|
L
 -100.0%
H
0.6
788400
|
L
H
0.6
788400
|
| Compass Therapeutics Inc |
|
927.5
|
5.2
|
L
 -4.5%
H
5.1
5.4
|
L
 -0.8%
H
5.1
5.5
|
L
 -16.5%
H
5.1
6.2
|
L
 3.2%
H
4.8
6.9
|
L
 129.9%
H
1.3
6.9
|
L
 60.4%
H
0.8
6.9
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
1.4
|
2.3
|
L
 5.5%
H
2.2
2.3
|
L
 -6.2%
H
2.1
2.5
|
L
 -28.7%
H
2.1
3.6
|
L
 -64.8%
H
2.1
8.9
|
L
 -94.7%
H
2.1
45.8
|
L
 -100.0%
H
2.1
6600000
|
L
 -100.0%
H
2.1
125550000
|
L
H
2.1
256050000
|
| Context Therapeutics Inc |
|
264.6
|
2.9
|
L
 -3.7%
H
2.8
3
|
L
 -14.3%
H
2.7
3.6
|
L
 28.6%
H
2.1
3.6
|
L
 126.8%
H
1.1
3.6
|
L
 274.0%
H
0.5
3.6
|
L
 336.4%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
14.2
|
1.0
|
L
 -5.5%
H
1.0
1.1
|
L
H
1
1.1
|
L
 2.0%
H
1.0
1.1
|
L
 4.0%
H
0.9
1.2
|
L
 -33.6%
H
0.9
2.7
|
L
 -44.0%
H
0.9
3.3
|
L
 -94.6%
H
0.9
41.5
|
L
 -99.5%
H
0.9
309.6
|
| Co-Diagnostics Inc |
|
5.4
|
2.6
|
L
 -2.3%
H
2.5
4.0
|
L
 -7.5%
H
2.2
4.0
|
L
 9.8%
H
2.2
4.0
|
L
 -67.3%
H
2.2
8.1
|
L
 -82.3%
H
2.2
46.5
|
L
 -95.5%
H
2.2
66.9
|
L
 -99.4%
H
2.2
449.1
|
L
H
2.2
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
65.1
|
11.3
|
L
H
10.5
11.3
|
L
 -6.2%
H
10.5
12.6
|
L
 -1.7%
H
10.5
14
|
L
 -22.9%
H
10.5
16.0
|
L
 15.3%
H
6.3
21.4
|
L
 -59.6%
H
2.3
43.8
|
L
 13.7%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,417.9
|
33.4
|
L
 -3.6%
H
32.7
35
|
L
 -1.8%
H
32.7
37.2
|
L
 -10.6%
H
32.7
40.5
|
L
 -15.6%
H
32.7
41.4
|
L
 357.9%
H
3.7
43.7
|
L
 194.9%
H
3.7
43.7
|
L
 279.7%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Collegium pharma Inc |
|
1,125.3
|
35.4
|
L
 -2.4%
H
35.3
36.6
|
L
 2.7%
H
34.7
37.1
|
L
 -21.2%
H
34.3
46.4
|
L
 -27.5%
H
34.3
50.8
|
L
 18.4%
H
23.2
50.8
|
L
 47.4%
H
20.8
50.8
|
L
 37.8%
H
14.0
50.8
|
L
 123.9%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
3,684.8
|
34.6
|
L
 1.6%
H
34.5
36.4
|
L
 7.7%
H
32.0
36.4
|
L
 -0.5%
H
31.8
38.2
|
L
 -58.6%
H
28.7
85.3
|
L
 -39.9%
H
28.7
117.3
|
L
 65.7%
H
20.8
117.3
|
L
 35.2%
H
15.8
117.3
|
L
 696.3%
H
4.1
117.3
|
| Cosmos Health Inc |
|
12.7
|
0.3
|
L
 6.3%
H
0.3
0.3
|
L
 -5.6%
H
0.3
0.4
|
L
 -8.1%
H
0.3
0.4
|
L
 -30.6%
H
0.3
0.6
|
L
 -33.3%
H
0.3
1.3
|
L
 -88.9%
H
0.3
4.1
|
L
 -99.7%
H
0.3
194.3
|
L
 -99.8%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
42.3
|
2.8
|
L
 -1.7%
H
2.8
2.9
|
L
 -6.9%
H
2.7
3.4
|
L
 -27.4%
H
2.7
5.0
|
L
 -35.8%
H
2.7
5.4
|
L
 -42.0%
H
1.9
6.3
|
L
 41.5%
H
1.0
7.3
|
L
 -14.2%
H
1.0
7.5
|
L
 -34.8%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
2,783.2
|
22.8
|
L
 2.1%
H
22.2
22.9
|
L
 -1.9%
H
22.2
23.6
|
L
 -6.2%
H
22.2
25.4
|
L
 -4%
H
22.1
25.5
|
L
 -1.6%
H
19.1
26.6
|
L
 39.0%
H
11.1
26.6
|
L
 421.5%
H
4.2
26.6
|
L
 1934.8%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
151.0
|
8.6
|
L
 -3.8%
H
8.6
9.1
|
L
 -8.6%
H
8.6
10.1
|
L
 15.9%
H
7.3
10.5
|
L
 5.9%
H
7.2
10.5
|
L
 43.3%
H
4.6
20.6
|
L
 24.5%
H
3.0
61.9
|
L
 -87.8%
H
2.1
71.7
|
L
 -83.8%
H
2.1
323.4
|
| Caribou Biosciences Inc |
|
180.7
|
1.9
|
L
 -5.1%
H
1.9
2.0
|
L
 -0.5%
H
1.8
2
|
L
 3.9%
H
1.7
2.2
|
L
 11.3%
H
1.4
2.2
|
L
 87%
H
0.7
3.5
|
L
 -61.7%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
103.9
|
0.9
|
L
 -2.1%
H
0.9
1.0
|
L
 -8.8%
H
0.9
1.1
|
L
 -7%
H
0.9
1.1
|
L
 -7.9%
H
0.9
1.1
|
L
 -21.9%
H
0.8
1.6
|
L
 89.8%
H
0.5
3.1
|
L
 -80.4%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
10.6
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -19.0%
H
0.8
1.0
|
L
 -30.6%
H
0.8
1.2
|
L
 -28.0%
H
0.8
1.2
|
L
 -72%
H
0.8
3.1
|
L
 -92.5%
H
0.8
20
|
L
 -99.7%
H
0.8
348
|
L
 -99.5%
H
0.8
372
|
| CorMedix Inc |
|
494.1
|
6.3
|
L
 -0.8%
H
6.2
6.3
|
L
 -3.1%
H
6.2
6.6
|
L
 -11.1%
H
6.1
7.4
|
L
 -48%
H
6.1
13.0
|
L
 -42.5%
H
5.6
17.4
|
L
 82.7%
H
2.6
17.4
|
L
 -37.2%
H
2.6
17.4
|
L
 -50.8%
H
0.9
22.7
|
| Crinetics Pharma Inc |
|
3,724.4
|
35.6
|
L
 -0.7%
H
35.1
36.0
|
L
 -5.1%
H
35.1
38.5
|
L
 -18.1%
H
35.1
45.2
|
L
 -25.9%
H
35.1
58.0
|
L
 3.6%
H
24.1
58.0
|
L
 111.1%
H
15.2
62.5
|
L
 115.7%
H
14.8
62.5
|
L
H
10.6
62.5
|
| Cronos Grp Inc |
|
905.9
|
2.4
|
L
 -2.9%
H
2.4
2.5
|
L
 -4.4%
H
2.4
2.6
|
L
 -11.5%
H
2.4
2.8
|
L
 -19.3%
H
2.4
3.0
|
L
 31.3%
H
1.6
3.4
|
L
 27.8%
H
1.6
3.4
|
L
 -76.5%
H
1.6
10.2
|
L
H
0.2
25.1
|
| CRISPR Therapeutics AG |
|
4,438.4
|
46.2
|
L
 -1.5%
H
45.9
47.7
|
L
 -5.2%
H
45.9
50.2
|
L
 -13.5%
H
45.9
61.8
|
L
 -17.2%
H
45.5
61.8
|
L
 12.3%
H
30.0
78.5
|
L
 4.0%
H
30.0
91.1
|
L
 -64.3%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Corvus Pharma Inc |
|
1,119.6
|
13.3
|
L
 -5.4%
H
13.0
14.4
|
L
 -13.0%
H
13.0
15.9
|
L
 -19.6%
H
13.0
18.7
|
L
 78.0%
H
6.4
27.0
|
L
 216.6%
H
2.5
27.0
|
L
 1860.3%
H
0.6
27.0
|
L
 334.2%
H
0.6
27.0
|
L
H
0.6
27.0
|
| Champions Oncology Inc |
|
81.4
|
5.9
|
L
 -5.5%
H
5.9
6.2
|
L
 -3.9%
H
5.8
6.3
|
L
 0.7%
H
5.5
6.3
|
L
 -18.8%
H
5.5
7.7
|
L
 -42.2%
H
5.5
10.2
|
L
 46.1%
H
3.6
12.0
|
L
 -53.0%
H
3.6
13.1
|
L
 67.4%
H
1.1
17.9
|
| CytomX Therapeutics Inc |
|
757.3
|
4.5
|
L
 -6.9%
H
4.4
4.8
|
L
 -4.9%
H
4.4
8.2
|
L
 -18.1%
H
4.4
8.2
|
L
 11.3%
H
3.9
8.2
|
L
 564.2%
H
0.4
8.2
|
L
 141.8%
H
0.4
8.2
|
L
 -46.2%
H
0.4
10.1
|
L
 -64.2%
H
0.4
35
|
| Cue Biopharma Inc |
|
29.2
|
0.3
|
L
 3.9%
H
0.3
0.3
|
L
 -3.6%
H
0.2
0.3
|
L
 -3.6%
H
0.2
0.4
|
L
H
0.2
0.5
|
L
 -71.9%
H
0.2
1.1
|
L
 -91.3%
H
0.2
5.1
|
L
 -98.1%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
15.2
|
6.5
|
L
 -6.5%
H
6.4
7.1
|
L
 -11.9%
H
6.4
7.9
|
L
 -4.7%
H
6.4
9.0
|
L
 -8.3%
H
4.9
9.0
|
L
 -66.6%
H
4.9
20.0
|
L
 443.3%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Cyclacel Pharma Inc |
|
4.6
|
0.9
|
L
 2.2%
H
0.9
1.0
|
L
 14.6%
H
0.8
1.0
|
L
 -9.6%
H
0.7
1.1
|
L
 -32.4%
H
0.7
1.7
|
L
 -98.7%
H
0.7
100.8
|
L
 -100.0%
H
0.7
3168
|
L
 -100.0%
H
0.7
30564
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
6.1
|
1.6
|
L
 5.3%
H
1.4
1.6
|
L
 9.7%
H
1.3
1.6
|
L
 18.7%
H
1.2
1.6
|
L
 9.7%
H
1.0
2.3
|
L
 -41.3%
H
1.0
3.8
|
L
 -85.4%
H
1.0
12.0
|
L
 -98.0%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
7,599.1
|
61.7
|
L
 -2.0%
H
61.0
64.0
|
L
 2.7%
H
59.2
64.0
|
L
 -9.2%
H
58.4
70.4
|
L
 -1.6%
H
58.4
71.0
|
L
 43.2%
H
29.3
71.0
|
L
 75.3%
H
26.0
110
|
L
 148.2%
H
17.7
110
|
L
 893.6%
H
5.8
110
|
| Cellectis (ADR) |
|
336.0
|
3.3
|
L
 -4.0%
H
3.2
3.4
|
L
 -2.3%
H
3.2
3.7
|
L
 -14.4%
H
3.2
4.3
|
L
 -23.6%
H
3.2
5.1
|
L
 163.0%
H
1.1
5.5
|
L
 75.8%
H
1.0
5.5
|
L
 -84.4%
H
1.0
22.2
|
L
 -87.7%
H
1.0
38.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
11.0
|
1.8
|
L
 -7.8%
H
1.7
1.9
|
L
 -2.7%
H
1.7
2.2
|
L
 13.4%
H
1.4
2.2
|
L
 -5.8%
H
1.4
2.2
|
L
 -67.0%
H
1.4
5.9
|
L
 -70.1%
H
1.4
10.2
|
L
 -99.1%
H
1.4
288
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
614.1
|
5.4
|
L
 -5.6%
H
5.4
5.9
|
L
 -15.3%
H
5.4
6.5
|
L
 -32.8%
H
5.4
8.1
|
L
 -15.1%
H
5.4
8.9
|
L
 82.8%
H
2.3
8.9
|
L
 -36.2%
H
2.3
12.8
|
L
 -86.2%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Centessa Pharma PLC (ADR) |
|
4,000.0
|
27.1
|
L
 -4.5%
H
26.7
28.8
|
L
 2.8%
H
26.3
29.2
|
L
 10.5%
H
24.4
29.2
|
L
 8.9%
H
21.5
29.2
|
L
 66.1%
H
9.6
30.6
|
L
 593.8%
H
3.4
30.6
|
L
H
2.9
30.6
|
L
H
2.9
30.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
153.8
|
2.8
|
L
 -3.8%
H
2.7
2.9
|
L
 2.6%
H
2.6
3
|
L
 4.2%
H
2.4
3.0
|
L
 21.6%
H
2.0
3.2
|
L
 236.6%
H
0.5
3.3
|
L
 109.1%
H
0.5
3.3
|
L
 -85.1%
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
19.4
|
1.4
|
L
 4.6%
H
1.3
1.4
|
L
 -5.6%
H
1.3
1.5
|
L
 -17.6%
H
1.3
1.7
|
L
 -34.9%
H
1.3
2.2
|
L
 -52.8%
H
1.3
9.2
|
L
 -88.3%
H
0.3
13.2
|
L
 -94.4%
H
0.3
30.1
|
L
 -99.5%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
2,214.7
|
21.4
|
L
 0.2%
H
21.3
21.4
|
L
 0.6%
H
21.3
21.4
|
L
 82%
H
10.0
21.4
|
L
 132.0%
H
8.4
21.4
|
L
 157.4%
H
5.6
21.4
|
L
 16.8%
H
5.6
21.4
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
220.5
|
6.6
|
L
 -4.6%
H
6.6
7.1
|
L
 -8.2%
H
6.6
7.8
|
L
 -22%
H
6.6
9.1
|
L
 -15.8%
H
6.6
9.6
|
L
 19.0%
H
5.5
9.6
|
L
 345.0%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
4.0
|
L
 -5.0%
H
3.9
4.3
|
L
 -5.4%
H
3.9
4.6
|
L
 -13.2%
H
3.6
5.1
|
L
 -47.1%
H
3.6
8.6
|
L
 -54.2%
H
3.6
13.1
|
L
 -55.2%
H
3.6
14.4
|
L
 -94.7%
H
3.6
80.3
|
L
 -100.0%
H
3.6
17437.5
|
| DiaMedica Therapeutics Inc |
|
352.0
|
6.8
|
L
 -3.7%
H
6.7
7.0
|
L
 -7.1%
H
6.7
7.4
|
L
 -19.7%
H
6.7
8.7
|
L
 -20.3%
H
6.7
9.0
|
L
 31.5%
H
3.2
10.4
|
L
 286.3%
H
1.5
10.4
|
L
 -32.4%
H
1.1
10.7
|
L
 154.1%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,198.8
|
20.2
|
L
 2.1%
H
19.6
20.5
|
L
 -1.9%
H
18.9
21.2
|
L
 -0.1%
H
18.9
22.6
|
L
 19.7%
H
15.3
23.8
|
L
 38.1%
H
10.6
23.8
|
L
 -13.5%
H
10.6
33.3
|
L
 -67.5%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
46.4
|
2.9
|
L
 -2.7%
H
2.8
2.9
|
L
 -6.8%
H
2.8
3.3
|
L
 -17.3%
H
2.8
3.5
|
L
 -37.6%
H
2.8
5.1
|
L
 -33.8%
H
2.8
8.4
|
L
 -13.3%
H
0.8
13.6
|
L
 -87.8%
H
0.8
24.1
|
L
 -97.8%
H
0.8
308.4
|
| DarioHealth Corp |
|
54.0
|
8.0
|
L
 -3.0%
H
7.9
8.1
|
L
 -11.2%
H
7.6
9.4
|
L
 -29.2%
H
7.6
12
|
L
 -30.8%
H
7.6
13.6
|
L
 -43.3%
H
5.9
17.7
|
L
 -90.0%
H
5.9
91.6
|
L
 -98.0%
H
5.9
533
|
L
 -99.5%
H
5.9
2360.0
|
| Dermata Therapeutics Inc |
|
4.1
|
1.5
|
L
 20.7%
H
1.4
1.8
|
L
 22.7%
H
1.2
1.8
|
L
 8.2%
H
1.1
1.8
|
L
 -31.8%
H
1.1
4.7
|
L
 23.7%
H
0.6
7.1
|
L
 -8.2%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| Bright Minds Biosciences Inc |
|
701.0
|
71.6
|
L
 -0.9%
H
70.8
74.5
|
L
 -0.5%
H
69.3
76.8
|
L
 -16.2%
H
69.0
91
|
L
 -14.7%
H
69.0
123.8
|
L
 105.3%
H
23.2
123.8
|
L
 2934.7%
H
0.9
123.8
|
L
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
635.8
|
10.3
|
L
 0.5%
H
10.2
10.5
|
L
 1.9%
H
10.0
11.2
|
L
 2.0%
H
9.7
11.2
|
L
 6.5%
H
8.2
11.2
|
L
 122.2%
H
2.6
11.2
|
L
 58.1%
H
1.9
11.2
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
161.2
|
6.5
|
L
 -3.0%
H
6.4
6.9
|
L
 15.0%
H
5.5
7.6
|
L
 72.0%
H
3.8
7.6
|
L
 45.2%
H
3.5
7.6
|
L
 21.6%
H
3.5
8.8
|
L
 685.5%
H
0.3
19.4
|
L
 -41.2%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
2,897.9
|
17.6
|
L
 -1.4%
H
17.3
18.8
|
L
 -2.0%
H
17.2
19.0
|
L
 18.0%
H
14
20.0
|
L
 -11.5%
H
14
21
|
L
 43.2%
H
6.4
25
|
L
 45.6%
H
6.4
47.5
|
L
 11.1%
H
4.3
47.5
|
L
H
4.3
47.5
|
| DBV Tech (ADR) |
|
1,062.5
|
19.1
|
L
 -1.9%
H
18.9
20.1
|
L
 -7.0%
H
18.9
20.7
|
L
 -11.0%
H
18.6
24.1
|
L
 -16.1%
H
16.5
25.4
|
L
 261.6%
H
3.9
26.2
|
L
 24.0%
H
0.5
26.2
|
L
 -65.7%
H
0.5
68.8
|
L
 -93.8%
H
0.5
505.7
|
| Editas Medicine Inc |
|
229.0
|
2.3
|
L
 -0.4%
H
2.3
2.5
|
L
 -4.1%
H
2.2
2.6
|
L
 30.7%
H
1.8
2.8
|
L
H
1.7
2.8
|
L
 70.8%
H
0.9
4.5
|
L
 -71.5%
H
0.9
11.9
|
L
 -94.8%
H
0.9
73.0
|
L
 -92.0%
H
0.9
100.0
|
| Edesa Biotech Inc |
|
61.4
|
7.4
|
L
 1.7%
H
6.7
9.4
|
L
 23.3%
H
4.9
9.4
|
L
 818.8%
H
0.8
9.4
|
L
 396.6%
H
0.7
9.4
|
L
 197.6%
H
0.7
9.4
|
L
 -2.8%
H
0.7
9.4
|
L
 -80.9%
H
0.7
84
|
L
 -99.6%
H
0.7
1734.6
|
| Eledon Pharma Inc |
|
229.3
|
2.9
|
L
 1.1%
H
2.9
3.1
|
L
 7.1%
H
2.7
3.1
|
L
 31.5%
H
2.1
3.2
|
L
 75.6%
H
1.4
3.2
|
L
 -16.3%
H
1.4
4.6
|
L
 22.6%
H
1.1
5.4
|
L
 -80.1%
H
1.1
14.8
|
L
 -99.7%
H
1.1
1425.6
|
| Elicio Therapeutics Inc |
|
199.6
|
10.9
|
L
 -9.4%
H
10.7
12
|
L
 -11.1%
H
10.7
12.7
|
L
 24%
H
8.6
14.9
|
L
 36.7%
H
7.4
14.9
|
L
 33.6%
H
4.6
14.9
|
L
 117%
H
3.0
24.4
|
L
 -93.9%
H
3.0
188.8
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,736.0
|
29.0
|
L
 -3.4%
H
28.6
30.3
|
L
 4.5%
H
26.7
31.8
|
L
 11.6%
H
25.8
31.8
|
L
 72.1%
H
14.8
31.8
|
L
 38.8%
H
13.3
31.8
|
L
 32.3%
H
9.8
31.8
|
L
 -28.0%
H
3.9
41.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
291.9
|
6.1
|
L
 -12.5%
H
6
7.1
|
L
 -13.1%
H
6
7.4
|
L
 8.5%
H
5.6
8.0
|
L
 42.8%
H
3.5
8.0
|
L
 377.3%
H
1.1
8.0
|
L
 90.3%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
242.1
|
1.0
|
L
 -5.6%
H
1.0
1.1
|
L
 -1.9%
H
1.0
1.1
|
L
 1.0%
H
1
1.3
|
L
 21.4%
H
0.7
1.3
|
L
 -6.4%
H
0.7
2.1
|
L
 -72.1%
H
0.7
4.6
|
L
 -92.5%
H
0.7
14.0
|
L
 -99.1%
H
0.7
125.2
|
| Enochian Biosciences Inc |
|
-
|
0.5
|
L
 23.7%
H
0.4
0.6
|
L
 161.1%
H
0.2
0.7
|
L
 -13.0%
H
0.2
0.7
|
L
 -55.2%
H
0.2
1.1
|
L
 46.9%
H
0.1
1.7
|
L
 -58.8%
H
0.1
2.3
|
L
 -87.9%
H
0.1
13.8
|
L
 -76.3%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
2.1
|
0.6
|
L
H
0.5
0.6
|
L
 41.5%
H
0.4
0.7
|
L
 45%
H
0.4
0.8
|
L
 -50%
H
0.3
1.2
|
L
 -83.7%
H
0.3
4.9
|
L
 -91.4%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Enanta Pharma Inc |
|
363.0
|
12.5
|
L
 -3.8%
H
12.4
13.2
|
L
 -1.5%
H
12.4
13.7
|
L
 -7.4%
H
12.4
15.7
|
L
 -18.7%
H
12.1
17.2
|
L
 94.3%
H
4.1
17.2
|
L
 -70.0%
H
4.1
43.1
|
L
 -76.0%
H
4.1
102
|
L
 -53.8%
H
4.1
127.8
|
| Entera Bio Ltd |
|
50.9
|
1.1
|
L
 -6.7%
H
1.1
1.3
|
L
 -12.6%
H
1.1
1.5
|
L
 -24.5%
H
1.1
1.7
|
L
 -37.3%
H
1
2.0
|
L
 -42.5%
H
1
3.2
|
L
 4.7%
H
0.5
3.4
|
L
 -75.7%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Enveric Biosciences Inc |
|
2.8
|
2.0
|
L
 4.1%
H
1.9
2.0
|
L
 7.4%
H
1.9
2.1
|
L
 -8.1%
H
1.8
2.5
|
L
 -59.8%
H
1.8
5.3
|
L
 -90.2%
H
1.8
21.5
|
L
 -99.3%
H
1.8
1256.4
|
L
 -100.0%
H
1.8
33660
|
L
 -100.0%
H
1.8
12150000
|
| Evolus Inc |
|
301.9
|
4.6
|
L
 -4.5%
H
4.6
4.9
|
L
 -7.4%
H
4.6
5.2
|
L
 6.2%
H
4.1
6.3
|
L
 -34.4%
H
4.1
7.3
|
L
 -65.0%
H
4.1
13.3
|
L
 -44.8%
H
4.1
17.8
|
L
 -66.6%
H
4.1
17.8
|
L
H
2.9
39.5
|
| Equillium Inc |
|
129.7
|
2.1
|
L
 -0.5%
H
2.0
2.3
|
L
 -13.8%
H
2.0
2.7
|
L
 22.4%
H
1.6
2.7
|
L
 85.2%
H
1.1
2.7
|
L
 166.3%
H
0.3
2.7
|
L
 222.7%
H
0.3
3.3
|
L
 -72.7%
H
0.3
8.3
|
L
H
0.3
27.1
|
| Erasca Inc |
|
4,537.7
|
14.6
|
L
 -4.3%
H
14.6
15.5
|
L
 7.2%
H
12.9
15.5
|
L
 16.4%
H
12.7
16.4
|
L
 323.2%
H
3.3
16.4
|
L
 886.5%
H
1.0
16.4
|
L
 380.3%
H
1.0
16.4
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
654.9
|
2.6
|
L
 -1.9%
H
2.5
2.6
|
L
 4.5%
H
2.4
2.8
|
L
 -26.7%
H
2.4
3.5
|
L
 -35.1%
H
2.4
4.2
|
L
 57.4%
H
0.7
4.2
|
L
 65.6%
H
0.7
4.2
|
L
 -91.3%
H
0.7
30.5
|
L
 -83.5%
H
0.7
82.7
|
| Eton Pharma Inc |
|
598.6
|
22.3
|
L
 7.5%
H
20.4
23.0
|
L
 17.9%
H
18.6
23.0
|
L
 24.5%
H
16.1
23.0
|
L
 36.4%
H
14.3
23.0
|
L
 51.0%
H
11.1
23
|
L
 466.5%
H
2.4
23
|
L
 179.3%
H
2.0
23
|
L
H
2.0
23
|
| Edgewise Therapeutics Inc |
|
3,117.3
|
29.1
|
L
 -3.3%
H
28.9
30.4
|
L
 -1.8%
H
28.9
31.8
|
L
 -0.9%
H
26.8
31.8
|
L
 13.7%
H
19.8
31.8
|
L
 22%
H
10.6
31.8
|
L
 292.7%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Exelixis Inc |
|
10,718.2
|
41.3
|
L
 0.0%
H
40.9
41.7
|
L
 0.1%
H
40.9
42.1
|
L
 -5.4%
H
39.7
45.9
|
L
 -6.8%
H
39.7
47.2
|
L
 11%
H
32.4
49.6
|
L
 125.2%
H
17.9
49.6
|
L
 76.4%
H
14.9
49.6
|
L
 966.4%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
27.7
|
3.3
|
L
 -10.2%
H
3.3
3.7
|
L
 -8.4%
H
3.3
4.0
|
L
 -0.6%
H
2.8
4.0
|
L
 -10.9%
H
2.8
4.5
|
L
 127.1%
H
0.9
17.2
|
L
 -98.6%
H
0.0
468
|
L
 -99.4%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,103.8
|
13.2
|
L
 -4.1%
H
13.1
13.9
|
L
 0.2%
H
13.0
14.1
|
L
 -13.7%
H
12.9
18.9
|
L
 -24.1%
H
12.1
19
|
L
 116.9%
H
3.9
19.1
|
L
 444.4%
H
2.2
31.0
|
L
 25.4%
H
2.2
31.0
|
L
 -49.3%
H
2.2
42.5
|
| Evaxion Biotech A/S (ADR) |
|
32.6
|
3.9
|
L
 -2.3%
H
3.8
4.1
|
L
 -8.2%
H
3.6
4.2
|
L
 18.8%
H
3.0
4.6
|
L
 -16.8%
H
2.9
5.5
|
L
 105.8%
H
1.2
12.2
|
L
 -62.0%
H
0.8
18.5
|
L
 -94.9%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Evotec SE (ADR) |
|
863.8
|
2.4
|
L
 -0.8%
H
2.4
2.5
|
L
 5.2%
H
2.3
2.5
|
L
 -31.2%
H
2.3
3.5
|
L
 -17.6%
H
2.3
3.9
|
L
 -31.0%
H
2.3
4.8
|
L
 -74.6%
H
2.3
13.5
|
L
 -86.4%
H
2.3
26.6
|
L
 37.3%
H
1.8
26.6
|
| Fate Therapeutics Inc |
|
127.9
|
1.1
|
L
 1.9%
H
1.1
1.1
|
L
 -6.0%
H
1.0
1.2
|
L
 -24.7%
H
1.0
1.7
|
L
 4.8%
H
1.0
1.7
|
L
 17.0%
H
0.7
1.9
|
L
 -80.2%
H
0.7
8.8
|
L
 -98.8%
H
0.7
97.4
|
L
 -39.9%
H
0.7
121.2
|
| Fortress Biotech Inc |
|
92.8
|
3.0
|
L
 -4.8%
H
3.0
3.1
|
L
 -3.6%
H
3.0
3.2
|
L
 -11.0%
H
3.0
4.2
|
L
 -15.5%
H
2.9
4.5
|
L
 75.9%
H
1.3
4.5
|
L
 -71.9%
H
1.2
12.8
|
L
 -95.3%
H
1.2
91.5
|
L
 -93.4%
H
1.2
91.5
|
| Forte Biosciences Inc |
|
294.4
|
23.5
|
L
 -4.5%
H
22.0
24.6
|
L
 -12.1%
H
22.0
29.0
|
L
 -19.1%
H
22.0
33.0
|
L
 -20.9%
H
21.9
35.6
|
L
 211.7%
H
4.9
35.6
|
L
 -4.5%
H
4.1
35.6
|
L
 -96.6%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
439.2
|
8.6
|
L
 -4.1%
H
8.6
9.1
|
L
 3.4%
H
8.2
9.9
|
L
 -4.6%
H
8.0
10.5
|
L
 -0.8%
H
7.0
10.5
|
L
 129.6%
H
2.2
12.3
|
L
 -50.8%
H
2.2
36.3
|
L
 -80.3%
H
2.2
45.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
250.0
|
7.3
|
L
 -4.3%
H
7.3
7.7
|
L
 -2.7%
H
7.3
8.1
|
L
 -16.3%
H
7.3
9.2
|
L
 -4.4%
H
7.3
9.2
|
L
 10.6%
H
4.7
9.9
|
L
 -9.4%
H
4.0
11.9
|
L
 2.8%
H
3.8
11.9
|
L
 297.8%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
28.8
|
7.1
|
L
 -2.3%
H
7.1
7.4
|
L
 2.3%
H
6.7
7.5
|
L
 -14.3%
H
6.7
8.6
|
L
 -17.1%
H
6.7
9.8
|
L
 -15.3%
H
4.9
12.6
|
L
 -98.6%
H
4.5
522.5
|
L
 -99.2%
H
4.5
903.1
|
L
 -98.4%
H
4.5
1713.8
|
| Foghorn Therapeutics Inc |
|
293.5
|
5
|
L
 2.3%
H
4.8
5.1
|
L
 2.0%
H
4.7
5.2
|
L
 -12.7%
H
4.6
6.0
|
L
 -4.6%
H
4.6
7.0
|
L
 21.4%
H
2.9
7.0
|
L
 3.5%
H
2.7
10.2
|
L
 -69.0%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Q32 Bio Inc |
|
84.3
|
6.7
|
L
 0.2%
H
6.2
7.0
|
L
 -2.1%
H
5.5
7.0
|
L
 42.4%
H
4.2
7.8
|
L
 125.7%
H
2.9
7.8
|
L
 221.2%
H
1.3
7.8
|
L
 -59.2%
H
1.3
53.8
|
L
 -96.5%
H
1.3
200.5
|
L
H
1.3
572.4
|
| ZeroStack Corp |
|
23.4
|
9.6
|
L
 17.4%
H
7.8
9.7
|
L
 15.0%
H
7.8
9.7
|
L
 16%
H
6.3
9.7
|
L
 31.9%
H
5.9
15.0
|
L
 -62.4%
H
5.9
47
|
L
 -96.3%
H
5.9
261.0
|
L
H
5.9
16731
|
L
H
5.9
16731
|
| Amicus Therapeutics Inc |
|
4,531.0
|
14.4
|
L
 0.4%
H
14.4
14.4
|
L
 0.4%
H
14.4
14.4
|
L
 0.6%
H
14.3
14.4
|
L
 1.8%
H
14.2
14.4
|
L
 58.9%
H
5.5
14.4
|
L
 25.0%
H
5.5
14.6
|
L
 40.8%
H
5.5
14.6
|
L
 83.6%
H
4.4
25.4
|
| Frequency Therapeutics Inc |
|
-
|
10.8
|
L
 -2.8%
H
10.5
11.1
|
L
 -16.0%
H
10.5
13.7
|
L
 -3.2%
H
10.5
14.8
|
L
 36.4%
H
7.7
14.9
|
L
 -28.9%
H
5.2
55.9
|
L
 -56.2%
H
5.2
55.9
|
L
 -99.4%
H
5.2
1870
|
L
H
5.2
2918.5
|
| Fulcrum Therapeutics Inc |
|
450.9
|
6.8
|
L
 -3.8%
H
6.7
7.2
|
L
 -11.5%
H
6.7
8
|
L
 -38.5%
H
6.7
11.4
|
L
 -44.9%
H
6.7
12.9
|
L
 124.2%
H
2.3
15.7
|
L
 96.2%
H
2.3
15.7
|
L
 -40.4%
H
2.3
33.1
|
L
H
2.3
33.1
|
| First Wave BioPharma Inc |
|
3.2
|
2.1
|
L
 -1.9%
H
2.0
2.1
|
L
 -9.3%
H
2.0
2.6
|
L
 -20.5%
H
2.0
2.8
|
L
 -12.0%
H
2.0
5.3
|
L
 388.1%
H
0.4
5.8
|
L
 -96.7%
H
0.4
73
|
L
 -100.0%
H
0.4
62580.4
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
177.3
|
2.8
|
L
 -1.8%
H
2.7
2.9
|
L
 -11%
H
2.6
3.3
|
L
 -7.4%
H
2.6
3.5
|
L
 -37.2%
H
2.6
4.4
|
L
 79.7%
H
1.1
7.1
|
L
 38.2%
H
0.7
7.1
|
L
 22.2%
H
0.7
7.1
|
L
 103.7%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
75.0
|
2.0
|
L
 2.6%
H
1.9
2.0
|
L
 -19.8%
H
1.9
2.7
|
L
 0.5%
H
1.9
3.1
|
L
 -32.3%
H
1.6
3.5
|
L
 -14.9%
H
1.4
4.3
|
L
 -60.2%
H
0.9
6.2
|
L
 -84.0%
H
0.9
17.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
12.9
|
1.1
|
L
 4.8%
H
1
1.1
|
L
 3.8%
H
1
1.1
|
L
 4.8%
H
1.0
1.1
|
L
 -22.0%
H
0.7
1.6
|
L
 -58.7%
H
0.7
3.7
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
935.2
|
1.5
|
L
 -5.8%
H
1.5
1.6
|
L
 -7.6%
H
1.4
1.7
|
L
 -22.3%
H
1.4
2.0
|
L
 9.8%
H
1.3
2.0
|
L
 -16.6%
H
1.0
2.0
|
L
 -40.7%
H
1.0
5.3
|
L
 -20.2%
H
1.0
5.3
|
L
 -49.0%
H
0.8
7.0
|
| GH Research PLC |
|
866.6
|
14.0
|
L
 -5.7%
H
13.9
14.9
|
L
 -6.6%
H
13.9
15.6
|
L
 -10.5%
H
13.9
16.5
|
L
 7.8%
H
12.2
19
|
L
 15.7%
H
8.0
19.5
|
L
 101.0%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Gilead Sciences |
|
170,335.3
|
137.2
|
L
 -2.8%
H
136.5
141
|
L
 -5.4%
H
136.5
146.7
|
L
 -9.4%
H
136.5
152.5
|
L
 10.4%
H
116.9
157.3
|
L
 29.6%
H
93.4
157.3
|
L
 72.7%
H
62.1
157.3
|
L
 112.9%
H
57.2
157.3
|
L
 52.0%
H
56.6
157.3
|
| Galmed Pharma Ltd |
|
3.9
|
0.6
|
L
 3.5%
H
0.6
0.6
|
L
 -4.8%
H
0.6
0.7
|
L
 11.1%
H
0.5
0.7
|
L
 -29.4%
H
0.5
0.9
|
L
 -73.8%
H
0.5
2.7
|
L
 -99.2%
H
0.2
93.6
|
L
 -99.9%
H
0.2
734.4
|
L
 -99.9%
H
0.2
4870.8
|
| Greenwich LifeSciences Inc |
|
333.9
|
24.1
|
L
 -6.9%
H
23.9
26.3
|
L
 -9.9%
H
23.9
30.3
|
L
 0.2%
H
21.6
30.3
|
L
 85.2%
H
13.1
34.1
|
L
 112.5%
H
7.8
34.1
|
L
 91.1%
H
7.6
34.1
|
L
 -19.7%
H
6.8
69.8
|
L
H
3.3
158.1
|
| Galecto Inc |
|
1,092.8
|
18.1
|
L
 -5.5%
H
16.5
20.4
|
L
 -31.1%
H
16.5
27.2
|
L
 -39.5%
H
16.5
34.0
|
L
 -33.2%
H
16.5
38.3
|
L
 338.2%
H
2.0
38.3
|
L
 835.1%
H
0.5
38.3
|
L
 156.6%
H
0.5
38.3
|
L
H
0.5
38.3
|
| Monte Rosa Therapeutics Inc |
|
1,337.1
|
15.6
|
L
 -2.7%
H
15.6
16.3
|
L
 -2.4%
H
15.4
16.9
|
L
 -17.7%
H
15.4
20.4
|
L
 0.6%
H
13.7
25.8
|
L
 121.4%
H
3.5
25.8
|
L
 125.2%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| GlycoMimetics Inc |
|
703.4
|
10.9
|
L
 2.6%
H
10.6
11.1
|
L
 -2.5%
H
9.9
11.8
|
L
 -6.4%
H
9.9
13.5
|
L
 -8.0%
H
8.7
14.7
|
L
 -59.8%
H
8.7
28.8
|
L
 -92.4%
H
8.7
353
|
L
 -96.8%
H
8.7
416
|
L
 -98.2%
H
8.7
2605
|
| Genelux Corp |
|
107.3
|
2.4
|
L
 -5.5%
H
2.3
2.5
|
L
 -7.7%
H
2.3
2.8
|
L
 -9.1%
H
2.3
3.0
|
L
 -42.9%
H
2.3
5.0
|
L
 -39.7%
H
2.0
8.5
|
L
 -91.4%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
4.3
|
1.9
|
L
 -2.1%
H
1.8
2.0
|
L
 -6.5%
H
1.8
2.1
|
L
 5.6%
H
1.8
2.6
|
L
 -11.7%
H
1.7
3.6
|
L
 394.7%
H
0.1
13.0
|
L
 147.4%
H
0.1
13.0
|
L
 -63.0%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
98.6
|
0.4
|
L
 -6.7%
H
0.4
0.5
|
L
 -4.6%
H
0.4
0.5
|
L
 -80.3%
H
0.3
0.6
|
L
 -87.8%
H
0.3
3.8
|
L
 -68.9%
H
0.3
3.9
|
L
 -65.3%
H
0.3
3.9
|
L
 -95.5%
H
0.3
15.2
|
L
H
0.3
27.2
|
| Geovax Labs Inc |
|
3.3
|
1.5
|
L
 2.8%
H
1.3
1.5
|
L
 -14.5%
H
1.3
1.8
|
L
 -3.9%
H
1.3
2.0
|
L
 -63.1%
H
1.3
5.6
|
L
 -95.6%
H
1.3
35.2
|
L
 -99.4%
H
1.3
296.3
|
L
 -99.9%
H
1.3
2812.5
|
L
 -100.0%
H
1.3
379518072.3
|
| Graphite Bio Inc |
|
610.3
|
10.5
|
L
 -8.8%
H
10.4
11.5
|
L
 -13.7%
H
10.4
12.7
|
L
 -9.6%
H
10.4
15.0
|
L
 -41.8%
H
10.4
21.8
|
L
 -60.9%
H
10.4
50.4
|
L
 -91.2%
H
10.4
413
|
L
H
10.4
1666
|
L
H
10.4
1666
|
| GT Biopharma Inc |
|
14.5
|
0.5
|
L
 9.5%
H
0.4
0.5
|
L
 9.5%
H
0.4
0.5
|
L
H
0.4
0.5
|
L
 -39.5%
H
0.4
0.9
|
L
 -79.7%
H
0.4
3.9
|
L
 -16.4%
H
0.2
10.7
|
L
 -93.0%
H
0.2
19.7
|
L
 -100.0%
H
0.2
4845
|
| Galapagos NV (ADR) |
|
2,109.4
|
32.0
|
L
 -1.6%
H
31.8
32.6
|
L
 1.0%
H
31.8
33.4
|
L
 -5.2%
H
31.6
36.2
|
L
 -1.1%
H
31.6
36.2
|
L
 24.5%
H
22.6
37.8
|
L
 -15.7%
H
22.4
45.2
|
L
 -61.1%
H
22.4
83.8
|
L
 -23.7%
H
22.4
274.0
|
| Genmab (ADR) |
|
15,409.2
|
25.1
|
L
 -2.5%
H
25.0
25.7
|
L
 -4.0%
H
25.0
26.8
|
L
 -14.3%
H
25.0
29.9
|
L
 -22.5%
H
25.0
35.4
|
L
 26.5%
H
17.2
35.4
|
L
 -30.2%
H
17.2
43
|
L
 -22.5%
H
17.2
49.1
|
L
 102.4%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
14.8
|
0.6
|
L
 1.6%
H
0.6
0.7
|
L
 -28.4%
H
0.6
0.9
|
L
 -37%
H
0.6
1.1
|
L
 -56.6%
H
0.6
1.7
|
L
 -83.9%
H
0.6
10
|
L
 -89.8%
H
0.6
10
|
L
H
0.6
13.1
|
L
H
0.6
13.1
|
| Grifols SA (ADR) - Level III |
|
5,158.8
|
7.6
|
L
 -2.5%
H
7.5
7.8
|
L
 -2.9%
H
7.5
8.1
|
L
 -19.4%
H
7.5
9.3
|
L
 -16.0%
H
7.5
9.8
|
L
 -4.1%
H
6.2
11.1
|
L
 13.8%
H
5.3
12.2
|
L
 -52.9%
H
5.3
19.1
|
L
 -50.0%
H
5.3
25.7
|
| Halozyme Therapeutics Inc |
|
7,485.8
|
63.4
|
L
 0.3%
H
62.5
63.8
|
L
 -0.4%
H
62.5
65.8
|
L
 -10.6%
H
62.5
71.5
|
L
 -5.8%
H
62.5
82.2
|
L
 -1.4%
H
47.5
82.2
|
L
 82.2%
H
29.9
82.2
|
L
 43.7%
H
29.9
82.2
|
L
 656.0%
H
7.7
82.2
|
| HCW Biologics Inc |
|
4.3
|
0.7
|
L
 -1.3%
H
0.7
0.8
|
L
 42.3%
H
0.7
1.2
|
L
 27.6%
H
0.5
1.2
|
L
 -52.9%
H
0.5
1.7
|
L
 -93.8%
H
0.2
17.8
|
L
 -98.3%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
39.0
|
3.3
|
L
 -1.8%
H
3.3
3.4
|
L
 -18.4%
H
3.2
4.4
|
L
 -29.1%
H
3.2
5.3
|
L
 43.1%
H
2.4
5.8
|
L
 149.6%
H
1.1
9.1
|
L
 -84.4%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Hoth Therapeutics Inc |
|
14.3
|
0.9
|
L
H
0.9
1.0
|
L
 -10.7%
H
0.9
1.1
|
L
 -12.4%
H
0.9
1.3
|
L
 -15.6%
H
0.8
1.3
|
L
 -14.0%
H
0.7
2.1
|
L
 -55.3%
H
0.6
4.3
|
L
 -98.3%
H
0.6
78.8
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
38.3
|
0.8
|
L
 -2.5%
H
0.8
0.8
|
L
 1.3%
H
0.8
0.9
|
L
 17.9%
H
0.5
0.9
|
L
 14.5%
H
0.5
0.9
|
L
 -27.5%
H
0.5
2.4
|
L
 -67.4%
H
0.5
8.2
|
L
H
0.5
24.0
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,603.3
|
27.7
|
L
 -0.3%
H
27.5
28.0
|
L
 0.4%
H
27.1
28.9
|
L
 -4.9%
H
25.9
29.4
|
L
 -26.7%
H
25.9
39.6
|
L
 -20.6%
H
25.5
40.9
|
L
 -36.9%
H
18.6
45.1
|
L
 -11.6%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,239.0
|
33.3
|
L
 -3.3%
H
33.1
34.9
|
L
 -2.4%
H
33.1
35.6
|
L
 -36%
H
33.1
54.5
|
L
 -28.3%
H
33.1
54.9
|
L
 18.5%
H
20.9
54.9
|
L
 91.8%
H
7.6
59.2
|
L
 351.6%
H
5.4
59.2
|
L
 666.8%
H
1.4
59.2
|
| Heron Therapeutics Inc |
|
147.1
|
0.8
|
L
 -4.9%
H
0.8
0.8
|
L
 -11.4%
H
0.8
0.9
|
L
 -33.9%
H
0.8
1.3
|
L
 -40%
H
0.8
1.6
|
L
 -67.5%
H
0.8
2.6
|
L
 -62.5%
H
0.5
3.9
|
L
 -95.0%
H
0.5
19.0
|
L
 -95.4%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
8.6
|
2.2
|
L
 -5.1%
H
2.2
2.4
|
L
 -9.7%
H
2.2
2.5
|
L
 -39.3%
H
2.1
3.9
|
L
 -74.8%
H
2.1
11.5
|
L
 -66.8%
H
2.1
38.3
|
L
 -97.6%
H
2.1
136.5
|
L
 -98.5%
H
2.1
146.3
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
150.5
|
0.8
|
L
 -8.2%
H
0.7
0.9
|
L
 -32.8%
H
0.7
1.2
|
L
 -31.0%
H
0.7
1.3
|
L
 -29.7%
H
0.7
1.3
|
L
 -75.5%
H
0.7
3.4
|
L
 -70.9%
H
0.7
10.0
|
L
 -92.8%
H
0.7
17.5
|
L
H
0.7
17.5
|
| HUTCHMED (China) Ltd (ADR) |
|
2,396.3
|
13.9
|
L
 0.9%
H
13.7
14.0
|
L
 -0.3%
H
13.7
14.5
|
L
 -8.8%
H
13.1
15.2
|
L
 2.9%
H
13.1
16.3
|
L
 -13.6%
H
11.5
19.5
|
L
 3.8%
H
10.7
21.9
|
L
 -52.0%
H
7.4
43.9
|
L
 3.3%
H
7.4
43.9
|
| ImmunityBio Inc |
|
8,708.1
|
8.5
|
L
 -4.0%
H
8.4
9.3
|
L
 1.0%
H
8.0
9.3
|
L
 -2.6%
H
7.8
12.4
|
L
 307.2%
H
2.0
12.4
|
L
 208%
H
1.8
12.4
|
L
 527.4%
H
1.3
12.4
|
L
 -76.2%
H
1.2
39.6
|
L
H
1.2
40.8
|
| Immucell Corp |
|
54.9
|
6.1
|
L
 -1.3%
H
6
6.3
|
L
 -4.7%
H
6
6.5
|
L
 -5.5%
H
6
6.7
|
L
 1.7%
H
5.8
7.1
|
L
 23.1%
H
4.5
7.6
|
L
 16.7%
H
3.3
7.6
|
L
 -45.6%
H
3.3
11.5
|
L
 -12.2%
H
3.3
13.2
|
| Ideaya Biosciences Inc |
|
2,875.9
|
32.8
|
L
 0.5%
H
32.2
33.5
|
L
 -1.0%
H
32.2
35.3
|
L
 2.4%
H
31
35.7
|
L
 -2.4%
H
29.5
39.3
|
L
 77.6%
H
13.5
39.3
|
L
 118.9%
H
13.3
47.7
|
L
 45.0%
H
8.1
47.7
|
L
H
3.0
47.7
|
| InflaRx N.V. |
|
63.7
|
0.9
|
L
 3.3%
H
0.9
1
|
L
 -1.1%
H
0.8
1.0
|
L
 4.4%
H
0.8
1.0
|
L
 -15.3%
H
0.8
1.2
|
L
 -25.4%
H
0.7
1.9
|
L
 -43.7%
H
0.7
7.3
|
L
 -79.6%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
63.6
|
5.7
|
L
H
5.5
5.9
|
L
 -3.7%
H
5.4
6.5
|
L
 -18.7%
H
5.4
7.2
|
L
 -7.9%
H
5.4
7.6
|
L
 -63.8%
H
5.4
18
|
L
 -87.2%
H
5.4
91.7
|
L
H
5.4
451.3
|
L
H
5.4
451.3
|
| Inhibikase Therapeutics Inc |
|
218.3
|
1.8
|
L
 -1.6%
H
1.8
1.9
|
L
 -10%
H
1.8
2.1
|
L
 2.3%
H
1.8
2.3
|
L
 4.7%
H
1.5
2.3
|
L
 -25.6%
H
1.3
2.5
|
L
 -50%
H
0.8
4.9
|
L
 -94.8%
H
0.8
41.8
|
L
H
0.8
70.8
|
| Illumina Inc |
|
19,010.1
|
124.3
|
L
 -1.8%
H
123
128.2
|
L
 4.5%
H
117.5
128.2
|
L
 5.7%
H
115.3
134.8
|
L
 -7.8%
H
112.7
155.5
|
L
 46.6%
H
68.7
155.5
|
L
 -43.4%
H
68.7
233.4
|
L
 -70.1%
H
68.7
526
|
L
 -17.2%
H
68.7
555.8
|
| IM Cannabis Corp |
|
3.7
|
0.6
|
L
 -4.6%
H
0.6
0.7
|
L
 -31.1%
H
0.5
0.9
|
L
 -34.7%
H
0.5
1.1
|
L
 -60.3%
H
0.5
1.6
|
L
 -65.2%
H
0.5
7.1
|
L
 -85.2%
H
0.4
8.6
|
L
 -99.9%
H
0.4
504
|
L
H
0.4
697.8
|
| Immix Biopharma Inc |
|
482.4
|
9.1
|
L
 -5.9%
H
8.9
10.1
|
L
 -8.9%
H
8.9
11.6
|
L
 13.9%
H
7.8
11.6
|
L
 59.3%
H
4.2
11.6
|
L
 400.6%
H
1.3
11.6
|
L
 414.7%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immunome Inc |
|
2,263.8
|
20.0
|
L
 -3.9%
H
20.0
21.3
|
L
 -1.7%
H
20.0
21.3
|
L
 -6.9%
H
19.8
22.9
|
L
 -6.7%
H
19.2
27.7
|
L
 131.1%
H
5.2
27.7
|
L
 254.2%
H
4.4
31.0
|
L
 -44.5%
H
2.1
41.7
|
L
H
2.1
63.8
|
| Imunon Inc |
|
9.8
|
2.9
|
L
 -2.7%
H
2.9
3.1
|
L
 -4.0%
H
2.9
3.2
|
L
 -10.9%
H
2.9
3.6
|
L
 -23.5%
H
2.9
4.2
|
L
 -79.9%
H
2.9
47.4
|
L
 -85.5%
H
2.9
54.8
|
L
 -99.4%
H
2.9
486
|
L
 -99.9%
H
2.9
5607
|
| Immuneering Corp (Class A) |
|
324.6
|
5.0
|
L
 3.3%
H
4.8
5.0
|
L
 -0.6%
H
4.7
5.1
|
L
 0.4%
H
4.7
5.8
|
L
 -11.2%
H
4.0
8.5
|
L
 204.2%
H
1.1
10.1
|
L
 -36.1%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immatics N.V |
|
1,264.5
|
9.4
|
L
 -2.9%
H
9.3
9.9
|
L
 2.1%
H
9.3
10.3
|
L
 -6.3%
H
9.1
10.6
|
L
 -8.2%
H
8.6
10.9
|
L
 77.9%
H
3.3
12.4
|
L
 27.8%
H
3.3
13.8
|
L
 -33.5%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunic Inc |
|
143.5
|
1.1
|
L
 -5.2%
H
1.1
1.2
|
L
 -6.0%
H
1.1
1.3
|
L
 17.0%
H
0.8
1.5
|
L
 93.0%
H
0.5
1.5
|
L
 -3.5%
H
0.5
1.5
|
L
 -34.1%
H
0.5
3.1
|
L
 -93.0%
H
0.5
17.0
|
L
 -99.7%
H
0.5
390
|
| Immunovant Inc |
|
4,677.2
|
23.0
|
L
 -2.8%
H
22.8
24.0
|
L
 -5.9%
H
22.8
25.4
|
L
 -13.6%
H
22.8
29.3
|
L
 -13.9%
H
22.8
29.3
|
L
 16.7%
H
12.7
29.3
|
L
 37.6%
H
12.7
45.6
|
L
 35.2%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
19.7
|
2
|
L
 16.3%
H
1.7
2.0
|
L
 5.8%
H
1.7
2.1
|
L
 29.0%
H
1.5
2.1
|
L
 65.3%
H
1.2
2.7
|
L
 769.6%
H
0.1
4.2
|
L
 66.7%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
2,886.3
|
60.9
|
L
 -6.1%
H
60.2
64.3
|
L
 -11.4%
H
60.2
72.7
|
L
 -22.5%
H
60.2
82.6
|
L
 -29.3%
H
60.2
94.6
|
L
 332.1%
H
10.8
94.6
|
L
 182.4%
H
10.8
94.6
|
L
 174.9%
H
7.7
94.6
|
L
H
7.7
94.6
|
| Incyte |
|
18,066.5
|
90.8
|
L
 -2.3%
H
90.3
93.3
|
L
 -1.9%
H
90.3
94.9
|
L
 -10.4%
H
90.3
103.2
|
L
 -11.6%
H
90.3
112.3
|
L
 49.9%
H
53.6
112.3
|
L
 22.3%
H
50.3
112.3
|
L
 14.4%
H
50.3
112.3
|
L
 39.5%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
3.8
|
1.7
|
L
 -3.4%
H
1.6
1.8
|
L
 -4.0%
H
1.6
2.0
|
L
 -15.8%
H
1.6
2.2
|
L
 -16.3%
H
1.5
3.7
|
L
 123.7%
H
0.3
13.4
|
L
 1.2%
H
0.3
13.4
|
L
 -90.9%
H
0.3
28.8
|
L
 -99.5%
H
0.3
8800
|
| Indivior PLC |
|
3,664.4
|
29.3
|
L
 -3.9%
H
28.6
30.7
|
L
 -5.8%
H
28.6
32.2
|
L
 -13.5%
H
28.6
35.4
|
L
 -16.8%
H
28.6
37.7
|
L
 202.7%
H
8.6
38
|
L
 74.8%
H
7.3
38
|
L
 1593.6%
H
1.6
38
|
L
 1162.9%
H
0.4
38
|
| MiNK Therapeutics Inc |
|
44.2
|
9.4
|
L
 -3.4%
H
9.3
9.6
|
L
 -3.4%
H
8.9
10.1
|
L
 -17.2%
H
8.9
16.9
|
L
 -18.8%
H
8.9
16.9
|
L
 11.9%
H
6.3
76
|
L
 -54.8%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| InMed Pharma Inc |
|
2.4
|
0.8
|
L
H
0.7
0.8
|
L
 6.5%
H
0.7
0.9
|
L
 -4.7%
H
0.7
1.0
|
L
 -31.1%
H
0.7
1.4
|
L
 -70.7%
H
0.7
8.0
|
L
 -97.2%
H
0.7
41.6
|
L
 -100.0%
H
0.7
2095
|
L
 -100.0%
H
0.7
32175
|
| INmune Bio Inc |
|
31.1
|
1.2
|
L
 -4.1%
H
1.2
1.3
|
L
 -10.7%
H
1.2
1.4
|
L
 -10.7%
H
1.2
1.5
|
L
 -36.1%
H
1.2
1.9
|
L
 -85.6%
H
1.2
11.6
|
L
 -81.1%
H
1.2
14.7
|
L
 -91.6%
H
1.2
30.4
|
L
H
1.2
30.4
|
| Inovio Pharma Inc |
|
109.0
|
1.6
|
L
 -4.2%
H
1.6
1.7
|
L
 -4.8%
H
1.6
1.7
|
L
 -8.7%
H
1.6
2.0
|
L
 -30.7%
H
1.5
2.4
|
L
 -18.6%
H
1.3
3.0
|
L
 47.7%
H
0.3
14.8
|
L
 -84.4%
H
0.3
14.8
|
L
 -77.8%
H
0.3
33.8
|
| Insmed Inc |
|
29,315.1
|
136
|
L
 -5.6%
H
135.7
143.6
|
L
 -2.5%
H
135.7
147.4
|
L
 -17.5%
H
135.7
167
|
L
 -22.2%
H
135.7
186.2
|
L
 72.7%
H
60.4
212.8
|
L
 699.1%
H
16.0
212.8
|
L
 262.5%
H
16.0
212.8
|
L
 1046.7%
H
9.0
212.8
|
| Innoviva Inc |
|
1,607.4
|
21.7
|
L
 -1.8%
H
21.6
22.3
|
L
 -1.5%
H
21.6
22.4
|
L
 -7.2%
H
21.6
25.1
|
L
 8.6%
H
19
25.1
|
L
 26.1%
H
16.5
25.1
|
L
 93.9%
H
11.0
25.1
|
L
 77.0%
H
10.6
25.1
|
L
 77.4%
H
7.6
25.1
|
| IO Biotech Inc |
|
13.0
|
0.2
|
L
 -5.3%
H
0.2
0.2
|
L
 -5.3%
H
0.1
0.2
|
L
 -47.1%
H
0.1
0.4
|
L
 -72.7%
H
0.1
0.8
|
L
 -81.1%
H
0.1
2.8
|
L
 -90.9%
H
0.1
2.8
|
L
H
0.1
17.9
|
L
H
0.1
17.9
|
| Ionis Pharma Inc |
|
11,727.0
|
71.0
|
L
 -0.5%
H
70.5
72.6
|
L
 -0.3%
H
70.5
73.3
|
L
 -14.6%
H
70.4
85.5
|
L
 -10.8%
H
70.4
86.7
|
L
 116.9%
H
24.0
86.7
|
L
 99.4%
H
24.0
86.7
|
L
 31.0%
H
24.0
86.7
|
L
 83.7%
H
19.6
86.7
|
| Iovance Biotherapeutics Inc |
|
1,520.1
|
3.7
|
L
 -4.7%
H
3.6
4.0
|
L
 -6.8%
H
3.6
4.1
|
L
 28.6%
H
2.8
5.6
|
L
 48.8%
H
2.2
5.6
|
L
 4.2%
H
1.6
5.6
|
L
 -41.7%
H
1.6
18.3
|
L
 -88.2%
H
1.6
34.0
|
L
 -26.2%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
434.9
|
2.4
|
L
 -2.8%
H
2.4
2.7
|
L
 3.4%
H
2.2
2.7
|
L
 17.5%
H
2.0
3.0
|
L
 168.9%
H
0.8
3.0
|
L
 340%
H
0.3
3.0
|
L
 -38.6%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,219.8
|
58.2
|
L
 -1.7%
H
58.1
60.6
|
L
 -3.1%
H
57.7
62.4
|
L
 -5.2%
H
57.7
69.4
|
L
 -27.3%
H
40
83.9
|
L
 9.3%
H
30.8
99.5
|
L
 169.2%
H
18.3
99.5
|
L
 -66.2%
H
11.6
178.3
|
L
H
11.6
190.9
|
| Ironwood Pharma Inc (Class A) |
|
495.7
|
3.0
|
L
 -5.9%
H
3.0
3.3
|
L
 -9.8%
H
3.0
3.5
|
L
 -23.2%
H
3.0
4.0
|
L
 -2.9%
H
3.0
5.8
|
L
 98.7%
H
0.5
5.8
|
L
 -70.9%
H
0.5
15.7
|
L
 -73.0%
H
0.5
15.7
|
L
 -64.6%
H
0.5
17.7
|
| Iterum Therapeutics PLC |
|
8.5
|
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -23.8%
H
0.1
0.3
|
L
 -56.8%
H
0.1
0.4
|
L
 -89.0%
H
0.1
1.5
|
L
 -85.5%
H
0.1
3.0
|
L
 -99.4%
H
0.1
37.8
|
L
H
0.1
195
|
| Invivyd Inc |
|
390.0
|
1.4
|
L
 -4.8%
H
1.4
1.5
|
L
 -20.7%
H
1.4
1.9
|
L
 -11.0%
H
1.4
2.0
|
L
 -40%
H
1.4
3.0
|
L
 86.5%
H
0.5
3.1
|
L
 -10.4%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| I-Mab (ADR) |
|
295.1
|
2.6
|
L
 -4.8%
H
2.5
2.8
|
L
 -9.5%
H
2.5
3.1
|
L
 -22.2%
H
2.5
3.9
|
L
 -38.9%
H
2.5
5.2
|
L
 197.7%
H
0.6
6.8
|
L
 -28.1%
H
0.6
6.8
|
L
 -95.2%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immunocore Holdings PLC (ADR) |
|
1,516.3
|
29.9
|
L
 -0.4%
H
29.5
30.8
|
L
 -3.1%
H
29.5
31.2
|
L
 -8.5%
H
29.5
34.9
|
L
 -16.9%
H
29.5
37.3
|
L
 -1.7%
H
23.2
40.7
|
L
 -41.4%
H
23.2
77.0
|
L
 -31.1%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
58.9
|
0.4
|
L
 -2.4%
H
0.4
0.4
|
L
 -16.7%
H
0.4
0.5
|
L
 -85.7%
H
0.4
3.0
|
L
 -84.8%
H
0.4
3.3
|
L
 -79.0%
H
0.4
3.5
|
L
 -77.8%
H
0.4
3.9
|
L
 -86.6%
H
0.4
5.4
|
L
 -87.1%
H
0.4
8.0
|
| Immuron Ltd (ADR) |
|
5.7
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -10.3%
H
0.7
0.8
|
L
 -2.8%
H
0.7
0.9
|
L
 -25.5%
H
0.7
1.3
|
L
 -61.3%
H
0.7
2.4
|
L
 -63.0%
H
0.7
6.0
|
L
 -89.1%
H
0.7
6.7
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
109.7
|
1.2
|
L
 -7.9%
H
1.2
1.3
|
L
 -22%
H
1.2
1.5
|
L
 -27.8%
H
1.2
1.8
|
L
 -33.1%
H
1.2
1.9
|
L
 -41.5%
H
1.2
2.6
|
L
 -61.3%
H
1.2
3.6
|
L
 -74%
H
1.2
12.0
|
L
H
1.2
12.0
|
| Inventiva (ADR) |
|
1,200.2
|
5.8
|
L
 -4.3%
H
5.7
6.1
|
L
 -3.5%
H
5.7
6.3
|
L
 -14.4%
H
5.7
7.1
|
L
 37.3%
H
4.2
7.3
|
L
 96.6%
H
2.7
8.0
|
L
 35.4%
H
1.5
8.0
|
L
 -53.9%
H
1.5
16.9
|
L
H
1.5
19.1
|
| Jaguar Health Inc |
|
4.7
|
0.4
|
L
H
0.4
0.4
|
L
 -16%
H
0.4
0.5
|
L
 -31.2%
H
0.4
1.0
|
L
 -64.1%
H
0.4
1.9
|
L
 -93.3%
H
0.4
15.5
|
L
 -99.1%
H
0.4
76.2
|
L
 -100.0%
H
0.4
30780
|
L
 -100.0%
H
0.4
999999
|
| Janux Therapeutics Inc |
|
855.3
|
14.1
|
L
 -0.7%
H
13.8
14.3
|
L
 3.5%
H
13.6
14.4
|
L
 7.5%
H
13.0
14.5
|
L
 2.0%
H
12.1
15.5
|
L
 -53.8%
H
12.1
35.3
|
L
 20.2%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jazz Pharma PLC |
|
11,119.0
|
180.6
|
L
 -0.7%
H
179.2
184
|
L
 1.2%
H
178.3
184.7
|
L
 4.9%
H
169.4
198
|
L
 8.2%
H
157.0
198
|
L
 28.5%
H
95.5
198
|
L
 30.9%
H
95.5
198
|
L
 4.8%
H
95.5
198
|
L
 52.7%
H
86.9
198
|
| Jasper Therapeutics Inc |
|
34.4
|
1.2
|
L
 0.8%
H
1.2
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 -6.8%
H
1.2
1.5
|
L
 -33.9%
H
1.1
2.1
|
L
 -76.8%
H
1.1
7.2
|
L
 -37.9%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kala Pharma Inc |
|
218.7
|
0.2
|
L
 -4%
H
0.2
0.3
|
L
 -14.3%
H
0.2
0.3
|
L
 -36.8%
H
0.2
0.5
|
L
 -61.3%
H
0.2
0.7
|
L
 -96.5%
H
0.2
20.6
|
L
 -98.1%
H
0.2
20.6
|
L
 -99.9%
H
0.2
419.2
|
L
H
0.2
1337.5
|
| KalVista Pharma Inc |
|
859.3
|
17
|
L
 3.5%
H
16.3
17.2
|
L
 0.4%
H
15.1
17.4
|
L
 7.4%
H
15.1
18.7
|
L
 11.6%
H
14.2
19
|
L
 41.7%
H
9.2
19
|
L
 142.2%
H
6.3
19
|
L
 -47.5%
H
4.1
33.4
|
L
 73.6%
H
4.1
45
|
| Kamada Ltd |
|
490.3
|
8.5
|
L
 -1.4%
H
8.4
8.7
|
L
 -2.3%
H
8.4
9.1
|
L
 -3.4%
H
8.4
9.4
|
L
 16.8%
H
6.9
9.4
|
L
 27.8%
H
5.5
9.4
|
L
 100%
H
4.1
9.4
|
L
 33.0%
H
3.7
9.4
|
L
 120.2%
H
3.5
13.3
|
| Kiniksa Pharma Ltd (Class A) |
|
3,526.8
|
46.1
|
L
 1.0%
H
44.6
46.3
|
L
 0.7%
H
44.4
47.8
|
L
 -3.5%
H
41.1
49.1
|
L
 6.7%
H
37.0
49.1
|
L
 93.5%
H
18.3
49.1
|
L
 314.4%
H
10.3
49.1
|
L
 128.8%
H
7.4
49.1
|
L
H
5.0
49.1
|
| Kodiak Sciences Inc |
|
1,358.3
|
22.3
|
L
 -1.8%
H
22.2
23.6
|
L
 -4.1%
H
21.3
24.3
|
L
 -12.0%
H
21.3
28.9
|
L
 -14.4%
H
20.9
31.2
|
L
 593.2%
H
1.9
31.2
|
L
 342.3%
H
1.4
31.2
|
L
 -82.9%
H
1.4
133.7
|
L
H
1.4
171.2
|
| Kiora Pharma Inc |
|
7.7
|
2.1
|
L
 3.0%
H
2
2.1
|
L
H
2.0
2.1
|
L
 5.6%
H
1.9
2.2
|
L
 -3.2%
H
1.9
2.5
|
L
 -34.3%
H
1.8
4.2
|
L
 -38.0%
H
0.4
5.6
|
L
 -99.1%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2400
|
| Karyopharm Therapeutics Inc |
|
140.0
|
7.6
|
L
 -1.3%
H
7.4
9.0
|
L
 -2.8%
H
7.4
9.0
|
L
 -21.1%
H
7.3
11.0
|
L
 9.9%
H
5.9
11.0
|
L
 24.3%
H
3.5
11.0
|
L
 -85.6%
H
0.6
73.1
|
L
 -95.8%
H
0.6
221.0
|
L
 -93.9%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
216.1
|
11.0
|
L
 -1.4%
H
10.7
11.4
|
L
 -0.5%
H
10.6
11.4
|
L
 -32.4%
H
10.5
16.1
|
L
 -45.9%
H
10.5
21.8
|
L
 -4.2%
H
9.1
22.6
|
L
 -74.7%
H
9.1
73
|
L
 -81.5%
H
9.1
73
|
L
H
9.1
88.8
|
| Krystal Biotech Inc |
|
7,357.2
|
251.7
|
L
 -2.5%
H
249.4
263.8
|
L
 1.8%
H
246
263.8
|
L
 -3.9%
H
244.5
277.0
|
L
 4.5%
H
235.6
298.3
|
L
 33.4%
H
122.8
298.3
|
L
 236.4%
H
72.2
298.3
|
L
 228.7%
H
38.9
298.3
|
L
H
8.0
298.3
|
| TuHURA Biosciences Inc |
|
109.6
|
1.9
|
L
 8.4%
H
1.8
2.0
|
L
 2.1%
H
1.8
2.3
|
L
 68.7%
H
1.1
2.3
|
L
 136.6%
H
0.4
2.3
|
L
 -51.5%
H
0.4
4.4
|
L
 -98.5%
H
0.2
209.3
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
190225
|
| Pasithea Therapeutics Corp |
|
18.5
|
0.8
|
L
 2.6%
H
0.8
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
H
0.7
0.9
|
L
 -31.0%
H
0.7
1.3
|
L
 -32.2%
H
0.3
3.8
|
L
 90.5%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kura Oncology Inc |
|
729.6
|
8.3
|
L
 -2.0%
H
8.2
8.6
|
L
 -4.5%
H
8.2
8.8
|
L
 -2.4%
H
7.8
9.6
|
L
 -16.1%
H
7.4
11.3
|
L
 5.2%
H
5.4
12.5
|
L
 -32.7%
H
5.4
24.2
|
L
 -69.3%
H
5.4
30.4
|
L
 90.3%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,360.8
|
77.9
|
L
 -2.1%
H
77.2
81.5
|
L
 -1.4%
H
76.9
82.5
|
L
 -10.9%
H
76.9
95.9
|
L
 -7.2%
H
66.2
95.9
|
L
 134.6%
H
19.4
103
|
L
 153.0%
H
9.6
103
|
L
 74.5%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
47.1
|
6.4
|
L
 -4.0%
H
6.4
6.8
|
L
 -6.1%
H
6.4
7.0
|
L
 -5.9%
H
6.4
7.5
|
L
 1.4%
H
6.0
7.5
|
L
 15.2%
H
3.5
7.5
|
L
 -82.5%
H
0.7
37.4
|
L
 -90.0%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Kazia Therapeutics Ltd (ADR) |
|
84.8
|
7.5
|
L
 -5.4%
H
7.3
8.0
|
L
 -0.1%
H
7.0
8.5
|
L
 21.8%
H
5.6
10.5
|
L
 -31.2%
H
4.9
11.1
|
L
 53.3%
H
2.9
17.4
|
L
 -84.1%
H
2.9
84
|
L
 -98.7%
H
2.9
744.5
|
L
 -98.3%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
17.7
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 1.4%
H
0.7
0.8
|
L
 9.2%
H
0.6
0.9
|
L
 22.4%
H
0.5
0.9
|
L
 -55.1%
H
0.5
1.9
|
L
 -71.9%
H
0.5
6.9
|
L
 -88.2%
H
0.5
12.5
|
L
 -81.8%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
150.7
|
4.0
|
L
 -1.0%
H
3.9
4.1
|
L
 -38.5%
H
3.9
6.5
|
L
 -43.6%
H
3.9
7.5
|
L
 -50%
H
3.9
9.0
|
L
 -38.9%
H
3.9
9.0
|
L
 29.7%
H
2.7
11.5
|
L
 -64.8%
H
1.5
12.9
|
L
 -61.4%
H
1.5
15.6
|
| Lifevantage Corp |
|
59.7
|
4.7
|
L
 -1.3%
H
4.6
4.8
|
L
 -10.0%
H
4.6
5.3
|
L
 -3.7%
H
4.3
5.4
|
L
 -24.7%
H
3.9
6.8
|
L
 -71.3%
H
3.9
16.3
|
L
 35.4%
H
3.0
27.4
|
L
 -49.8%
H
3.0
27.4
|
L
 -49.7%
H
2.9
27.4
|
| Ligand Pharma Inc (Class B) |
|
4,084.1
|
204.8
|
L
 -2.7%
H
204.0
214.3
|
L
 0.9%
H
201.9
214.5
|
L
 11.3%
H
178.7
227.9
|
L
 2.2%
H
175.9
227.9
|
L
 87.2%
H
93.6
227.9
|
L
 185.7%
H
49.3
227.9
|
L
 98.4%
H
46.8
227.9
|
L
 220.7%
H
36.9
227.9
|
| Longeveron Inc (Class A) |
|
28.7
|
1.0
|
L
 -11.7%
H
1.0
1.1
|
L
 1.0%
H
0.8
1.2
|
L
 69.0%
H
0.5
1.2
|
L
 75%
H
0.5
1.2
|
L
 -44.3%
H
0.5
1.9
|
L
 -96.4%
H
0.5
44
|
L
 -98.6%
H
0.5
450
|
L
H
0.5
450
|
| Atyr Pharma Inc |
|
79.4
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -4.7%
H
0.8
0.9
|
L
 -22.1%
H
0.8
1.1
|
L
 8%
H
0.7
1.1
|
L
 -78.5%
H
0.6
7.3
|
L
 -57.8%
H
0.6
7.3
|
L
 -85.6%
H
0.6
13.1
|
L
 -98.9%
H
0.6
90.9
|
| Lixte biotech Holdings Inc |
|
23.8
|
2.7
|
L
 -5.8%
H
2.7
3.0
|
L
 -11.9%
H
2.7
3.2
|
L
 -9.9%
H
2.4
3.3
|
L
 -36.6%
H
2.4
4.3
|
L
 109.2%
H
0.6
6.3
|
L
 -59.7%
H
0.6
9.6
|
L
 -92.7%
H
0.6
49.5
|
L
 -79.2%
H
0.6
110.4
|
| Lipocine Inc |
|
52.2
|
7.2
|
L
 -2.2%
H
6.9
7.3
|
L
 -2.6%
H
6.9
8
|
L
 -27.0%
H
6.9
10.5
|
L
 68.2%
H
4.1
12.4
|
L
 104.3%
H
2.5
12.4
|
L
 29.3%
H
2.3
12.4
|
L
 -74.8%
H
2.3
32.1
|
L
 -95.8%
H
2.3
215.2
|
| Leap Therapeutics Inc |
|
58.7
|
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 20.7%
H
0.6
0.8
|
L
 4.5%
H
0.5
0.8
|
L
 -46.2%
H
0.5
1.3
|
L
 70.7%
H
0.2
3.7
|
L
 -80%
H
0.2
10.2
|
L
 -97.2%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Liquidia Corp |
|
3,208.2
|
36.4
|
L
 -2.5%
H
36.2
37.6
|
L
 -0.7%
H
35.1
37.6
|
L
 8.4%
H
29.1
39.6
|
L
 5.4%
H
29.1
46.7
|
L
 135.8%
H
11.3
46.7
|
L
 412.8%
H
5.7
46.7
|
L
 1214.4%
H
2.3
46.7
|
L
H
2.3
46.7
|
| Larimar Therapeutics Inc |
|
465.1
|
4.5
|
L
 0.5%
H
4.4
4.9
|
L
 -2.4%
H
4.2
4.9
|
L
 51.2%
H
2.7
6.4
|
L
 23.0%
H
2.7
6.4
|
L
 78.9%
H
1.6
6.4
|
L
 -7.0%
H
1.6
13.7
|
L
 -75.4%
H
1.5
18.4
|
L
 -93.9%
H
1.5
148.3
|
| Lisata Therapeutics Inc |
|
45.3
|
5.0
|
L
 -0.2%
H
5
5.0
|
L
 -0.4%
H
5
5.1
|
L
 11.8%
H
4.0
5.1
|
L
 143.2%
H
1.8
5.1
|
L
 119.7%
H
1.8
5.1
|
L
 53.7%
H
1.8
5.1
|
L
 -84.4%
H
1.8
32.1
|
L
 -95.9%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
23.8
|
2.1
|
L
 -1.4%
H
2.0
2.2
|
L
 -10.9%
H
2.0
2.6
|
L
 -18.4%
H
2.0
3.1
|
L
 -34.7%
H
2.0
3.7
|
L
 -42.7%
H
2.0
5.7
|
L
 -54.2%
H
2.0
12.0
|
L
 -90.0%
H
2.0
21.8
|
L
H
2.0
24.8
|
| Lexicon Pharma Inc |
|
660.9
|
1.6
|
L
 -3.7%
H
1.5
1.6
|
L
 -7.7%
H
1.5
1.7
|
L
 6.1%
H
1.4
1.8
|
L
 33.3%
H
1.1
1.8
|
L
 358.8%
H
0.3
1.8
|
L
 -31.0%
H
0.3
3.8
|
L
 -76.7%
H
0.3
6.8
|
L
 -87.2%
H
0.3
19.6
|
| Lyell Immunopharma Inc |
|
445.6
|
19.1
|
L
 -7.9%
H
19.0
21.5
|
L
 -10.0%
H
18.9
22.6
|
L
 -10.7%
H
18.9
27.8
|
L
 -42.6%
H
18.9
45
|
L
 79.4%
H
7.7
45
|
L
 -55.9%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Legend Biotech Corp (ADR) |
|
3,220.1
|
17.4
|
L
 -2.6%
H
17.4
18.8
|
L
 -7.2%
H
17.4
19.3
|
L
 -3.9%
H
17.4
21.6
|
L
 -20.6%
H
16.2
24.1
|
L
 -53.8%
H
16.2
45.3
|
L
 -62.3%
H
16.2
77.3
|
L
 -34.3%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
6.2
|
0.9
|
L
H
0.8
0.9
|
L
 -9.6%
H
0.8
1.0
|
L
 -15%
H
0.8
1.0
|
L
 -22.0%
H
0.5
1.2
|
L
 -41.0%
H
0.5
7
|
L
 -99.7%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Microbot Medical Inc |
|
170.6
|
2.5
|
L
 -2.7%
H
2.5
2.6
|
L
 -5.6%
H
2.5
2.8
|
L
 23.3%
H
2.0
2.9
|
L
 22.1%
H
1.6
2.9
|
L
 53.0%
H
1.4
4.7
|
L
 12.9%
H
0.8
4.7
|
L
 -71.1%
H
0.8
9.6
|
L
 -99.4%
H
0.8
598.4
|
| Moleculin Biotech Inc |
|
10.2
|
2.1
|
L
H
2.0
2.1
|
L
 1.0%
H
2.0
2.2
|
L
 -16.3%
H
1.8
2.7
|
L
 -47.2%
H
1.8
5.3
|
L
 -92.4%
H
1.8
33
|
L
 -99.4%
H
1.8
3318.8
|
L
 -99.9%
H
1.8
3318.8
|
L
H
1.8
21555
|
| Seres Therapeutics Inc |
|
76.9
|
8.5
|
L
 -6.4%
H
8.4
9.1
|
L
 -1.5%
H
8.4
9.5
|
L
 -0.6%
H
8.1
9.6
|
L
 -43.3%
H
7.9
16.4
|
L
 1064.4%
H
0.4
30.0
|
L
 54.8%
H
0.4
30.0
|
L
 -60.4%
H
0.4
30.0
|
L
 -65.7%
H
0.4
38.5
|
| Madrigal Pharma Inc |
|
10,120.2
|
441.2
|
L
 -2.9%
H
438.9
466.9
|
L
 -0.8%
H
427.8
466.9
|
L
 1.4%
H
416.2
466.9
|
L
 -25.4%
H
416.2
615
|
L
 31.6%
H
265
615
|
L
 72.4%
H
119.8
615
|
L
 276.8%
H
52.3
615
|
L
 5373.4%
H
6.6
615
|
| MediWound Ltd |
|
217.9
|
17.0
|
L
 -0.1%
H
16.7
17.3
|
L
 2.3%
H
16.7
17.6
|
L
 -5.1%
H
16.4
18.3
|
L
 -9.6%
H
16.3
19.7
|
L
 -0.5%
H
14.1
22.5
|
L
 55.3%
H
7.1
24
|
L
 -56.2%
H
7.1
43.5
|
L
 -69.1%
H
7.1
62.3
|
| MEI Pharma Inc |
|
42.5
|
1.2
|
L
H
1.2
1.2
|
L
 -0.9%
H
1.2
1.3
|
L
 5.4%
H
1.0
1.3
|
L
 -18.2%
H
1.0
1.7
|
L
 -49.4%
H
1.0
9
|
L
 -75.7%
H
1.0
9
|
L
 -98.5%
H
1.0
78.2
|
L
 -95.1%
H
1.0
102.8
|
| Macrogenics Inc |
|
181.8
|
2.9
|
L
 -1.4%
H
2.8
2.9
|
L
 -4.7%
H
2.8
3.2
|
L
 68.2%
H
1.6
3.5
|
L
 90.7%
H
1.5
3.5
|
L
 36.2%
H
1.0
3.5
|
L
 -57.2%
H
1.0
21.9
|
L
 -90.6%
H
1.0
36.5
|
L
 -82.3%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
2.6
|
0.2
|
L
 -55.6%
H
0.2
0.4
|
L
 -57.9%
H
0.2
0.4
|
L
 -69.8%
H
0.2
0.6
|
L
 -77.5%
H
0.2
1.0
|
L
 -96.3%
H
0.2
5.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
77.8
|
L
 -2.8%
H
75.8
82.5
|
L
 -0.1%
H
75.8
82.5
|
L
 56.9%
H
48.9
88.0
|
L
 83.2%
H
35.8
88.0
|
L
 294.9%
H
16.6
88.0
|
L
 539.5%
H
9.1
88.0
|
L
 -61.0%
H
5.1
227.2
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
579.5
|
7.2
|
L
 -2.0%
H
7.2
7.5
|
L
 -2.6%
H
7.2
7.9
|
L
 -3.4%
H
6.6
8.0
|
L
 -10.3%
H
6.6
8.5
|
L
 -5.9%
H
4.6
9.7
|
L
 31.4%
H
3.5
9.7
|
L
 -55.1%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mirum Pharma Inc |
|
5,340.8
|
88.5
|
L
 -2.4%
H
86.9
91.7
|
L
 -2.4%
H
86.9
96.7
|
L
 -15.8%
H
84.3
109.3
|
L
 13.9%
H
73.8
109.3
|
L
 84.9%
H
36.9
109.3
|
L
 275.0%
H
21.8
109.3
|
L
 350.7%
H
12.8
109.3
|
L
H
6.5
109.3
|
| Milestone Pharma Inc |
|
115.8
|
1.4
|
L
 -20%
H
1.4
1.6
|
L
 -20%
H
1.4
1.8
|
L
 -20%
H
1.4
1.8
|
L
 -36.7%
H
1.4
2.3
|
L
 -30.3%
H
0.6
3.1
|
L
 -59.0%
H
0.6
4.5
|
L
 -80.7%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,167.0
|
16.3
|
L
 -2.5%
H
16.0
16.9
|
L
 -5.0%
H
16.0
17.5
|
L
 -13.3%
H
16.0
19.5
|
L
 21.5%
H
11.1
19.5
|
L
 -60.0%
H
6.0
62.8
|
L
 -23.7%
H
6.0
65.0
|
L
 58.0%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mineralys Therapeutics Inc |
|
1,983.4
|
24.1
|
L
 3.4%
H
22.6
24.4
|
L
 -8.1%
H
22.6
27.0
|
L
 -13.7%
H
22.6
31
|
L
 -34.7%
H
22.6
38.2
|
L
 43.9%
H
10.4
47.7
|
L
 62.1%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Mannkind Corp |
|
761.0
|
2.5
|
L
 -2.0%
H
2.4
2.5
|
L
 -10.8%
H
2.4
2.9
|
L
 -55.4%
H
2.4
5.7
|
L
 -57.7%
H
2.4
6.5
|
L
 -53.0%
H
2.4
6.5
|
L
 -39.3%
H
2.4
7.6
|
L
 -33.6%
H
2.4
7.6
|
L
 -75.3%
H
0.7
11.2
|
| Mind Medicine Inc |
|
1,834.4
|
18.4
|
L
 -1.4%
H
18.2
19.7
|
L
 1.9%
H
17.3
19.7
|
L
 7.4%
H
16.5
19.7
|
L
 44.9%
H
12.6
19.7
|
L
 176.7%
H
4.7
19.7
|
L
 536.7%
H
2.4
19.7
|
L
 -56.0%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
76.8
|
1.6
|
L
 12.2%
H
1.4
1.6
|
L
 15.6%
H
1.4
1.6
|
L
 4%
H
1.3
1.6
|
L
 9.1%
H
1.2
1.9
|
L
 3.3%
H
1.1
2.0
|
L
 -24.6%
H
1.1
2.7
|
L
 -73.1%
H
1.1
5.8
|
L
 -73.3%
H
1.1
14.5
|
| Monopar Therapeutics Inc |
|
368.9
|
55.2
|
L
 -5.9%
H
55.0
58.4
|
L
 -8.5%
H
54.2
64.9
|
L
 -0.4%
H
50.7
64.9
|
L
 -19.6%
H
50.7
76.1
|
L
 23.4%
H
26.1
105
|
L
 310.5%
H
1.4
105
|
L
 56.6%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
22.3
|
1.3
|
L
 1.5%
H
1.3
1.4
|
L
 0.8%
H
1.3
1.5
|
L
 -7.6%
H
1.3
1.7
|
L
 4.7%
H
1.3
2.5
|
L
 7.2%
H
0.8
4.1
|
L
 -24.3%
H
0.7
9.7
|
L
 -94.5%
H
0.7
36.5
|
L
 -98.3%
H
0.7
135.5
|
| Moderna |
|
20,376.6
|
51.4
|
L
 -1.9%
H
50.6
53.0
|
L
 -2.3%
H
50.6
56.5
|
L
 3.0%
H
48.1
59.6
|
L
 52.0%
H
29.1
59.6
|
L
 58.3%
H
22.3
59.6
|
L
 -66.7%
H
22.3
170.5
|
L
 -64.3%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
436.2
|
3.0
|
L
 -1.7%
H
3.0
3.1
|
L
 -3.3%
H
3.0
3.3
|
L
 -3.9%
H
3.0
3.9
|
L
 -13.1%
H
2.9
4.1
|
L
 24.2%
H
1.7
4.1
|
L
 -79.1%
H
1.7
16.6
|
L
 -91.6%
H
1.7
63.6
|
L
H
1.7
63.6
|
| Mannatech Inc |
|
12.8
|
6.8
|
L
 0.3%
H
6.5
6.8
|
L
 2.3%
H
6.1
6.9
|
L
 -5.5%
H
6.1
7.1
|
L
 -16.8%
H
6.1
9.5
|
L
 -31.1%
H
6.1
12.5
|
L
 -60.9%
H
6.1
18.4
|
L
 -61.6%
H
6.1
49.1
|
L
 -66.3%
H
6.1
49.1
|
| MaxCyte Inc |
|
81.1
|
0.8
|
L
 1.3%
H
0.7
0.8
|
L
 -7.3%
H
0.7
0.8
|
L
 2.7%
H
0.7
0.9
|
L
 -49.3%
H
0.6
1.7
|
L
 -75.2%
H
0.6
3.2
|
L
 -81.9%
H
0.6
5.5
|
L
 -87.0%
H
0.6
17.4
|
L
H
0.6
17.4
|
| TNF Pharma Inc |
|
28.8
|
3.7
|
L
 -6.9%
H
3.5
4.0
|
L
 -4.7%
H
3.5
4.6
|
L
 4.3%
H
3.4
5.0
|
L
 -24.8%
H
3.4
6.3
|
L
 -90.0%
H
2.5
44.4
|
L
 -99.9%
H
2.5
7050
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| Mainz Biomed N.V. |
|
6.6
|
0.5
|
L
 -10.2%
H
0.5
0.6
|
L
 -28.4%
H
0.5
0.7
|
L
 -13.1%
H
0.5
0.9
|
L
 -55.8%
H
0.5
1.6
|
L
 -89.0%
H
0.5
4.8
|
L
 -99.8%
H
0.5
268
|
L
H
0.5
1200
|
L
H
0.5
1200
|
| Mesoblast Ltd (ADR) |
|
1,850.3
|
14.4
|
L
 -2.8%
H
14.2
14.9
|
L
 -1.3%
H
14.2
14.9
|
L
 -14.9%
H
13.5
17.3
|
L
 -26.3%
H
13.5
21.5
|
L
 5.0%
H
9.6
21.5
|
L
 354.4%
H
1.0
22
|
L
 53.9%
H
1.0
22
|
L
 40.5%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
171.3
|
4.6
|
L
 -2.4%
H
4.4
4.7
|
L
 8.5%
H
4.2
5.0
|
L
 -8.4%
H
4.1
5.4
|
L
 4.3%
H
4.0
5.4
|
L
 7.8%
H
3.4
5.4
|
L
 -23.7%
H
3.3
12.7
|
L
 -80.8%
H
3.3
32.0
|
L
 -84.6%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
54.1
|
0.3
|
L
 -5.6%
H
0.3
0.4
|
L
 -12.8%
H
0.3
0.4
|
L
 -19.1%
H
0.3
0.4
|
L
 -83%
H
0.2
2.4
|
L
 -86.7%
H
0.2
3.1
|
L
 -54.1%
H
0.2
5.0
|
L
 -91.5%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Natural Alternatives Intl Inc |
|
15.8
|
2.6
|
L
 -2.3%
H
2.5
2.6
|
L
 -5.2%
H
2.5
2.8
|
L
 -2.7%
H
2.5
2.9
|
L
 -20.3%
H
2.3
5.0
|
L
 -29.1%
H
2.3
5.0
|
L
 -71.9%
H
2.3
9.7
|
L
 -84.7%
H
2.3
19.9
|
L
 -78.1%
H
2.3
19.9
|
| NewAmsterdam Pharma Co NV |
|
3,327.4
|
28.9
|
L
 -5.0%
H
28.9
31.4
|
L
 1.1%
H
28.7
31.4
|
L
 -18.7%
H
28.5
36.9
|
L
 -17.6%
H
28.5
37.8
|
L
 20.2%
H
14.1
42
|
L
 129.1%
H
5.6
42
|
L
 189.1%
H
5.6
42
|
L
H
5.6
42
|
| Nature`s Sunshine Products Inc |
|
415.5
|
23.7
|
L
 -1.2%
H
23.3
24.1
|
L
 -3.1%
H
22.7
25.2
|
L
 -11.7%
H
22.7
28.1
|
L
 6.7%
H
20.9
28.1
|
L
 88.5%
H
11.0
28.1
|
L
 121.2%
H
9.8
28.1
|
L
 17.7%
H
7.9
28.1
|
L
 170.0%
H
5.5
28.1
|
| Nautilus biotech Inc |
|
383.5
|
3.0
|
L
 10.2%
H
2.7
3.1
|
L
 30.0%
H
2.3
3.1
|
L
 7.5%
H
2.2
3.1
|
L
 56.2%
H
1.8
3.1
|
L
 203%
H
0.6
3.1
|
L
 31.7%
H
0.6
4.7
|
L
 -77.3%
H
0.6
15.0
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
12,814.4
|
127.7
|
L
 -1.6%
H
126.7
130.2
|
L
 -1.6%
H
126.7
132.3
|
L
 -0.7%
H
126.6
134.8
|
L
 -11.9%
H
122.1
148.6
|
L
 16%
H
84.2
160.2
|
L
 31.3%
H
84.2
160.2
|
L
 38.5%
H
71.9
160.2
|
L
 264.2%
H
33.6
160.2
|
| Minerva Neurosciences Inc |
|
326.3
|
7.5
|
L
 -6.6%
H
7.5
8.2
|
L
 -3.7%
H
7.5
8.8
|
L
 19.5%
H
5.0
8.8
|
L
 86.6%
H
3.8
8.8
|
L
 335.8%
H
1.2
12.5
|
L
 374.2%
H
1.2
13.5
|
L
 -69.1%
H
1.2
28.3
|
L
 -83.7%
H
1.2
126.7
|
| Nektar Therapeutics |
|
2,071.8
|
72.2
|
L
 -3.5%
H
70.8
75.5
|
L
 -1.4%
H
70.8
76.7
|
L
 -2.1%
H
62.5
77
|
L
 54.2%
H
33.4
77
|
L
 451.3%
H
6.5
77
|
L
 417.7%
H
6.2
77
|
L
 -77.8%
H
6.2
339.3
|
L
 -61.8%
H
6.2
1670.4
|
| Nkarta Inc |
|
152.0
|
2.1
|
L
 -1.4%
H
2.1
2.2
|
L
 -5.3%
H
2.1
2.4
|
L
 -8.2%
H
2.1
2.8
|
L
 19.6%
H
1.7
2.8
|
L
 42.7%
H
1.3
2.8
|
L
 -45.1%
H
1.3
16.2
|
L
 -94.7%
H
1.3
43.2
|
L
H
1.3
79.2
|
| NLS Pharmaceutics Ltd |
|
10.8
|
2.4
|
L
 -3.3%
H
2.4
2.5
|
L
 -13.5%
H
2.4
2.8
|
L
 -12.2%
H
2.4
3.1
|
L
 -8.9%
H
1.9
3.3
|
L
 -84.2%
H
1.9
30.8
|
L
 -99.6%
H
1.2
640
|
L
 -99.9%
H
1.2
1772
|
L
H
1.2
2940
|
| Neoleukin Therapeutics Inc |
|
-
|
19.1
|
L
 -0.7%
H
18.5
20
|
L
 -11.4%
H
18.2
22.1
|
L
 8.0%
H
17.6
26.4
|
L
 -7.3%
H
15.9
26.4
|
L
 5.9%
H
14.7
37.3
|
L
 41.3%
H
12.2
37.3
|
L
 -91.9%
H
7.5
268
|
L
 -88.6%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7.4
|
L
 -7.0%
H
7.3
7.9
|
L
 -6.6%
H
7.3
8.0
|
L
 -9.7%
H
7.3
8.4
|
L
 1.5%
H
7.1
8.8
|
L
 3.2%
H
6.2
8.8
|
L
 456.8%
H
0.0
8.8
|
L
 -80.0%
H
0.0
37.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
4.7
|
1.4
|
L
 -4.7%
H
1.4
1.5
|
L
 -12.4%
H
1.4
1.6
|
L
 -9.0%
H
1.3
1.7
|
L
 -83.6%
H
1.3
10
|
L
 -91.7%
H
1.3
23.1
|
L
 -97.6%
H
1.3
83.6
|
L
 -100.0%
H
1.3
17344.8
|
L
H
1.3
1424940
|
| Nurix Therapeutics Inc |
|
1,484.0
|
14.4
|
L
 -3.3%
H
14.4
15.5
|
L
 -4.1%
H
14.4
15.7
|
L
 -8.6%
H
14.4
16.5
|
L
 -22.1%
H
14.4
20.2
|
L
 4.0%
H
8.2
22.5
|
L
 51.6%
H
4.2
29.6
|
L
 -56.4%
H
4.2
37.4
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
25.0
|
0.8
|
L
 -5.1%
H
0.8
0.8
|
L
 -12.8%
H
0.8
1.1
|
L
 -16.7%
H
0.8
1.1
|
L
 -7.4%
H
0.7
1.1
|
L
 -29.9%
H
0.7
2.6
|
L
 -58.8%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
59.0
|
1.9
|
L
 0.5%
H
1.8
1.9
|
L
 -0.5%
H
1.8
2.2
|
L
 0.5%
H
1.6
2.2
|
L
 -21.9%
H
1.6
2.8
|
L
 -10.6%
H
1.6
3.8
|
L
 -73.6%
H
1.1
54
|
L
 -99.4%
H
1.1
570
|
L
H
1.1
769.9
|
| Intellia Therapeutics Inc |
|
1,516.8
|
12.8
|
L
 -2.4%
H
12.8
13.6
|
L
 0.6%
H
12.7
13.7
|
L
 1.6%
H
12.4
15.5
|
L
 39.1%
H
8.9
17.1
|
L
 47.6%
H
5.9
28.3
|
L
 -66.4%
H
5.9
47.5
|
L
 -80.5%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
7,450.5
|
94.8
|
L
 -2.4%
H
94.4
98.7
|
L
 -3.2%
H
94.4
100.9
|
L
 -5.7%
H
94.4
107.6
|
L
 -8.7%
H
94.4
113.0
|
L
 22.1%
H
55.5
113.0
|
L
 216.6%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,567.4
|
9.6
|
L
 -1.2%
H
9.4
10
|
L
 -6.1%
H
9.4
10.9
|
L
 4.6%
H
9.1
12.0
|
L
 44.4%
H
6.6
12.0
|
L
 24.6%
H
5.0
12.0
|
L
 60.9%
H
3.5
23.9
|
L
 -95.8%
H
3.5
277.8
|
L
 -90.5%
H
3.5
331.7
|
| Nuvectis Pharma Inc |
|
218.0
|
8.2
|
L
 1.9%
H
7.8
8.3
|
L
 -8.9%
H
7.8
9.3
|
L
 -2.7%
H
7.8
9.9
|
L
 5.8%
H
7.2
9.9
|
L
 -12.0%
H
5.6
11.5
|
L
 -33.9%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
35.6
|
10.0
|
L
 -0.9%
H
9.6
10.4
|
L
 -21.2%
H
9.6
13
|
L
 -27.2%
H
9.6
14.5
|
L
 -12.2%
H
9.6
14.7
|
L
 35.6%
H
2.8
15.7
|
L
 -48.6%
H
2.8
30.8
|
L
 -93.0%
H
2.8
146.0
|
L
H
2.8
1308
|
| NuCana PLC (ADR) |
|
6.9
|
1.7
|
L
 -3.5%
H
1.6
1.8
|
L
 -13.6%
H
1.6
2
|
L
 -21.4%
H
1.6
2.3
|
L
 -53.7%
H
1.6
3.8
|
L
 -100.0%
H
1.6
53600
|
L
 -100.0%
H
1.6
1750000
|
L
 -100.0%
H
1.6
5660000
|
L
H
1.6
32000000
|
| Ocugen Inc |
|
668.9
|
2.0
|
L
 -8.9%
H
2.0
2.3
|
L
 -17.7%
H
2.0
2.7
|
L
 27.5%
H
1.5
2.7
|
L
 45.7%
H
1.3
2.7
|
L
 251.7%
H
0.6
2.7
|
L
 114.7%
H
0.3
2.7
|
L
 -77.1%
H
0.3
17.7
|
L
 -98.6%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,441.5
|
24.9
|
L
 -2.0%
H
24.5
26.0
|
L
 -2.2%
H
24.5
27.1
|
L
 -14.8%
H
24.5
30.7
|
L
 17.0%
H
19.6
30.7
|
L
 26.6%
H
14
30.7
|
L
 220.8%
H
6.3
30.7
|
L
H
6.3
30.7
|
L
H
6.3
30.7
|
| Ocular Therapeutix Inc |
|
1,780.7
|
8.2
|
L
 -1.1%
H
8.0
8.4
|
L
 -6.6%
H
8.0
9.0
|
L
 5.1%
H
7.7
11.5
|
L
 -34.9%
H
6.2
13.1
|
L
 10.0%
H
5.8
16.4
|
L
 68.3%
H
2
16.4
|
L
 -60.4%
H
2
21.2
|
L
 -9.5%
H
2
24.3
|
| Opus Genetics Inc |
|
312.3
|
4.4
|
L
 -4.2%
H
4.3
4.7
|
L
 -12.7%
H
4.3
5.3
|
L
 29.5%
H
3.3
5.3
|
L
 119.5%
H
1.9
5.3
|
L
 281.7%
H
0.7
5.3
|
L
 17.7%
H
0.7
6.6
|
L
 -39.4%
H
0.7
7.3
|
L
 -97.1%
H
0.7
340.8
|
| Insight Molecular Diagnostics Inc |
|
122.2
|
4.3
|
L
 8.7%
H
3.9
4.3
|
L
 -13.2%
H
3.9
5.0
|
L
 -22.4%
H
3.9
6.2
|
L
 -21.3%
H
3.9
7.5
|
L
 29.1%
H
2.3
8.5
|
L
 -11.3%
H
1.9
8.5
|
L
 -95.6%
H
1.9
125
|
L
 -96.1%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
80.7
|
1.6
|
L
 -3.1%
H
1.5
1.7
|
L
 -5.4%
H
1.5
1.7
|
L
 -7.7%
H
1.5
1.9
|
L
 -22.7%
H
1.5
3.2
|
L
 24.6%
H
1.0
3.4
|
L
 0.6%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Olema Pharma Inc |
|
1,227.2
|
14.1
|
L
 -5.9%
H
14.0
15.0
|
L
 -4.3%
H
14.0
16.8
|
L
 -41.5%
H
13.0
25.3
|
L
 -49.6%
H
13.0
29.5
|
L
 241.8%
H
2.9
36.3
|
L
 290.0%
H
2.9
36.3
|
L
 -68.2%
H
2
43.9
|
L
H
2
60.3
|
| Omeros Corp |
|
779.9
|
11
|
L
 -1.1%
H
10.9
11.2
|
L
 -1.7%
H
10.7
11.4
|
L
 -8.6%
H
10.7
12.1
|
L
 14.6%
H
8.6
17.7
|
L
 20.9%
H
3.0
17.7
|
L
 238.5%
H
0.9
17.7
|
L
 -44.8%
H
0.9
20.5
|
L
 -26.3%
H
0.9
27.1
|
| Oncolytics Biotech Inc |
|
102.2
|
1.0
|
L
 -3.1%
H
0.9
1
|
L
 -3.1%
H
0.9
1.0
|
L
 -1.0%
H
0.9
1.2
|
L
 -5.9%
H
0.8
1.3
|
L
 50.8%
H
0.3
1.5
|
L
 -26.4%
H
0.3
3.4
|
L
 -68.9%
H
0.3
4.8
|
L
 -76.5%
H
0.3
8.5
|
| Traws Pharma Inc |
|
17.1
|
2.1
|
L
 -1.8%
H
2.1
2.2
|
L
 7%
H
1.9
2.2
|
L
 32.9%
H
1.4
2.5
|
L
 67.2%
H
1.1
3.0
|
L
 -25.7%
H
1.0
3.3
|
L
 -87.6%
H
1.0
36.3
|
L
 -99.5%
H
1.0
457.5
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
4.4
|
1.7
|
L
 -5.6%
H
1.7
1.7
|
L
 -6.7%
H
1.7
1.9
|
L
 -16.8%
H
1.7
2.3
|
L
 -15.2%
H
1.7
3.4
|
L
 -54.2%
H
1.4
5.3
|
L
 -92.6%
H
0.3
28.0
|
L
 -98.7%
H
0.3
135
|
L
 -99.7%
H
0.3
1197.6
|
| ORIC Pharma Inc |
|
1,250.0
|
11.2
|
L
 0.5%
H
10.8
11.4
|
L
 -6.2%
H
10.6
12.5
|
L
 0.5%
H
10.6
14.3
|
L
 38.8%
H
7.8
14.3
|
L
 48.6%
H
3.9
14.9
|
L
 148.6%
H
3.9
16.7
|
L
 -57.8%
H
2.4
27.1
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
138.9
|
3.5
|
L
 -3.3%
H
3.5
3.6
|
L
 1.8%
H
3.4
3.7
|
L
 8.4%
H
3.2
3.8
|
L
 19.1%
H
2.8
3.8
|
L
 47.3%
H
1.8
3.8
|
L
 59.4%
H
1.7
5.3
|
L
 -61.9%
H
1.7
31.5
|
L
 -43.4%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
29.1
|
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -10.3%
H
0.3
0.4
|
L
 -14.6%
H
0.3
0.5
|
L
 -82.6%
H
0.3
2.1
|
L
 -76.4%
H
0.3
3.0
|
L
 -99.9%
H
0.3
812
|
L
 -100.0%
H
0.3
1308
|
L
H
0.3
17568
|
| Ovid Therapeutics Inc |
|
186.6
|
2.6
|
L
 13.9%
H
2.4
2.7
|
L
 33.0%
H
1.9
2.7
|
L
 78.2%
H
1.4
2.7
|
L
 78.2%
H
1.4
2.7
|
L
 509.3%
H
0.2
2.7
|
L
 14.4%
H
0.2
4.1
|
L
 -41.4%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
2,057.5
|
50.8
|
L
 -3.1%
H
49.9
52.6
|
L
 2.6%
H
49.9
54.2
|
L
 -3.9%
H
45.2
56.0
|
L
 36.3%
H
36.5
56.3
|
L
 132.7%
H
16.2
56.3
|
L
 241.4%
H
9.4
56.3
|
L
 101.2%
H
9.4
56.3
|
L
 96.6%
H
9.4
56.3
|
| Palisade Bio Inc |
|
282.0
|
1.9
|
L
 -5.0%
H
1.9
2.0
|
L
 -2.6%
H
1.9
2.1
|
L
 18.1%
H
1.6
2.1
|
L
 3.3%
H
1.5
2.6
|
L
 142.3%
H
0.5
2.6
|
L
 -92.7%
H
0.4
54.8
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
1041300
|
| Passage Bio Inc |
|
23.8
|
7.4
|
L
 0.7%
H
7.2
7.5
|
L
 -0.3%
H
6.8
8.1
|
L
 -13.7%
H
6.8
9.8
|
L
 -22.5%
H
6.8
20
|
L
 -22.0%
H
5.1
20
|
L
 -66.5%
H
5.1
35.8
|
L
 -98.1%
H
5.1
399.7
|
L
H
5.1
764.6
|
| Paranovus Entertainment Tech Ltd (Class A) |
|
1.1
|
0.3
|
L
 10.7%
H
0.3
0.3
|
L
 -80.9%
H
0.2
1.4
|
L
 -74.8%
H
0.2
2.4
|
L
 -86.1%
H
0.2
3.0
|
L
 -99.8%
H
0.2
140
|
L
 -99.9%
H
0.2
542.9
|
L
 -100.0%
H
0.2
4360
|
L
H
0.2
12200
|
| Puma biotech Inc |
|
311.4
|
6.1
|
L
 -0.5%
H
6.1
6.2
|
L
 3.7%
H
6.0
6.3
|
L
 -10.4%
H
5.5
7.7
|
L
 8.7%
H
5.5
7.7
|
L
 79.5%
H
2.6
7.7
|
L
 147.8%
H
2.1
7.7
|
L
 -44.1%
H
1.6
12.0
|
L
 -84.5%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
895.2
|
22.1
|
L
 -2.0%
H
21.8
22.8
|
L
 -4.9%
H
21.2
24.1
|
L
 -4.8%
H
20.6
24.1
|
L
 -16.1%
H
18.8
27.0
|
L
 -7.2%
H
18.8
27.6
|
L
 -44.3%
H
11.2
48.6
|
L
 -68.4%
H
11.2
82.2
|
L
 -53.8%
H
11.2
82.2
|
| Processa Pharma Inc |
|
5.3
|
2.3
|
L
 -0.4%
H
2.1
2.5
|
L
 -21.4%
H
2.1
3.3
|
L
 10.5%
H
1.8
3.3
|
L
 -38.6%
H
1.8
4.3
|
L
 -78.2%
H
1.8
19.6
|
L
 -98.9%
H
1.8
450
|
L
 -100.0%
H
1.8
6694.5
|
L
 -99.9%
H
1.8
17937.5
|
| Vaxcyte Inc |
|
7,875.3
|
54.7
|
L
 1.4%
H
53.2
56.2
|
L
 0.3%
H
53.2
56.5
|
L
 -6.5%
H
53.2
65
|
L
 17.9%
H
43.9
65
|
L
 -26.5%
H
27.7
76.6
|
L
 41.4%
H
27.7
121.1
|
L
 115.3%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PDS biotech Corp |
|
31.2
|
0.6
|
L
 -8.1%
H
0.5
0.7
|
L
 -9.5%
H
0.5
0.7
|
L
 -12.3%
H
0.5
0.7
|
L
 -36.0%
H
0.5
1.2
|
L
 -58.1%
H
0.5
1.9
|
L
 -90.8%
H
0.5
10.3
|
L
 -89.4%
H
0.5
17.9
|
L
 -99.6%
H
0.5
355.4
|
| PepGen Inc |
|
324.8
|
4.7
|
L
 -1.5%
H
4.5
4.8
|
L
 -11.7%
H
4.5
5.5
|
L
 -24.4%
H
4.5
7.1
|
L
 -13.3%
H
4.2
7.8
|
L
 150%
H
0.9
7.8
|
L
 -72.3%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,160.5
|
3.3
|
L
 -1.2%
H
3.2
3.4
|
L
 -6.6%
H
3.1
3.6
|
L
 -25.1%
H
3.1
4.4
|
L
 -24.1%
H
3.1
5.5
|
L
 82.2%
H
1.1
5.5
|
L
 221.6%
H
0.7
5.5
|
L
 -60.0%
H
0.7
8.7
|
L
 -91.2%
H
0.7
39.5
|
| Phathom Pharma Inc |
|
883.3
|
11.2
|
L
 0.5%
H
11.1
11.9
|
L
 8.1%
H
10.3
11.9
|
L
 -1.8%
H
10.0
14.4
|
L
 -36.1%
H
10.0
18.3
|
L
 79.1%
H
2.2
18.3
|
L
 74.3%
H
2.2
19.7
|
L
 -74.2%
H
2.2
45.2
|
L
H
2.2
64.5
|
| Phio Pharma Corp |
|
14.2
|
1.2
|
L
 3.4%
H
1.2
1.2
|
L
 4.3%
H
1.1
1.3
|
L
 18.5%
H
1.0
1.3
|
L
 14.0%
H
0.8
1.9
|
L
 -8.3%
H
0.8
4.2
|
L
 -97.5%
H
0.6
110.4
|
L
 -99.6%
H
0.6
334.8
|
L
 -100.0%
H
0.6
194238
|
| Pharvaris NV |
|
1,688.9
|
26
|
L
 -0.5%
H
25.7
26.6
|
L
 2.3%
H
25.6
27.9
|
L
 -7.5%
H
25.0
29.0
|
L
 1.6%
H
23.6
29.0
|
L
 68.2%
H
11.5
29.8
|
L
 268.8%
H
6.3
33
|
L
 -21.8%
H
1.8
35.5
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
79.3
|
1.3
|
L
 -3.0%
H
1.3
1.3
|
L
 -4.4%
H
1.3
1.4
|
L
 4.0%
H
1.2
1.4
|
L
 4.9%
H
1.1
1.4
|
L
 -18.4%
H
1.1
2.0
|
L
 -95.3%
H
1.1
30.9
|
L
 -96.7%
H
1.1
42.3
|
L
H
1.1
43.9
|
| Pluri Inc |
|
31.3
|
3.1
|
L
 -0.6%
H
3.1
3.5
|
L
 -8.3%
H
3.1
3.5
|
L
 -15.0%
H
3.1
3.8
|
L
 -8.5%
H
2.9
3.9
|
L
 -30.1%
H
2.8
7.1
|
L
 -53.2%
H
0.7
8.6
|
L
 -93.0%
H
0.7
45.8
|
L
 -97.4%
H
0.7
169.6
|
| PharmaCyte Biotech Inc |
|
7.4
|
0.7
|
L
 -1.4%
H
0.6
0.8
|
L
H
0.6
0.8
|
L
 -1.4%
H
0.6
0.8
|
L
 -19.8%
H
0.6
1.1
|
L
 -58.7%
H
0.6
1.7
|
L
 -76.1%
H
0.6
3.2
|
L
 -97.7%
H
0.6
33
|
L
 -99.3%
H
0.6
253.4
|
| Praxis Precision Medicines Inc |
|
8,308.2
|
298.3
|
L
 0.3%
H
294.6
306.6
|
L
 1.5%
H
285
313
|
L
 -11.0%
H
285
356
|
L
 9.3%
H
266.5
356
|
L
 691.5%
H
26.7
356
|
L
 1812.2%
H
11.9
356
|
L
 -41.4%
H
11.9
559.2
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
1.8
|
2.3
|
L
 -0.4%
H
2.3
2.5
|
L
 -18.0%
H
2.3
2.8
|
L
 -34.1%
H
2.3
3.4
|
L
 159.1%
H
0.6
3.7
|
L
 -17.4%
H
0.6
3.7
|
L
 -93.1%
H
0.2
158.5
|
L
 -99.2%
H
0.2
470.4
|
L
H
0.2
471
|
| Prelude Therapeutics Inc |
|
188.4
|
3.0
|
L
 -6.3%
H
2.8
3.2
|
L
 -9.4%
H
2.8
3.7
|
L
 7.6%
H
2.5
4
|
L
 39.7%
H
1.8
4
|
L
 304.1%
H
0.6
4.2
|
L
 -55.6%
H
0.6
8.6
|
L
 -94.5%
H
0.6
60.0
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
635.5
|
3.5
|
L
 -4.4%
H
3.5
3.8
|
L
 -3.6%
H
3.5
3.8
|
L
 7.7%
H
3.2
4.8
|
L
 -3.3%
H
3.2
4.8
|
L
 75.1%
H
1.1
6.9
|
L
 -72.7%
H
1.1
17.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
273.2
|
1.9
|
L
 -1.0%
H
1.9
2.0
|
L
 -14.2%
H
1.9
2.3
|
L
 -7.7%
H
1.9
2.6
|
L
 -18.6%
H
1.7
2.6
|
L
 105.3%
H
0.5
7.1
|
L
 -80.5%
H
0.5
13.8
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| ProQR Therapeutics NV |
|
162.2
|
1.5
|
L
 -3.1%
H
1.5
1.7
|
L
 -15.4%
H
1.5
1.8
|
L
 6.9%
H
1.4
2.0
|
L
 -30.3%
H
1.3
2.3
|
L
 -5.5%
H
1.1
3.1
|
L
 -51.4%
H
1.1
4.6
|
L
 -72.7%
H
0.5
9.5
|
L
 -63.9%
H
0.5
24
|
| Prothena Corporation plc |
|
471.0
|
8.8
|
L
 2.5%
H
8.4
8.8
|
L
 -5.0%
H
8.4
9.3
|
L
 -3.0%
H
8.4
10.3
|
L
 -5.0%
H
8.2
10.5
|
L
 -32.0%
H
4.3
13.7
|
L
 -81.8%
H
4.3
79.7
|
L
 -64.1%
H
4.3
79.8
|
L
 -76.6%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
8.2
|
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 -7.9%
H
0.3
0.4
|
L
 -16.7%
H
0.3
0.5
|
L
 -51.4%
H
0.3
3.3
|
L
 -92.0%
H
0.3
15.8
|
L
 -99.4%
H
0.3
88
|
L
 -99.9%
H
0.3
899.5
|
L
 -99.9%
H
0.2
1310
|
| Plus Therapeutics Inc |
|
44.6
|
0.3
|
L
 4.2%
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -10.7%
H
0.2
0.4
|
L
 -56.1%
H
0.2
0.6
|
L
 -81.9%
H
0.2
1.8
|
L
 -94.0%
H
0.2
5.1
|
L
 -99.4%
H
0.2
53.1
|
L
 -100.0%
H
0.2
40500
|
| PTC Therapeutics Inc |
|
5,405.2
|
65.3
|
L
 -2.7%
H
65.1
68.2
|
L
 1.3%
H
64.7
68.9
|
L
 -7.6%
H
61.4
72.5
|
L
 -16.9%
H
61.4
80.2
|
L
 15.3%
H
36.0
87.5
|
L
 34.7%
H
17.5
87.5
|
L
 16.2%
H
17.5
87.5
|
L
 1001.2%
H
4.0
87.5
|
| Protagonist Therapeutics Inc |
|
6,308.8
|
98.9
|
L
 -2.8%
H
97.8
101.8
|
L
 7.1%
H
90.6
105.7
|
L
 19.5%
H
77
105.7
|
L
 14.9%
H
77
105.7
|
L
 86.4%
H
39.6
105.7
|
L
 334.0%
H
13.7
105.7
|
L
 217.4%
H
6.9
105.7
|
L
H
4.5
105.7
|
| Pulmatrix Inc |
|
9.1
|
2.5
|
L
 15.8%
H
2.1
2.5
|
L
 18.0%
H
2.0
2.5
|
L
 -12.3%
H
1.6
3.4
|
L
 5.1%
H
1.6
3.4
|
L
 -67.2%
H
1.6
9.4
|
L
 -17.5%
H
1.6
10.4
|
L
 -91.4%
H
1.6
30.4
|
L
 -99.6%
H
1.6
1396
|
| Polypid Ltd |
|
79.4
|
4.2
|
L
 -4.8%
H
4.2
4.3
|
L
 -0.7%
H
4.1
4.7
|
L
 -0.5%
H
4.0
4.7
|
L
 4.8%
H
3.9
5.1
|
L
 46.0%
H
2.3
5.1
|
L
 -74.0%
H
2.3
15.7
|
L
 -98.6%
H
2.3
304.9
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
91.5
|
1.5
|
L
 -4.6%
H
1.5
1.6
|
L
 -4.6%
H
1.5
1.7
|
L
 3.5%
H
1.3
1.7
|
L
 14.8%
H
1.0
2.2
|
L
 31.3%
H
0.8
5.6
|
L
 -37.7%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,070.1
|
15.4
|
L
 -0.7%
H
14.8
15.8
|
L
 5.9%
H
14.7
15.8
|
L
 -6.1%
H
14.5
17.3
|
L
 -7.6%
H
14.5
21.3
|
L
 72.2%
H
7.5
21.3
|
L
 50%
H
6.7
21.3
|
L
 15.8%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
3.6
|
4.0
|
L
 5.0%
H
3.7
4
|
L
 -2.9%
H
3.7
4.3
|
L
 -19.6%
H
3.7
5.7
|
L
 -43.8%
H
3.7
7.3
|
L
 -85.6%
H
3.7
29.4
|
L
 -100.0%
H
3.7
8640
|
L
 -100.0%
H
3.7
27000
|
L
 -100.0%
H
3.7
278000
|
| PureTech Health Plc ADR |
|
384.2
|
15.9
|
L
 -2.2%
H
15.8
16.3
|
L
 -4.5%
H
15.8
16.9
|
L
 -9.8%
H
15.8
18.1
|
L
 -6.7%
H
15.8
19.9
|
L
 -4.9%
H
13.3
20
|
L
 -41.1%
H
13.3
34
|
L
 -73.5%
H
13.3
65.9
|
L
H
13.3
65.9
|
| AIxCrypto Holdings Inc |
|
6.5
|
1.3
|
L
 1.6%
H
1.2
1.4
|
L
 10.5%
H
1.1
1.5
|
L
 1.6%
H
0.9
1.5
|
L
 -54.0%
H
0.9
3.0
|
L
 -59.9%
H
0.9
8.8
|
L
 -97.4%
H
0.1
68.5
|
L
 -99.9%
H
0.1
1560
|
L
 -100.0%
H
0.1
468750
|
| Qilian Intl Holding Grp ltd (Class A) |
|
120.4
|
0.6
|
L
 -34.1%
H
0.6
0.9
|
L
 -40.6%
H
0.6
1.0
|
L
 -42.3%
H
0.6
1.2
|
L
 -86.2%
H
0.6
4.7
|
L
 -93.3%
H
0.6
17.2
|
L
 -92.1%
H
0.6
17.2
|
L
 -97.6%
H
0.6
27.8
|
L
H
0.6
110
|
| Quince Therapeutics Inc |
|
4.5
|
0.1
|
L
 -11.1%
H
0.1
0.1
|
L
 -27.3%
H
0.1
0.1
|
L
 -46.7%
H
0.1
0.2
|
L
 -97.8%
H
0.1
3.8
|
L
 -94.2%
H
0.1
4.6
|
L
 -90.5%
H
0.1
4.6
|
L
 -99.8%
H
0.1
122.0
|
L
H
0.1
122.0
|
| uniQure NV |
|
1,006.1
|
16.1
|
L
 5.4%
H
15
17.7
|
L
 3.6%
H
14.2
17.7
|
L
 -31.3%
H
8.7
25.4
|
L
 -32.9%
H
8.7
28.8
|
L
 15.5%
H
7.8
71.5
|
L
 -16.6%
H
3.7
71.5
|
L
 -51.8%
H
3.7
71.5
|
L
 35.9%
H
3.7
82.5
|
| Quoin Pharma Ltd (ADR) |
|
12.8
|
7.9
|
L
 -3.9%
H
7.8
8.2
|
L
 -1.5%
H
7.4
8.5
|
L
 -7.8%
H
7.4
10.0
|
L
 -44.1%
H
7
14.7
|
L
 -96.1%
H
5.1
294
|
L
 -99.8%
H
5.1
8400
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Rain Oncology Inc |
|
110.2
|
3.0
|
L
 -1.0%
H
2.9
3.2
|
L
 3.4%
H
2.8
3.8
|
L
 17.0%
H
2.5
3.8
|
L
 -58.6%
H
2.1
8.5
|
L
 46.4%
H
1.7
9.2
|
L
 -61.0%
H
0.8
10.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
110.2
|
1.1
|
L
 -1.7%
H
1.1
1.2
|
L
 -14.4%
H
1.1
1.4
|
L
 -12.4%
H
1.1
1.4
|
L
 -25.2%
H
1.1
1.5
|
L
 -24.7%
H
0.4
3.9
|
L
 -82.1%
H
0.4
8.8
|
L
 -99.5%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Ultragenyx Pharmaceutical Inc |
|
1,920.0
|
19.9
|
L
 -2.7%
H
19.9
20.7
|
L
 -6.9%
H
19.9
22.2
|
L
 -12.5%
H
19.9
23.8
|
L
 -40.7%
H
18.4
35.1
|
L
 -48.9%
H
18.4
42.4
|
L
 -49.1%
H
18.4
60.4
|
L
 -84.1%
H
18.4
126.3
|
L
 -64.7%
H
18.4
179.7
|
| Rocket Pharmaceuticals Inc |
|
449.5
|
4.1
|
L
 -5.7%
H
4.1
4.6
|
L
 -12.5%
H
4.1
4.9
|
L
 9.5%
H
3.8
5.5
|
L
 28.2%
H
3
5.5
|
L
 -50.2%
H
2.2
8.8
|
L
 -76.6%
H
2.2
32.5
|
L
 -92.4%
H
2.2
58.2
|
L
 -86.4%
H
2.2
67.5
|
| Regeneron Pharma |
|
77,478.9
|
732.9
|
L
 -0.6%
H
728.6
744.9
|
L
 -1.7%
H
727.9
771.2
|
L
 -6%
H
727.9
794.8
|
L
 -4.6%
H
718.4
821.1
|
L
 10.6%
H
476.5
821.1
|
L
 -3.5%
H
476.5
1211.2
|
L
 54.7%
H
451.6
1211.2
|
L
 101.1%
H
271.4
1211.2
|
| Replimune Grp Inc |
|
576.4
|
7.0
|
L
 1.3%
H
6.8
7.2
|
L
 -2.2%
H
6.5
7.6
|
L
 -19.2%
H
6.5
9.1
|
L
 -29.4%
H
6.5
10.3
|
L
 -39.8%
H
2.7
13.2
|
L
 -65.8%
H
2.7
24.8
|
L
 -80.3%
H
2.7
40.2
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
4.4
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
 -5.6%
H
1.1
1.3
|
L
 -16.2%
H
1.1
1.4
|
L
 -66.7%
H
1.1
5.8
|
L
 -96.6%
H
1.1
44.8
|
L
 -100.0%
H
1.1
9561.6
|
L
 -100.0%
H
1.1
2276064
|
L
H
1.1
2276064
|
| Regencell Bioscience Holdings Ltd |
|
13,534.2
|
27.4
|
L
 1.3%
H
26.3
28.7
|
L
 17.8%
H
22.3
29.5
|
L
 -6.2%
H
20
29.7
|
L
 38.2%
H
19.4
69
|
L
 2219.5%
H
0.6
83.6
|
L
 3754.9%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
6,415.0
|
113.9
|
L
 -3.2%
H
113.6
117.8
|
L
 -0.3%
H
113.5
122.6
|
L
 -16.1%
H
112.5
139.4
|
L
 -29.9%
H
112.5
175.8
|
L
 -18.3%
H
103.0
175.8
|
L
 -33.9%
H
103.0
211.1
|
L
 -44.2%
H
103.0
327.3
|
L
 372.9%
H
21.1
327.3
|
| Regenxbio Inc |
|
418.1
|
8.1
|
L
 -3.1%
H
8.1
8.5
|
L
 -5.5%
H
8.0
9
|
L
 -0.5%
H
7.8
10.8
|
L
 -44.5%
H
7.6
16.2
|
L
 -3.1%
H
5.0
16.2
|
L
 -61.2%
H
5.0
28.8
|
L
 -79.7%
H
5.0
46.5
|
L
 -30.3%
H
5.0
85.1
|
| Rigel Pharma |
|
479.6
|
26.0
|
L
 -0.5%
H
25.5
26.5
|
L
 0.0%
H
25.0
27.3
|
L
 -26.8%
H
25.0
36.7
|
L
 -37.6%
H
25.0
49.1
|
L
 27.4%
H
15.5
52.2
|
L
 1741.1%
H
0.7
52.2
|
L
 550.6%
H
0.6
52.2
|
L
 1166.3%
H
0.6
52.2
|
| Relay Therapeutics Inc |
|
1,771.2
|
9.9
|
L
 -0.9%
H
9.7
10.8
|
L
 -4.3%
H
9.7
10.8
|
L
 13.9%
H
8.6
11.5
|
L
 18.0%
H
7.0
11.5
|
L
 204.9%
H
1.8
11.5
|
L
 -36.6%
H
1.8
19.2
|
L
 -73.4%
H
1.8
39.7
|
L
H
1.8
64.4
|
| Relmada Therapeutics Inc |
|
445.1
|
6.1
|
L
 -2.9%
H
5.8
6.7
|
L
 2.7%
H
5.8
6.7
|
L
 47.0%
H
4.0
7.5
|
L
 39.5%
H
3.2
7.5
|
L
 1923.3%
H
0.2
7.5
|
L
 150.8%
H
0.2
7.5
|
L
 -83.4%
H
0.2
40
|
L
 10.0%
H
0.2
54
|
| TransCode Therapeutics Inc |
|
8.2
|
9.0
|
L
 -3.5%
H
8.8
9.3
|
L
 -8.2%
H
8.8
9.8
|
L
 -7.3%
H
8.8
10.4
|
L
 13.4%
H
6.1
12.6
|
L
 -58.4%
H
6.1
46.8
|
L
 -100.0%
H
6.1
362374.6
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| RenovoRx Inc |
|
36.6
|
1
|
L
 -1.0%
H
1.0
1.0
|
L
 19.1%
H
0.8
1.1
|
L
 9.9%
H
0.8
1.1
|
L
 7.5%
H
0.8
1.3
|
L
 1.0%
H
0.7
1.5
|
L
 -66.4%
H
0.6
4.6
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
19,824.9
|
27.7
|
L
 -0.4%
H
27.1
28.0
|
L
 -1.3%
H
27.1
29.0
|
L
 2.0%
H
26.9
30.3
|
L
 23.6%
H
20.8
30.3
|
L
 152.5%
H
8.7
30.3
|
L
 218.0%
H
6.6
30.3
|
L
 183.5%
H
2.5
30.3
|
L
H
2.5
30.3
|
| Royalty Pharma PLC (Class A) |
|
19,433.1
|
45.4
|
L
 -0.4%
H
44.7
46.1
|
L
 -0.6%
H
44.7
46.4
|
L
 0.5%
H
44.7
47.9
|
L
 17.5%
H
38.3
47.9
|
L
 35.4%
H
29.7
47.9
|
L
 28.2%
H
24.1
47.9
|
L
 -3.1%
H
24.1
47.9
|
L
H
24.1
56.5
|
| Revolution Medicines Inc |
|
18,981.0
|
95.8
|
L
 -3.5%
H
94.9
99.0
|
L
 1.0%
H
94.9
100.5
|
L
 -5.9%
H
94.7
107.5
|
L
 21.6%
H
76.3
124.5
|
L
 148.8%
H
29.2
124.5
|
L
 340.0%
H
15.5
124.5
|
L
 98.0%
H
14.1
124.5
|
L
H
14.1
124.5
|
| Reviva Pharma Holdings Inc |
|
4.7
|
0.8
|
L
 -3.6%
H
0.8
0.9
|
L
 -67.6%
H
0.7
2.7
|
L
 -83.8%
H
0.7
5.1
|
L
 -93.3%
H
0.7
12.5
|
L
 -96.4%
H
0.7
23.4
|
L
 -99.0%
H
0.7
185
|
L
 -99.5%
H
0.7
190
|
L
H
0.7
302
|
| Recursion Pharma Inc (Class A) |
|
1,716.7
|
3.3
|
L
 -3.6%
H
3.2
3.4
|
L
 -5.0%
H
3.2
3.5
|
L
 -5.0%
H
3.2
4.1
|
L
 -23.7%
H
3.0
5.2
|
L
 -49.9%
H
3.0
7.2
|
L
 -55.2%
H
3.0
16.7
|
L
H
3.0
42.8
|
L
H
3.0
42.8
|
| Rhythm Pharma Inc |
|
5,971.5
|
87.5
|
L
 -3.2%
H
86.5
100
|
L
 0.1%
H
84
100
|
L
 -12.4%
H
82
103.3
|
L
 -22.0%
H
82
115.0
|
L
 61.3%
H
45.9
122.2
|
L
 394.1%
H
15.5
122.2
|
L
 241.9%
H
3.0
122.2
|
L
H
3.0
122.2
|
| Rezolute Inc |
|
238.3
|
2.5
|
L
 0.8%
H
2.4
2.5
|
L
 -4.2%
H
2.3
2.7
|
L
 -24.3%
H
2.3
3.7
|
L
 40.7%
H
1.8
4.1
|
L
 -19.4%
H
1.1
11.5
|
L
 23.9%
H
0.7
11.5
|
L
 -68.1%
H
0.7
17.4
|
L
 -95.0%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.5
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 -10.2%
H
0.8
1.1
|
L
 -25.4%
H
0.8
1.4
|
L
 -68.6%
H
0.8
3.3
|
L
 -99.4%
H
0.8
145
|
L
 -100.0%
H
0.8
11180
|
L
 -100.0%
H
0.8
16540
|
| SAB Biotherapeutics Inc |
|
178.5
|
3.8
|
L
 -0.8%
H
3.7
3.8
|
L
 -9.6%
H
3.7
4.3
|
L
 5.0%
H
3.5
5.2
|
L
 -6.0%
H
3.4
5.2
|
L
 135.9%
H
1
6.6
|
L
 621.2%
H
0.4
6.6
|
L
 -62.1%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
830.0
|
3.1
|
L
 -1.9%
H
3.1
3.3
|
L
 -7.4%
H
3.0
3.5
|
L
 -22.4%
H
3
4.5
|
L
 -28.7%
H
3
5.2
|
L
 37.6%
H
1.3
6.6
|
L
 -11.6%
H
1.3
12
|
L
 -90.3%
H
1.3
33.8
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
86.5
|
1.8
|
L
 -2.2%
H
1.8
1.9
|
L
 -10.1%
H
1.8
2.0
|
L
 -16.0%
H
1.8
2.5
|
L
 -17.9%
H
1.8
2.5
|
L
 -35.1%
H
1.2
5.0
|
L
 -93.2%
H
1.2
42.2
|
L
 -96.9%
H
1.2
146.2
|
L
 -87.8%
H
0.8
146.2
|
| Sunshine Biopharma Inc |
|
5.1
|
1.0
|
L
 -4.6%
H
1.0
1.1
|
L
 -5.5%
H
1.0
1.2
|
L
 -11.9%
H
1.0
1.3
|
L
 -25.2%
H
1.0
1.4
|
L
 -53.4%
H
1.0
3.9
|
L
 -98.7%
H
0.1
140
|
L
 -100.0%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
52.9
|
7.5
|
L
 -3.6%
H
7.3
7.9
|
L
 -9.2%
H
7.3
8.7
|
L
 -7.4%
H
7.3
9.8
|
L
 -47.6%
H
7.3
14.8
|
L
 2585.7%
H
0.2
34.3
|
L
 -5.3%
H
0.2
34.3
|
L
 -24.0%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
41.5
|
0.9
|
L
 4.5%
H
0.9
0.9
|
L
 8.1%
H
0.9
1.0
|
L
 19.2%
H
0.7
1.0
|
L
 47.6%
H
0.6
1.0
|
L
 -10.6%
H
0.6
1.3
|
L
 -19.1%
H
0.6
3.9
|
L
 -88.9%
H
0.6
10.3
|
L
 -97.8%
H
0.6
55.1
|
| Seer Inc (Class A) |
|
94.8
|
1.7
|
L
 -2.3%
H
1.7
1.7
|
L
 -7.2%
H
1.7
1.8
|
L
 -15.2%
H
1.7
2.1
|
L
 -6.2%
H
1.7
2.2
|
L
 -11.6%
H
1.6
2.4
|
L
 -58.4%
H
1.5
5.7
|
L
 -96.8%
H
1.5
57.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,008.1
|
6.5
|
L
 -0.9%
H
6.4
6.7
|
L
 -11.9%
H
6.4
8.0
|
L
 -6.1%
H
6.4
9.3
|
L
 -9.8%
H
6.1
9.3
|
L
 -36.6%
H
6.0
15.6
|
L
 -36.5%
H
6.0
15.6
|
L
 -36.5%
H
6.0
15.6
|
L
 -36.5%
H
6.0
15.6
|
| Sangamo Therapeutics Inc |
|
122.7
|
0.3
|
L
 -2.9%
H
0.3
0.4
|
L
 -13.2%
H
0.3
0.4
|
L
 -13.2%
H
0.3
0.6
|
L
 -26.7%
H
0.3
0.6
|
L
 -60.7%
H
0.3
0.9
|
L
 -82.9%
H
0.3
3.2
|
L
 -97.5%
H
0.3
13.9
|
L
 -93.9%
H
0.3
27.5
|
| Shuttle Pharma Holdings Inc |
|
5.0
|
0.9
|
L
 -6.3%
H
0.9
1.0
|
L
 -5.3%
H
0.9
1.1
|
L
 -16.0%
H
0.8
1.1
|
L
 -48.3%
H
0.8
4.4
|
L
 -91.2%
H
0.8
13.6
|
L
 -99.7%
H
0.8
550
|
L
H
0.8
25252
|
L
H
0.8
25252
|
| SIGA Tech Inc |
|
353.9
|
4.9
|
L
 -2.8%
H
4.9
5.1
|
L
 -6.1%
H
4.8
5.5
|
L
 -26.8%
H
4.8
6.9
|
L
 -21.2%
H
4.8
7.1
|
L
 -12.4%
H
4.8
9.6
|
L
 -10.7%
H
4.2
12.8
|
L
 -27.6%
H
4.2
27.0
|
L
 798.2%
H
0.4
27.0
|
| SILO Pharma Inc |
|
5.1
|
0.4
|
L
 9.1%
H
0.3
0.4
|
L
 12.5%
H
0.3
0.4
|
L
 24.1%
H
0.3
0.4
|
L
 -5.3%
H
0.2
0.4
|
L
 -73.7%
H
0.2
1.4
|
L
 -81.0%
H
0.2
4.5
|
L
 -97.8%
H
0.2
496
|
L
 -99.3%
H
0.2
496
|
| Solid Biosciences Inc |
|
547.7
|
7.0
|
L
 -1.3%
H
7.0
7.6
|
L
 -3.8%
H
6.8
8.0
|
L
 23.1%
H
5.5
8.7
|
L
 18.4%
H
4.9
8.7
|
L
 49.6%
H
2.4
8.7
|
L
 91.0%
H
1.8
15.1
|
L
 -91.9%
H
1.8
93.8
|
L
H
1.8
822.6
|
| Sol-Gel Tech Ltd |
|
203.3
|
73.0
|
L
 -10.7%
H
72
78.9
|
L
 -13.1%
H
72
88.5
|
L
 -13.1%
H
68
98.0
|
L
 73.1%
H
40.1
98.0
|
L
 12481.0%
H
0.4
98.0
|
L
 2015.1%
H
0.3
98.0
|
L
 457.4%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Soleno Therapeutics Inc |
|
1,715.0
|
33.2
|
L
 -1.2%
H
32.6
33.8
|
L
 -1.6%
H
32.2
34.9
|
L
 -15.6%
H
32.2
41.9
|
L
 -30.6%
H
32.2
50.9
|
L
 -31.4%
H
32.2
90.3
|
L
 1544.6%
H
2.0
90.3
|
L
 39.3%
H
0.9
90.3
|
L
 -67.9%
H
0.9
117.8
|
| SELLAS Life Sciences Grp Inc |
|
854.6
|
4.8
|
L
 -8.5%
H
4.8
5.6
|
L
 -11.4%
H
4.7
5.7
|
L
 14.7%
H
4.3
6.1
|
L
 101.7%
H
2.4
6.1
|
L
 293.4%
H
1.0
6.1
|
L
 271.9%
H
0.5
6.1
|
L
 -55.2%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Summit Therapeutics Inc |
|
12,026.0
|
15.5
|
L
 -1.3%
H
15.4
16.3
|
L
 -3.8%
H
15.3
16.5
|
L
 -2.7%
H
14.6
16.8
|
L
 -13.0%
H
13.8
20.2
|
L
 -20.2%
H
13.8
36.9
|
L
 851.5%
H
1.3
36.9
|
L
 156.8%
H
0.7
36.9
|
L
 104.1%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
2,137.1
|
24.2
|
L
 1.0%
H
24
25.4
|
L
 3.1%
H
23.3
25.4
|
L
 23.1%
H
19.2
25.4
|
L
 16.7%
H
19.2
25.4
|
L
 71.8%
H
8.6
25.4
|
L
 4.8%
H
8.6
25.4
|
L
 5.6%
H
8.6
29.9
|
L
 110.3%
H
3.4
29.9
|
| Soligenix Inc |
|
12.1
|
1.2
|
L
 -1.6%
H
1.2
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 9.1%
H
1.1
1.3
|
L
 -13.0%
H
1.0
1.5
|
L
 -49.6%
H
1.0
6.2
|
L
 -96.5%
H
1.0
85.3
|
L
 -99.7%
H
1.0
432
|
L
 -99.9%
H
1.0
2160
|
| Sonoma Pharma Inc |
|
4.2
|
2.4
|
L
 -0.4%
H
2.4
2.4
|
L
 -1.2%
H
2.4
2.6
|
L
 -17.4%
H
2.3
3.1
|
L
 -31.9%
H
2.3
3.9
|
L
 -32.9%
H
1.8
6.9
|
L
 133.7%
H
0.1
6.9
|
L
 -68.2%
H
0.1
13.4
|
L
 -94.6%
H
0.1
74.2
|
| Synaptogenix Inc |
|
44.3
|
6.0
|
L
 5.5%
H
5.6
6.1
|
L
 5.5%
H
5.0
6.5
|
L
 52.6%
H
3.7
6.5
|
L
 18.3%
H
3.3
6.5
|
L
 126.2%
H
1.8
12.0
|
L
 643.8%
H
0.1
12.0
|
L
 -31.8%
H
0.1
14.5
|
L
H
0.1
14.5
|
| Sensei Biotherapeutics Inc |
|
39.8
|
31.6
|
L
 3.3%
H
30.1
33.6
|
L
 -2.2%
H
28.5
33.6
|
L
 -5.8%
H
26.1
36.8
|
L
 256.2%
H
8.4
36.8
|
L
 243.0%
H
5
36.8
|
L
 16.0%
H
5
38.8
|
L
 -89.8%
H
5
316.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
24.2
|
0.9
|
L
 2.2%
H
0.9
0.9
|
L
 -1.1%
H
0.9
1
|
L
 7.0%
H
0.8
1.0
|
L
 -23.3%
H
0.8
1.3
|
L
 -73.8%
H
0.8
5.1
|
L
 -92%
H
0.8
16.9
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
80.1
|
58.4
|
L
 -1.1%
H
56.1
62.6
|
L
 -2.8%
H
56.1
65
|
L
 17.5%
H
48.5
68.1
|
L
 -25.8%
H
48.1
91.1
|
L
 131.8%
H
4.3
240
|
L
 -66.1%
H
4.3
446.3
|
L
 -95.5%
H
4.3
1388.3
|
L
H
4.3
2670
|
| SciSparc Ltd |
|
2.6
|
4.6
|
L
 -0.6%
H
4.2
4.6
|
L
 6.2%
H
4.2
4.7
|
L
 -1.7%
H
3.6
6.2
|
L
 -64.8%
H
3.6
14.2
|
L
 -92.8%
H
3.6
94.5
|
L
 -99.8%
H
3.6
4471.7
|
L
H
3.6
41769
|
L
H
3.6
41769
|
| Spero Therapeutics Inc |
|
133.5
|
2.4
|
L
 -4.1%
H
2.4
2.5
|
L
 -8.1%
H
2.4
2.7
|
L
 3.0%
H
2.1
2.7
|
L
 2.2%
H
2.1
2.7
|
L
 203.9%
H
0.5
3.2
|
L
 71.7%
H
0.5
3.2
|
L
 -85.1%
H
0.5
19.9
|
L
H
0.5
23.6
|
| ARS Pharma Inc |
|
809.1
|
8.2
|
L
 -1.0%
H
8.1
8.5
|
L
 -2.6%
H
8
9.1
|
L
 -9.2%
H
8
9.7
|
L
 -22.1%
H
8
13.2
|
L
 -42.9%
H
6.7
18.9
|
L
 -2.7%
H
2.6
18.9
|
L
 -86.4%
H
2.6
61
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
223.2
|
4.5
|
L
 1.6%
H
4.2
4.5
|
L
 6.5%
H
4.0
4.6
|
L
 61.2%
H
2.8
4.6
|
L
 242.3%
H
1.2
4.6
|
L
 71.2%
H
1.2
5.3
|
L
 1136.1%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|